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ABSTRACT OF DISSERTATION 
 
 
 
 
HALO- AND SOLVATO-FLUOROCHROMIC POLYMER NANOASSEMBLIES  
FOR CANCER THERANOSTICS 
 
Theranostics is an emerging treatment approach that combines diagnostics with 
therapy in order to personalize treatment regimens for individual patients and decrease 
cancer mortality. Previously, nanoparticles entrapping conventional fluorescent dyes 
were developed for cancer theranostics, but fluorescent nanoparticles did not allow 
clinicians to significantly improve cancer treatments.  
 
The use of fluorescent dyes that are sensitive to solvent acidity (halo-
fluorochromism) and polarity (solvato-fluorochromism) may overcome the limitations of 
fluorescent nanoparticles and improve cancer therapy by enabling researchers to detect 
chemical properties within the nanoparticle core environment. The model halo- and 
solvato-fluorochromic dye Nile blue was attached to the core of nanoscale drug delivery 
systems called polymer nanoassemblies (PNAs), which were created by tethering 
hydrophilic polymers and hydrophobic groups to a cationic polymer scaffold. The 
fluorescence of empty PNAs increased by 100% at pH 5.0 compared to pH 7.4, and the 
fluorescence of drug-loaded PNAs increased up to 300% compared to empty PNAs. A 
comparison of the fluorochromic properties between PNAs with various core properties 
indicated that both hydrophobic pendant groups and scaffold amines contributed to the 
fluorochromism of PNAs. 
 
The halo-fluorochromism of PNAs allowed investigators to minimize the 
detection of fluorescence signals in healthy organs such as the liver. Fluorescence 
imaging of halo-fluorochromic PNAs diffused into tissue mimics indicated that 
fluorescence of PNAs in tissues increased by 100% at pH 7.0 compared to pH 7.4. In 
addition, halo-fluorochromic PNAs identified the acidic perimeter surrounding metastatic 
tumors in orthotopic metastatic tumor models. Computational simulations of metastatic 
lesions verified that some halo-fluorochromic PNAs accumulate in the hypoxic/acidic 
regions of metastatic tumors following intravenous administration. These simulations 
also indicated that the accumulation of PNAs in the hypoxic regions of tumors doubles at 
12 hours post-treatment compared to 1.8 hours post-treatment. 
 
The solvato-fluorochromism of PNAs enabled the fluorescence-based 
measurement of drug release from the nanoassembly core during dialysis-based drug 
release measurements. Solvato-fluorochromic methods indicated faster drug release rates 
than HPLC-based methods. Mechanistic modeling of drug release indicated that solvato-
fluorochromic methods were unaffected by released drugs that interfered with HPLC-
based methods. However, mechanistic modeling also indicated that drug rebinding and 
diffusion did not account for all of the differences between drug release rates determined 
by solvato-fluorochromic- and HPLC-based methods. Based on this evidence, it was 
hypothesized that solvato-fluorochromic drug release methods measure drug diffusion 
from near the scaffold of PNAs in a small region of the nanoassembly core, and that this 
process contributes to overall drug release but does not indicate apparent drug release 
rates for PNAs. 
 
In order to develop PNAs for potential clinical applications, ionizable amines 
were removed from the polymer scaffold to increase drug loading and sustain the release 
of model drugs carfilzomib and docetaxel. The removal of primary amines decreased 
drug diffusivity in the core of PNAs (D from 3.9*10-18 cm2/s to 0.1*10-19 cm2/s) and 
increased the drug release half-life (t1/2 from 4 to 26 hours). The controlled release of 
carfilzomib from PNAs reduced drug metabolism by 60% for up to one hour and 
sustained proteasome inhibition in cancer cells at 72 h post-treatment compared to free 
drug.  
 
Overall, this work provides insight into the design of theranostic nanoparticles 
with beneficial properties for improving cancer treatment.  
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1 FLUOROCHROMISM AND NANOTECHNOLOGY FOR IMPROVING 
CANCER THERANOSTICS  
1.1 Cancer Theranostics: Promise and Limitations 
 Theranostics is an emerging approach that combines therapy with diagnostics in 
order to identify effective treatments, improve disease detection and reduce mortality (1). 
In general, the use of theranostic methods enables clinicians to maximize the efficacy of 
therapeutic agents by treating a disease with a conventional therapeutic agent while also 
identifying patients who may respond poorly to that therapeutic regimen. For this subset 
of patients, clinicians can select more aggressive therapeutic regimens or switch to 
targeted therapeutic agents in order to improve patient outcomes (2). Theranostic 
methods can also enable researchers to increase the sensitivity and accuracy of disease 
detection in early stages (3). The biological and pharmacological indicators of many 
diseases can be difficult to elucidate from traditional diagnostic methods such as medical 
imaging (4). By measuring the physiological response of a disease in response to a 
treatment, theranostic methods can allow clinicians to identify more effective treatment 
approaches based on the biological properties of a disease state (5). Additionally, 
theranostics may also enable clinicians to monitor disease progression and adjust 
treatment over the course of a treatment regimen (6). Theranostics is an especially 
promising approach for difficult-to-treat diseases with variable biological properties. 
 Theranostic methods combining medical imaging with drug delivery can enable 
clinicians to overcome the limitations of biomarker-based theranostic methods by 
indicating drug delivery to a targeted site (7). Biomarker-based theranostic methods allow 
clinicians to detect genes or proteins that predict treatment efficacy in a patient (8, 9). 
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Unfortunately, the identification of biomarkers that predict treatment responses in 
patients and the development of clinical devices for biomarker detection remain difficult 
(10, 11). Biomarker-based theranostic methods also fail to indicate the amount of drug 
reaching solid tumors in patients. In contrast to biomarker-based theranostic methods, 
medical imaging-guided theranostic methods often use FDA-approved drug delivery 
systems that are modified with imaging agents. Clinicians can monitor the distribution of 
these drug delivery systems after systemic administration (12, 13). By combining the in 
vivo distribution and drug release profiles of these drug delivery systems, clinicians can 
estimate drug delivery to diseased tissues and adjust treatments to maximize their 
efficacy (14). Theranostic methods are expected to enable clinicians to measure the real-
time ADME of anticancer drugs and to provide timely, personalized treatment regimens 
that maximize anticancer drug accumulation in metastatic tumors (15-17).  
 Theranostic methods can also enable oncologists to detect small metastatic tumors 
in patients. Cancer is the second leading cause of death in the United States, and more 
than 90% of cancer-related deaths are attributed to metastasis (18). Metastasis is a disease 
state in which cancer cells migrate from primary tumors to adjacent tissues through blood 
vessels, lymphatic fluid or the peritoneal cavity (19). Cancer cells in metastatic tumors 
grow in a heterogeneous tissue microenvironment, in which micrometastatic colonies of 
cancer cells are surrounded by normal cells (20). The micrometastatic colonies within 
parenchyma are often too small and too dispersed throughout organs for clinicians to 
detect accurately. Theranostic methods allow clinicians to detect antigens or receptors on 
metastatic cancer cells, rather than the tissue properties of metastatic tumors, and 
accurately distinguish micrometastatic colonies from healthy tissues. 
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 Theranostic methods may allow clinicians to treat micrometastatic colonies while 
they remain susceptible to treatment. Traditional primary tumor treatment methods such 
as surgery, chemotherapy, radiotherapy, and heat ablation are often ineffective at treating 
large metastatic tumors that can be detected with traditional methods (21-23). In contrast 
to large metastatic tumors with an acidic extracellular microenvironment that can ionize 
some anticancer drugs and prevent their diffusion through cell membranes, small 
metastatic tumors remain susceptible to chemotherapy due to increased drug 
accumulation in metastatic cancer cells (24-27). Theranostic methods can allow clinicians 
to treat small metastatic tumors earlier in their development and to estimate drug 
concentrations in tumor metastasis.  
 Although fluorescence imaging is an established diagnostic method with several 
applications in theranostics, many fluorescent dyes can provide false signals unless they 
are used carefully (28). The non-selective cellular accumulation of dyes and nanoparticles 
has limited the applications of previous theranostic methods using fluorescence imaging. 
Clinicians using fluorescent dyes for theranostics must also consider the signal-to-noise 
ratios, quantum yields, and photo-bleaching of these dyes (29). Strategies for improving 
theranostic methods using fluorescence imaging are needed to increase the accuracy of 
metastatic tumor detection and improve the pharmacokinetic predictions for anticancer 
drugs.  
1.2 Halo- and Solvato-Fluorochromism for Theranostic Imaging 
 Fluorochromism is an optical property of fluorescent dyes in which fluorescence 
excitation wavelengths, emission wavelengths and quantum yields change depending on 
the solvent environment of the dye. The optical properties of fluorochromic dyes often 
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change based on solvent pH (halo-fluorochromism) and polarity (solvato-
fluorochromism) (30). The halo- and solvato- fluorochromic properties of dyes are 
controlled by the electronic mobility and conformation of dye molecules in the solvent 
environment (31, 32). The halo-fluorochromism of dyes is also controlled by the 
protonation state of ionizable groups such as amines or carboxylate anions that alter the 
electronic mobility and conformation of dyes. Differences between the molecular 
interactions among solvents and dye molecules such as solvent-induced dye conformation 
changes, induced dipole interactions and hydrogen bonding contribute to the solvato-
fluorochromism of dyes (33). By measuring the halo- or solvato-fluorochromism of dyes 
in solution, the chemical properties of their surrounding solvent environment can be 
quantified (34, 35).  
 The halo- and solvato-fluorochromism of dyes has allowed investigators to 
identify specific tissue regions in fluorescence images based on their chemical properties. 
Halo-fluorochromic dyes with increased fluorescence below pH 5.0 allowed for the 
identification of acidic lysosomes in cell images (36). In addition, solvato-fluorochromic 
dyes with strong fluorescence in lipids enabled the detection of intracellular lipid droplets 
in tissue samples (37). Solvato-fluorochromic dyes with increased fluorescence after 
binding to DNA permitted researchers to identify cell nuclei in microscopic fluorescence 
images (38). Fluorochromic dyes remaining in tumor tissue could be used by clinicians to 
monitor the tumor microenvironment and indicate treatment efficacy, but small molecule 
fluorochromic dyes often have poor retention in tissues. As a result, there is a critical 
need to increase the accumulation and retention of fluorochromic dyes in tumor tissue in 
order to investigate the tumor microenvironment. 
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1.3 Polymer Nanoassemblies (PNAs) Entrapping Fluorochromic Dyes 
 Nanotechnology has allowed scientists to increase anticancer drug accumulation 
in solid tumors with biocompatible nanomaterials that accumulate in the interstitial space 
surrounding leaky tumor blood vessels (39). One type of biocompatible nanomaterial 
with these properties is PNAs created from self-assembling or cross-linked copolymers, 
such as polymer micelles, vesicles and polyionic complexes. The physicochemical 
properties of PNAs, such as size, morphology and surface charge, can be controlled by 
altering their chemical composition. Controlling the size (< 100 nm in diameter) and 
surface charge (neutral or slightly anionic) of PNAs can increase their tumor 
accumulation compared to other drug delivery systems and fine-tune the pharmacokinetic 
profiles of entrapped drugs (40). PNAs often contain a hydrophobic core surrounded by a 
hydrophilic shell. The hydrophobic core can entrap water-insoluble drugs and protect 
drugs from metabolism, while the hydrophilic shell can prevent the non-specific binding 
of PNAs to plasma proteins and also reduce the uptake of drug-loaded PNAs by the 
mononuclear phagocyte system (41). The benefits of PNAs for anticancer drug delivery 
have been validated in several clinical trials (42, 43). 
 PNAs can function as theranostic tools and allow oncologists to reduce cancer 
mortality by combining anticancer drug delivery with fluorescence imaging capabilities. 
Previous studies demonstrated that PNAs with beneficial physicochemical properties 
allow clinicians to deliver many therapeutic, diagnostic and imaging molecules to tumors 
separately or in combination (44-47). The chemical conjugation of fluorescent dyes to 
PNAs prevents dyes from diffusing out of PNAs during imaging and allows researchers 
to measure quantitative fluorescence signals. PNA-entrapped fluorescent dyes have 
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reduced renal clearance compared to free dyes, because nanoassemblies cannot pass 
through renal glomeruli and enter the urine (48). As a result, PNAs can increase the half-
life of dyes in tumor tissue and extend the time window for successful fluorescence 
detection of tumors from less than 5 minutes up to about two hours (49). PNAs can also 
extend the imaging time window in healthy organs such as the liver and enable the 
detection of metastatic tumors (50-52).  
 PNAs with fluorochromism can allow investigators to overcome the limitations of 
previously developed fluorescent PNAs.  Fluorochromic dyes entrapped in PNAs may 
allow for the detection of the chemical properties within the nanoparticle core 
environment without interference from the surrounding environment, because 
fluorochromism occurs due to short-range molecular interactions (<0.1 nm distance) (53). 
Figure 1.1A describes the synthesis of PNAs with fluorochromism. 
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Figure 1.1. Graphical description of PNAs prepared through the unimolecular self-
assembling of polymer conjugates (A). Fluorochromic PNAs for the real-time 
determination of drug concentrations using solvato-fluorochromism (B) and the acid-
sensitive imaging of metastatic tumors using halo-fluorochromism (C). 
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 The solvato-fluorochromism of PNAs can allow researchers to measure drug 
release from the nanoassembly core in real time (Figure 1.1B). The entrapment and 
release of hydrophobic anticancer drugs from the PNA core may alter the hydrophobicity 
within the nanoassembly core environment. Solvato-fluorochromism may allow 
investigators to detect hydrophobicity changes of the PNA core environment in real time 
indicating drug release. By combining fluorescence measurements of drug release with 
the biodistribution of PNAs, the ADME of anticancer drugs in patients may be estimated 
in real time (54).  
 The halo-fluorochromism of PNAs can allow researchers to improve the 
sensitivity and accuracy of metastatic tumor detection by increasing the fluorescence 
signals of PNAs accumulated in the acidic tumor microenvironment (Figure 1.1C). The 
rapid glucose metabolism of cancer cells in tumors generates acidic by-products, such as 
lactic acid, that are transported into the extracellular space of tumors (55). The 
acidification of the extracellular tumor microenvironment, also known as the Warburg 
effect, has been observed in tumors with various sizes, shapes, locations and biological 
properties (56, 57). By detecting the acidity of the tumor microenvironment, clinicians 
can select anticancer drugs that remain effective in the tumor microenvironment 
conditions of patients (58, 59). 
 The fluorochromism of PNAs can also allow investigators to identify methods of 
sustaining drug release and increasing the activity of anticancer drugs in cancer cells. 
Sustained drug release from PNAs has improved cancer treatment efficacy by 
maintaining effective drug concentrations in tumors, priming tumors for effective future 
treatments and preventing cancer cells from developing resistance mechanisms (60-63). 
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Unfortunately, the relationship between nanoassembly core environment properties and 
drug release rates is difficult to determine (64). Solvato-fluorochromism may allow 
researchers to identify specific chemical properties within the nanoassembly core 
environment that control drug release profiles. By carefully considering the solvato-
fluorochromic characterization of the nanoassembly core environment, the therapeutic 
properties of PNAs may be improved in order to enhance the clinical efficacy of drug-
loaded polymer nanoassemblies for cancer treatment. 
 Therefore, the overall goal of this research is to synthesize fluorochromic PNAs 
and evaluate their potential for cancer theranostics. First, several fluorochromic PNAs are 
synthesized and their fluorescence properties are characterized. Measurement conditions 
for both halo- and solvato-fluorochromism are determined, and the necessary conditions 
for separating halo- and solvato-fluorochromism in experimental measurements are 
determined. Next, the diagnostic capabilities of fluorochromic PNAs for metastatic tumor 
detection and drug release measurement are evaluated. Finally, the therapeutic potential 
of PNAs to control drug release and sustain drug activity in cancer cells is determined. 
The results from this work may indicate the potential of fluorochromism as a beneficial 
approach for cancer theranostics. 
 
**Portions of Chapter 1 were previously published in (65). Reproduced with permission 
from Future Science Group: Therapeutic Delivery, Volume 6, Issue 10, 2015, Pages 
1221-1237, Figure 1 and Introduction. Copyright 2015 is given to the publication in 
which the material was originally published. 
Copyright (C) Derek Reichel 2017  
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2   SYNTHESIS AND CHARACTERIZATION OF POLYMER 
NANOASSEMBLIES WITH FLUOROCHROMISM 
2.1  Introduction 
 The development of PNAs with fluorochromism may improve cancer theranostics 
and decrease patient mortality, but fluorochromic dyes must be selected carefully to 
maximize their potential for theranostics. The theranostic applications of nanoparticles 
labelled with traditional fluorescent dyes are often limited by free dye impurities, which 
increase fluorescence background signals and reduce the fluorescence signals of 
nanoparticles in fluorescence images (66). Fluorescence signals from fluorochromic dyes 
should enable researchers to reduce signals from free dye impurities and enhance signals 
from entrapped dyes. The fluorochromism of dyes should also be detectable by 
fluorescence imaging systems used in the clinic. The fluorescence properties of these 
dyes should allow investigators to distinguish between the effects of halo- and solvato-
fluorochromism in fluorescence measurements. In order to account for signal fluctuations 
due to concentration changes of PNAs, fluorochromic dyes should also allow for an 
internal standard measurement condition (67). The fluorochromic properties of dyes must 
be carefully considered in order to design PNAs that enable the monitoring of the 
chemical properties within the nanoassembly core environment.  
 The chemical composition of the nanoassembly core could affect the 
fluorochromic properties of the dyes and prevent the sensitive monitoring of the 
nanoassembly core environment. For example, interactions between fluorochromic dyes 
and the polymer scaffold in the PNA core could prevent dyes from sensing the 
surrounding environment. Charged groups could also draw ionized or polar molecules 
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into the nanoassembly core and decrease the hydrophobicity of the nanoassembly core 
environment. In addition, hydrophobic groups within the nanoassembly core may also 
interfere with the ionization of dyes necessary for halo-fluorochromism (68). 
Hydrophobic groups in the nanoassembly core can also shield dyes from interactions with 
other hydrophobic molecules in the nanoassembly core. Therefore, polymer 
nanoassemblies with controlled core environments can allow investigators to elucidate 
the effects of the nanoassembly core environment on the fluorochromism of dyes. 
Nile Blue (NB) is a halo- and solvato-fluorochromic dye that emits strong 
fluorescence in nonpolar and acidic solvents, but its fluorescence is quenched in water 
(69). Fluorescence quenching of NB in water can minimize the background fluorescence 
signals of potential free dye impurities. NB has fluorescence excitation and emission 
wavelengths in the near-infrared light range, which is a commonly desired optical 
property for biomedical imaging applications of fluorescent dyes (70). Despite the 
beneficial optical properties of NB for biomedical imaging, free NB can be quickly 
removed from the body quickly through renal clearance, which limits its imaging 
applications (71). Because polymeric nanoparticles are typically larger than the pores on 
renal glomeruli, NB conjugation to the core of PNAs can prevent the renal clearance of 
dyes and enhance its capabilities for the theranostics of metastatic tumors. 
 PNAs with a controlled core environment can be developed by tethering 
hydrophilic polymers and hydrophobic groups to a modifiable polymer scaffold. By 
following this approach, simple, unimolecular nanoparticles with a hydrophobic core and 
a hydrophilic shell can be created to entrap hydrophobic anticancer drugs. In addition, 
fluorochromic dyes can be tethered to the polymer scaffold in the nanoassembly core. 
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Stable chemical bonds prevent fluorochromic dyes from diffusing out of the 
nanoassembly core and reducing the fluorescence signals from PNAs. The unimolecular 
design of PNAs prevents the nanoassembly core from dissociating at low concentrations 
and exposing fluorochromic dyes to the surrounding aqueous environment. The chemical 
conjugation of fluorochromic dyes to the polymer scaffold is expected to maintain an 
ordered arrangement of dye molecules near the primary amines on the polymer scaffold.  
The random distribution of functional groups onto the polymer scaffold following 
conjugation reactions should keep the dyes in contact with pendant groups in the core of 
the PNAs. Therefore, it is hypothesized that modulating the design parameters of PNAs 
can control the fluorochromic properties of entrapped dyes.  
 The purposes of this study are to confirm the feasibility of monitoring the 
nanoparticle core environment of PNAs with fluorochromism and to determine the 
effects of PNA core environment properties on halo- and solvato-fluorochromism. 
Polymer nanoassemblies were synthesized by tethering the hydrophilic polymer 
poly(ethylene glycol) (PEG) and the hydrophobic pendant palmitate (PAL) group onto a 
cationic polymer scaffold [poly(ethylene imine) (PEI) or poly(L-lysine) (PLL)] while 
modifying the core of the nanoassemblies with the fluorochromic dye NB. In addition, 
the remaining primary amines on PLL-based PNAs were end-capped by reacting the 
PNAs with acetic anhydride (AA). The simple design of these PNAs allowed the effects 
of PNA core environment properties on the optical properties of NB-conjugated PNAs to 
be elucidated. Four types of PNAs were used in this study: PEG-PEI-NB (2PN), PEG-
PEI-PAL-NB (3PN), PEG-PLL-PAL-NB (3P’N) and PEG-PLL-PAL-NB-AA (3P’NAA). 
2PN has ionizable groups in the core that can attract water and reduce NB fluorescence, 
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while 3PN has a hydrophobic core to increase the entrapment of hydrophobic anticancer 
drugs. 3P’N and 3P’NAA had fewer and no remaining amines in the nanoassembly core, 
respectively. By comparing the fluorochromism of 2PN and 3PN, the effects of 
hydrophobic groups on fluorochromism can be determined. In addition, by comparing the 
fluorochromism of 3PN to 3P’N or 3P’NAA, the effects of scaffold amines on 
fluorochromism can be investigated. The model anticancer drug carfilzomib (CFZ) was 
selected for this study as a clinically relevant, non-fluorescent, poorly soluble (5-10 μM 
in water) and lipophilic molecule (logP=4.2). Figure 2.1 contains the chemical structure 
of CFZ. A further description of the clinical applications of CFZ for cancer treatment is 
included in chapter 6.  
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Figure 2.1. Chemical structure of carfilzomib. 
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2.2  Materials and Methods 
2.2.1  Materials 
 α-Succinimidyloxysuccinyl-ω-methoxy-poly(ethylene glycol) (NHS-activated 
PEG, 5 kDa) was purchased from NanoCS (New York, NY). Branched PEI, PLL (15-30 
kDa), chloroacetyl chloride, palmitoyl chloride and acetic anhydride were purchased 
from Sigma Aldrich (St. Louis, MO). Acridine orange (AO), NB sulfate, HEPES buffer 
(pH 8.0, 1 M), phosphate buffered saline (PBS, pH 7.4, 150 mM), acetone, DMF, DMSO, 
ethanol, isopropanol (IPA), methanol, N-Methyl-2-pyrrolidone (NMP), pyridine, 
tetrahydrofuran (THF), and dialysis membrane with molecular weight cut-off (MWCO) 
of 8 and 100 kDa were purchased from Fisher Scientific (Waltham, MA). CFZ was 
purchased from LC Laboratories (Woburn, MA).  
2.2.2  Synthesis of Fluorochromic PNAs 
 PEI- and PLL-based PNAs were synthesized following the scheme in Figure 2.1. 
Before the reactions, branched PEI was dialyzed for 24 hours in water using a 100 kDa 
MWCO membrane in order to remove small impurities (72). PLL was also dialyzed for 
24 hours in basic solution using a 6-8 kDa MWCO membrane in order to remove 
bromide salts. All other reagents were used as provided. PEI (934.6 mg) was reacted with 
NHS-activated PEG (10.0 g) in a mixed solution of DMSO and HEPES (1:1) at room 
temperature for 2 days. The reaction product PEG-PEI (2P, 73.2% mass yield) was 
purified by dialysis in water for 5 days using a 100 kDa MWCO membrane and then 
collected after freeze drying. A portion of the product PEG-PEI (4.0 g) was reacted with 
palmitoyl chloride (900 μl) in THF at 40 °C for 2 hours.  Pyridine (1.8 ml) was added 
after 30 minutes to neutralize hydrochloric acid by-products by forming THF-insoluble 
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pyridinium salts. The reaction product PEG-PEI-PAL (3P, 85.7% mass yield) was 
purified by ether precipitation and dialysis and then collected after freeze drying. 2PN 
and 3PN were synthesized following a two-step coupling reaction scheme. First, 2P and 
3P (2.0 g each) were reacted with chloroacetyl chloride (300 μl for 2P, and 200 μl for 3P) 
in THF at 40 °C for 2 hours. Next, NB was dissolved in DMF at 10 mg/ml and added to 
the reaction solution (685.4 mg for 2P, and 457.0 mg for 3P). The temperature was 
increased to 60 °C and the reaction continued for 3 additional hours. Pyridine (300 μl for 
2P, and 200 μl for 3P) was added 30 minutes after adding NB to neutralize hydrochloric 
acid by-products. Reaction products 2PN (78.3% mass yield) and 3PN (87.0% mass 
yield) were purified by dialysis in a mixed solution of methanol and water (9:1) for 3 
days, followed by dialysis in pure water for an additional 3 days. The purified reaction 
products were then collected after freeze drying. The removal of free dyes and other 
impurities from 2PN and 3PN was confirmed by absence of small molecule peaks on Gel 
Permeation Chromatography (GPC, Asahipak GF-7M column, 300 mm length, 7.5 mm 
internal diameter, 7 μm particle size, 40 °C, peaks with >15 minute retention time, 200 
nm, PBS at pH 7.4, 0.5 ml/min) and a NB peak on High Performance Liquid 
Chromatography (HPLC, Agilent Eclipse XDB-C18 column, 150 mm length, 4.6 mm 
internal diameter, 5 μm particle size, 40 °C, 5.85 min, 600 nm, gradient elution from 10% 
ACN to 90% ACN, 1.0 ml/min). The chemical compositions of 2PN and 3PN were 
determined by proton NMR spectroscopy (Varian 400 MHz, DMSO-d6) and described in 
the results section (73). NB conjugation was confirmed by measuring the absorbance and 
fluorescence of 2PN (Ex 640/Em 680) and 3PN (Ex 600/Em 630) with a microplate 
reader (SpectraMax M5, Sunnyvale, CA). In addition, NB conjugation was further 
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confirmed by comparing the molecular weight of PNAs to a calibration curve of PEG 
standards with known molecular weights (74). By comparing the molecular weights of 
2PN and 3PN with intermediates 2P and 3P, respectively, the mass substitution of NB 
can be determined and the molar substitution of NB can be calculated. 
 PLL-based PNAs were also synthesized following Figure 2.2. PLL (183.6 mg) 
was reacted with NHS-activated PEG (2.0 g) in a mixed solution of water, DMSO and 
pyridine (2:1:1) at room temperature for 2 days. The reaction product PEG-PLL (2P’) 
was purified by dialysis in water for 5 days using a 100 kDa MWCO membrane, and then 
collected after freeze drying. PEG-PLL (1 g) was reacted with palmitoyl chloride (500 μl) 
in THF at 40 °C for 2 hours.  Pyridine (500 μl) was added after 30 minutes to neutralize 
hydrochloric acid by-products. The reaction product PEG-PLL-PAL (3P’) was purified 
by ether precipitation and dialysis, and then collected after freeze drying. 3P’N was 
synthesized following a two-step coupling reaction scheme. First, a portion of 3P’ (200 
mg) was reacted with chloroacetyl chloride (50 μl) in THF at 40 °C for 2 hours. Next, NB 
(266.8 mg) was dissolved in DMF at 10 mg/ml and added to the reaction solution. The 
temperature was increased to 60 °C and the reaction was continued for 3 additional hours. 
Pyridine (50 μl) was added 30 minutes after adding NB to neutralize hydrochloric acid 
by-products. The reaction product PEG-PLL-PAL-NB (3P’N) was purified by dialysis in 
methanol for 14 days, followed by dialysis in pure water for an additional 3 days. 
Purified 3P’N was collected after freeze drying. Some 3P’N (145 mg) was reacted with 
acetic anhydride (50 μl) overnight in DMSO. The reaction product PEG-PLL-PAL-NB-
AA (3P’NAA) was purified by dialysis in pure water for 2 days and collected after freeze 
drying. The removal of free dyes and other impurities from 3P’N and 3P’NAA was 
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confirmed by GPC and HPLC as described for 2PN and 3PN. Chemical compositions of 
3P’N and 3P’NAA were also determined by NMR spectroscopy and described in the 
results section. NB conjugation was further confirmed by absorbance and fluorescence 
spectroscopy.  
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Figure 2.2. Synthesis protocols for PEI-based PNAs with an ionic (2PN) or mostly 
hydrophobic core (3PN) and PLL-based PNAs with a reduced amine (3P’N) or negligible 
amine (3P’NAA) content in the nanoassembly core. 
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2.2.3  Physicochemical Characterization of Fluorochromic PNAs 
 The diameter and surface charge of PNAs were determined using dynamic light 
scattering (DLS, Zeta-sizer Nano, Malvern, UK). Hydrodynamic diameters were 
determined by measuring 173 degree back-scattered light from a He-Ne laser (4 mW, 633 
nm), and calculated using the Stokes-Einstein equation. Diameters were determined from 
number size distribution histograms. Zeta potentials were determined by measuring 
scattered light while applying voltage (automatic voltage selection), and calculated from 
light scattering data using the Smoluchowski equation. The molecular weight and 
uniformity of PNAs were determined by GPC. 
2.2.4  Evaluation of the Fluorochromic Properties of Nile Blue 
 NB was dissolved in various solvents used for biological assays and chemical 
reactions: deionized water, methanol, ethanol, THF, IPA, DMF, acetone, DMSO, 
pyridine, and NMP. Changes in light absorbance and fluorescence at various excitation 
(Ex) and emission (Em) wavelengths were determined for NB in various solvents. NB 
solutions (200 μl, 100 μg/ml) were added into clear glass vials for optical imaging. To 
determine the fluorescent properties of NB, NB solutions were serially diluted (250, 125, 
and 62.5 ng/ml) and imaged over a wide range of excitation and emission wavelengths 
(500 nm Ex/620 nm Em, 605 nm Ex/660 nm Em, and 640 nm Ex/700 nm Em) using an 
IVIS Spectrum imaging system (Caliper Life Sciences, Hopkinton, MA).  
2.2.5 Quantification of the Fluorochromic Properties of Poly(ethylenimine)-based PNAs 
 The fluorochromic properties of PNAs were determined in response to both drug 
loading and solution pH. In order to measure the effects of drug loading on 
fluorochromism, PNAs were loaded with CFZ by mixing drug and PNA solutions in 
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organic solvent and evaporating the solvent under reduced pressure. Drug-loaded PNAs 
were then reconstituted in water and centrifuged to remove free drug and other insoluble 
impurities. Drug loading of PNAs was verified by HPLC (Agilent Eclipse XDB-C18 
column, 55:45 v/v acetonitrile/water with 0.1% formic acid mobile phase, 1 ml/min, 40 
°C, 200 nm, 2.01 min retention time). The drug loading efficiency was defined as the 
weight percent ratio of drug to total formulation.  
 PNAs (10 mg/ml) with and without CFZ were dispersed in 50 mM buffer 
solutions at pH 7.4, 7.0, 6.0 and 5.0. Free dyes [NB (2 μg/ml) and AO (1 μg/ml)] were 
also dissolved in buffer solutions with and without suspended CFZ (1 mg/ml). Each 
solution (100 μl) was added to a 96 well plate and analyzed using fluorescence emission 
spectroscopy at multiple excitation wavelengths to determine the optimal fluorescence 
excitation and emission wavelength pairs. Two pairs were further imaged using a plate 
reader (500 nm Ex/600 nm Em and 640 nm Ex/680 nm Em) and an IVIS (500 nm Ex/620 
nm Em and 640 nm Ex/700 nm Em). Non-fluorescence of CFZ (1 mg/ml, ethanol) was 
verified by measuring fluorescence emission spectra for several excitation values 
between 400 and 700 nm.  
2.2.6 Evaluation of the Fluorochromic Properties of Poly(L-Lysine)-Based PNAs 
 PLL-based PNAs (10 mg/ml) with and without CFZ were dispersed in 50 mM 
buffer solutions at pH 7.4, 7.0, 6.0 and 5.0. Each solution (100 μl) was added to a 96 well 
plate and analyzed using fluorescence emission spectroscopy at multiple excitation 
wavelengths to determine optimal fluorescence excitation and emission pairs. These pairs 
were further imaged using an IVIS (640 nm Ex/680 nm Em and 675 nm Ex/720 nm Em).  
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2.2.7 Statistics 
 All values in figures are reported as mean±standard deviation for three 
measurements unless otherwise reported. Groups of measurements were compared by a 
one-way ANOVA with Bonferroni’s post-test correction, and pairs of measurements 
were compared by a Student’s t test unless otherwise noted. Statistical significance in 
each figure or table is indicated by * (p<0.05), ** (p<0.01) or *** (p<0.001). 
2.3  Results 
2.3.1  Synthesis of PNAs with a Hydrophobic, Ionic or Non-Ionic Core Environment 
 PEI-based PNAs were synthesized as described previously in Figure 2.2. Free NB 
was difficult to purify from NB-conjugated PNA solutions using traditional dialysis 
methods, because amphiphilic dye molecules bound to hydrophobic components of the 
nanoassemblies. However, the complete removal of amphiphilic NB from PNA solutions 
was achieved by dialysis using a 9:1 mixed solution of methanol and water. The absence 
of free NB in PNA solutions was further confirmed by performing centrifugal filtration 
with aliquots of the PNA solutions. The absorbance and fluorescence of each filtrate was 
measured to detect free NB filtered from the samples. Similar absorbance and 
fluorescence values between filtrates and deionized water indicated the complete removal 
of free NB from the PNA solutions. 
 PLL-based PNAs were synthesized as described in Figure 2.2. The complete 
removal of free NB from PNA solutions was achieved by dialysis using pure methanol. 
The absence of free NB in PLL-based PNAs was confirmed by following the method 
described in the previous paragraph. Because PLL-based PNAs were synthesized to 
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evaluate the effects of polymer scaffold amine on fluorochromism of PNAs, the physical 
properties of these PNAs were not analyzed in full detail. 
 PEG and PAL conjugation were further confirmed by NMR spectroscopy. Due to 
overlapping DMSO and PEI peaks, the area of peaks on the PEI scaffold with shifts 
between 2.4 and 2.6 ppm could not be accurately quantified. 2PN and 3PN had NMR 
peaks corresponding to PEG (3.54 ppm, s, relative area 1.000) and PEI (2.32 ppm, s, 
relative area 0.017; 2.44 ppm, s; 2.55 ppm, s; 2.60 ppm, s; 2.66 ppm, s, relative area 
0.019). In addition, 3PN had NMR peaks corresponding to PAL (0.83 ppm, d, relative 
area 0.022; 1.20 ppm, s, relative area 0.082). 3P’N and 3P’NAA had NMR peaks 
corresponding to PEG (3.54 ppm, s, relative area 1.000), PLL (2.23 ppm, m, relative area 
0.0013; 2.60 ppm, s, relative area 0.0005; 2.68 ppm, s, relative area 0.0008; 2.97 ppm, s, 
relative area 0.0009; 3.24 ppm, s, relative area 0.0114; 3.68 ppm, s, relative area 0.027; 
4.09 ppm, s, relative area 0.040; 7.78 ppm, s, relative area 0.009), and PAL (0.83 ppm, d, 
relative area 0.002; 1.23 ppm, s, relative area 0.027; 1.46 ppm, s, relative area 0.009). 
3P’NAA also had a peak corresponding to AA (1.78 ppm, s, relative area 0.024). 
 Based on a comparison of the NMR peak areas of each PNA component to the 
polymer scaffold, the molar substitution percent of each component to the initial moles of 
primary amines of the polymer scaffold (defined as the molar substitution) was 
calculated. Based on the analysis of Qiu et al., a 2.5% coefficient of variation was 
assumed for each measurement in order to account for error due to NMR accuracy (75). 
The molar substitution of PEG on 2PN and 3PN was 10.0±0.3%, while the molar 
substitution of PAL on 3PN was 55.0±1.4%. In addition, the molar substitution of PEG 
on 3P’N and 3P’NAA was 25.0±0.6%, while the molar substitution of PAL on 3P’N and 
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3P’NAA was 37.0±0.9%. The molar substitution of AA on 3P’NAA was 17.0±0.4%. In 
addition, the molar substitution percent of each component relative to the remaining 
moles of primary amines on the polymer scaffold before the reaction (defined as the 
molar substitution yield) was calculated for AA. The molar substitution yield of AA on 
3P’NAA was greater than 99%, indicating a complete substitution of the remaining 
primary amines. 
2.3.2 Diameters and Surface Charges of PNAs are not Controlled by the Nanoassembly 
Core Environment 
 Diameter and zeta potential measurements of 2PN and 3PN confirmed that PNAs 
were less than 40 nm in diameter and had a neutral surface charge (Table 2.1), which was 
similar to the physical properties of unlabeled PNAs 2P and 3P, respectively (76). PNAs 
have a smaller diameter (40 nm) than the pore size of the GPC resin (7 μm). Based on the 
neutral surface charge of PNAs (ζ<±30 mV), PNAs could due to van der Waals 
interactions (77). However, histograms from all DLS measurements were unimodal and 
had narrow size distributions. In addition, 2PN and 3PN maintained consistent diameters 
and at multiple concentrations, suggesting that PNAs remain unimolecular in solution at 
the concentrations used in this study likely due to the PEG shell. These results indicate 
that NB and palmitate substitution do not affect the diameter of PNAs and that the PEG 
shell efficiently shielded the charge, dyes, and hydrophobic groups within the core. 
Polydispersity measurements indicate that 3PN has a greater size distribution than 2PN, 
but GPC measurements (Figure 2.3) suggest that both PNAs have narrow size ranges. 
This observation suggests that weak interactions between PNAs and the GPC column 
may limit the accuracy of size distribution measurements from GPC compared to DLS.  
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Table 2.1. Physicochemical properties of 2PN and 3PN. 
PNA Diameter (nm) Zeta Potential (mV) 
Polydispersity Index 
(PDI) (unitless) 
Drug Loading 
Efficiency (%) 
2PN 26.5±8.8 -0.6±0.4 0.32±0.04** 3.0±0.1** 
3PN 34.3±3.5 -1.3±0.3 0.69±0.07** 8.7±0.4** 
PNA PEG (mol/mol primary amine on scaffold) (%) 
PAL (mol/mol primary 
amine on scaffold) (%) 
NB (mol/mol primary 
amine on scaffold) (%) 
2PN 10.0±0.3 --- 50±1.0*** 
3PN 10.0±0.3 55.0±1.4 25±0.5*** 
Diameter, zeta potential, PDI and drug loading efficiency are reported as mean±SD 
(n=3) for DLS or HPLC. PEG, PAL and NB substitution are reported as 
measurement±SE from the measurement error for NMR or GPC (n=1). PAL was not 
detectable on 2PN. Statistical significance is determined with a Student’s t test as 
described in the methods section. 
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Figure 2.3. Gel permeation chromatographs for 2PN (A) and 3PN (B). Chromatographs 
were measured by UV-visible absorbance detector at 220 nm.  
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GPC further indicated that PNAs were larger than their individual components 
and free of impurities from each component. Based on molecular weight comparisons of 
PNAs to PEG standards, the molecular weights of 2PN and 3PN were 165 and 176 kDa, 
respectively. The molecular weights of intermediates 2P and 3P were also determined to 
be 129 and 159 kDa, respectively. By comparing the molecular weights of each 
component to the available primary amines on PEI, the substitution yield of each 
component on PNA could be calculated and compared to the NMR quantification. For 
2PN, approximately 10% of the binding sites were substituted with PEG. For 3PN, 
approximately 10% and 55% of binding sites on PEI were substituted with PEG and 
PAL, respectively. GPC also allowed the estimation of the molar substitution of NB to 
2PN and 3PN. Due to the fluorochromic effects of NB, quantification of NB molar 
substitution based on spectroscopic comparisons of free NB to NB-conjugated PNAs may 
introduce measurement error and indicate false substitution values. Based on a 
comparison of the molecular weights of 2PN and 3PN to 2P and 3P, respectively, 2PN 
had 50% NB molar substitution while 3PN had 25% NB molar substitution. After 
normalizing these measurements to the amount of remaining primary amines on 2PN and 
3PN, 2PN had a 55% molar substitution yield of NB and 3PN had a 71% molar 
substitution yield of NB. Although palmitate substitution decreased the available binding 
sites for NB conjugation, the hydrophobic core environment increased the reaction yield 
for the remaining binding sites. For 2PN and 3PN, substitution yields calculated by GPC 
were in agreement with calculated NMR substitution yields.  
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2.3.3  Solvato-Fluorochromic Properties of Nile Blue are Sensitive to Non-Polar 
Solvent Environments  
 Figure 2.4 shows the optical properties of NB in various solvents. NB was blue in 
water, methanol, ethanol, IPA, and acetone; purple in DMSO; pale pink in THF; and 
bright pink in DMF, pyridine, and NMP (Figures 2.4A-B). There were no precipitates in 
any of the samples. Similar to the color properties of NB, the fluorescence of NB 
changed in a solvent-dependent manner based on excitation wavelength and decreased 
linearly as dye concentration decreased. At 500 nm Ex, NB fluoresced strongly in DMF, 
and weakly in acetone, pyridine and NMP (Figure 2.4C). At 605 nm Ex, NB fluoresced 
strongly in ethanol, methanol and IPA and fluoresced weakly in DMSO (Figure 2.4D). At 
640 nm Ex, NB fluoresced strongly in DMSO and weakly in ethanol, methanol and IPA 
(Figure 2.4E). Importantly, the fluorescence of NB in water remained undetectable under 
all conditions tested in this study (Figures 2.4C-E). It should be noted that weak 
fluorescence of NB can be detected in water at high concentrations (>1 μg/ml), but the 
fluorescence decreases at high concentrations due to dye aggregation. The fluorescence 
properties of NB in cell media were similar to fluorescence of NB in water, suggesting 
that interactions with small molecules in cell media do not prevent the fluorescence 
quenching of NB. Similar to NB in various organic solvents (Figure 2.4A), NB-
conjugated PNAs in water had red-shifted fluorescence compared to free NB in water. 
3PN with a hydrophobic core had stronger fluorescence than 2PN with a hydrophilic core 
that can attract water and quench NB fluorescence. 2PN also showed a minor red shift 
and fluoresced stronger than free NB. These results indicate that the hydrophobicity of 
the NB solvent environment increases in order of water, 2PN core and 3PN core.    
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Figure 2.4. Optical properties of Nile Blue in various solvents at high (A) and low 
concentrations (B). Fluorescence was measured under three detection conditions (C, D, 
and E) with varying excitation (Ex) and emission (Em) wavelengths at concentrations 
from part (B).  
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2.3.4  Halo-Fluorochromic Properties of Nile Blue are Sensitive to Acidic Solvent 
Environments 
 Figure 2.5 shows the optical properties of PNAs and free dyes as measured by an 
IVIS. AO, a common biological indicator for acidic lysosomes, was used as a control for 
the fluorescence quenching effects of NB in water. At 500 nm excitation (Ex) and 620 
nm emission (Em), the fluorescence intensity of AO increased below pH 6.0. At 640 nm 
Ex/700 nm Em, the fluorescence intensity of NB increased below pH 6.0. The 
fluorescence of AO and NB was minimally affected by suspended drug. It should be 
noted that the maximum and minimum fluorescence intensity threshold values are 
different in fluorescence images with and without drug. As a result, the fluorescence of 
AO and NB appear to decrease in the presence of drug, but plate reader measurements 
confirmed that the differences in fluorescence with and without drug were not statistically 
significant. In contrast to free dyes, fluorochromic PNAs allowed for the simultaneous 
detection of both pH and core hydrophobicity. These results suggest that the fluorescence 
properties of NB in the core of PNAs behaved as an environmental sensor, but that 
interactions with drug molecules did not interfere with the halo-fluorochromism of NB at 
640 nm Ex and 700 nm Em. IVIS quantification indicates that pH-dependent differences 
in the fluorescence of PNAs are significant enough to detect ex vivo. In order to 
quantitatively evaluate the fluorochromism of PNAs, the fluorescence of PNAs was also 
quantified using a plate reader. 
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Figure 2.5. Fluorescence excitation (Ex) and emission (Em) wavelength-dependent 
fluorochromic properties of free dyes (AO and NB) and PNAs with and without the model 
drug carfilzomib. The relative fluorescence values for each image are on the right. 
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2.3.5 Entrapment of Nile Blue in the Nanoassembly Core Enables the Fluorochromism 
of Poly(ethylenimine)-Based PNAs 
 Figure 2.6 shows pH-dependent changes in the fluorescence of PNAs, as 
quantified by a plate reader. These quantitative results confirmed the fluorescence 
behavior of PNAs in Figure 2.5. Empty 2PN and 3PN had pH-insensitive fluorescence 
properties at 500 nm Ex and 600 nm Em, but demonstrated pH-sensitive fluorescence 
properties at 640 nm Ex and 680 nm Em. Specifically, empty 2PN demonstrated 
decreased fluorescence as the pH decreased, but the fluorescence of empty 3PN increased 
as the pH decreased. Drug-loaded PNAs exhibited increased fluorescence at 500 nm Ex 
and 600 nm Em compared to empty PNAs. However, the fluorescence of drug-loaded 
3PN decreased in acidic conditions, presumably due to changes in the molecular 
conformation or ionization state of CFZ in the core of PNAs. CFZ ionization may also 
draw water into the core of PNAs and decrease NB fluorescence. Both empty and drug-
loaded 2PN and 3PN showed pH-dependent differences in fluorescence at 640 nm Ex and 
680 nm Em. 2PN demonstrated gradually decreased fluorescence as pH decreased, but 
the fluorescence of 3PN increased as pH decreased. Drug-loaded PNAs had minimal 
fluorescence changes compared to empty PNAs at 640 nm Ex and 680 nm Em. Based on 
IVIS observations and plate reader quantification, 3PN was selected for further ex vivo 
imaging studies in chapter 3. 
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Figure 2.6. Quantification of the fluorochromic properties of 2PN and 3PN (10 mg/ml) 
by fluorescence spectroscopy. The fluorescence of the PNAs was measured with and 
without the model drug carfilzomib.  
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2.3.6  Removal of Ionic Moieties from the Polymer Scaffold Reduces the 
Fluorochromism of Poly(L-Lysine)-Based PNAs 
 Figure 2.7 shows the fluorescence properties of PNAs without scaffold amines. 
Unfortunately, the fluorescence of 3P’N at concentrations up to 10 mg/ml could not be 
quantified using an IVIS or a plate reader due to weak PNA fluorescence. This 
observation indicates that the polymer scaffold affects the fluorescence properties of 
fluorochromic dyes in the core of PNAs. As a result, the fluorochromism of 3P’N was not 
investigated in detail. In contrast to 3P’N, the fluorescence of 3P’NAA could be detected 
by an IVIS. However, the fluorescence of 3P’NAA could not be detected by a plate 
reader due to a weak signal compared to 2PN or 3PN at a similar concentration. In 
comparison to 2PN and 3PN that changed fluorescence intensities and wavelengths in 
response to changes in pH and core hydrophobicity, 3P’NAA fluorescence was consistent 
in response to changes in pH and drug loading. Figure 2.8 shows the quantification of 
3P’NAA fluorescence. At 640 nm Ex and 680 nm Em, changes in fluorescence of 
3P’NAA in response to drug loading or pH are not statistically significant. In addition, at 
675 nm Ex and 725 nm Em, the fluorescence of drug-loaded 3P’NAA decreased at pH 
6.0 compared to drug-loaded 3P’NAA at other pH values. There were no overall trends in 
3P’NAA fluorescence in response to pH, but drug loading increased the fluorescence of 
3P’NAA by 21% at 675 nm Ex and 725 nm Em compared to empty 3P’NAA. Because 
the halo- and solvato-fluorochromism of 3P’NAA were minimal compared to 2PN and 
3PN, the applications of 3P’NAA were not further considered.  
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Figure 2.7. Fluorescence excitation (Ex) and emission (Em) wavelength-dependent 
fluorescence properties of 3P’NAA (10 mg/ml) at various pH values with and without the 
model drug carfilzomib.   
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Figure 2.8. Quantification of the non-fluorochromic properties of 3P’NAA using IVIS. 
3P’NAA was used at 10 mg/ml for all measurements. The Fluorescence of 3P’NAA was 
measured with and without the model drug carfilzomib. 
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2.4  Discussion 
2.4.1 PNAs were Synthesized by Bioconjugation Chemistry 
 PNAs were synthesized by tethering polymers and pendant groups to a polymer 
scaffold. In all of the studies throughout this dissertation, PNAs were synthesized in a 
single batch in order to avoid any batch-to-batch variations in the molar substitution of 
polymers or pendant groups. However, the future applications of PNAs would require the 
synthesis of additional batches of PNAs with similar properties. In order to tether 
polymers and pendant groups to the scaffold, NHS ester-activated PEG and acyl-chloride 
activated palmitate molecules were reacted with primary amines on the polymer 
scaffolds. The reaction of ester-activated carboxylic acids with primary amines is called 
transesterification. Transesterification reactions are commonly used in bioconjugation 
chemistry due to their versatility, reliability and biocompatibility (78). In addition, acid 
chloride groups are highly reactive with primary amines such as functional groups on the 
column. Therefore, the reactions used to produce PNAs are expected to be reliable and 
reproducible for synthesizing additional batches of PNAs. 
 The synthesis of PNAs for clinical applications requires a significant scale-up of 
the reaction, which could affect the molar substitution of polymers and pendant groups on 
the scaffold. In addition, alternative reaction schemes may be needed to replace costly 
reagents such as NHS-ester activated PEG that are used in this reaction. The scale-up of 
each reaction in this process should be carefully considered in order to assure that 
reaction yields are consistent. In addition, the variability in molar substitution of each 
component must be considered in order to determine if the dispersity of PNAs is 
acceptable for clinical applications. Although these considerations are beyond the scope 
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of this work, they are necessary to consider when evaluating the potential clinical 
applications of PNAs. 
2.4.2 Effects of the PNA Core Environment on the Fluorochromism of Nile Blue 
 Fluorochromism is an optical property of dyes that change their fluorescence 
spectra in response to environmental factors such as solvent polarity (solvato-
fluorochromism) or pH (halo-fluorochromism) (79). NB was selected as a model dye 
with fluorochromism that can change the fluorescence properties of nanoparticles 
depending on the amount of entrapped drug as well as the pH of the solvent environment. 
Other solvato-fluorochromic dyes such as pyrene have been used to detect polarity 
changes in the core environment of nanoparticles such as polymer micelles (80, 81). The 
fluorochromic properties of pyrene change slightly when the dye is entrapped in the 
nanoparticle core compared to water. By measuring the ratio of fluorescence peak 
intensities of pyrene, polarity changes of the dye environment corresponding to micelle 
entrapment can be detected. In contrast to the weak fluorochromism of pyrene, NB 
changes fluorescence significantly in solvents with different polarities. Because of this 
increased sensitivity, NB was able to detect polarity changes due to both the PNA core 
environment and hydrophobic drug loading. 
 The structure and morphology of chemical groups in the core of fluorochromic 
nanoparticles may contribute to fluorochromism of dyes. It can be assumed that pendant 
groups are randomly attached to primary amines on the polymer scaffold, and that 
hydrophilic polymers, hydrophobic groups and fluorochromic dyes are homogenously 
distributed across the scaffold. The distance between primary amines on the polymer 
scaffold prevents interactions between dye molecules that could affect fluorescence 
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spectra. The unimolecular nature of PNAs allows them to attain similar conformations in 
solution following reconstitution. Hydrophobic groups on PNAs are likely to enter the 
core environment, while hydrophilic groups remain in the shell. The shell of PNAs is 
likely composed entirely of PEG interacting with water molecules, because the high 
molecular weight of PEG compared to other pendant groups (5000 Da vs. ~300 Da) 
allow it to expand out of the core. The core of PNAs is mainly composed of NB, 
hydrophobic groups and a polymer scaffold. In addition, the core of the PNAs may 
contain end portions of PEG molecules that have refolded towards the core (82). By 
keeping the dye molecules in the core, PNAs reduce NB interactions with water that 
prevent the detection of NB fluorescence. In the core of 2PN, dye molecules can interact 
with entrapped drug molecules, PEG or amines on the PEI scaffold. In the core of 3PN, 
dye molecules can interact with entrapped drug molecules, PEG, palmitate or amines on 
the PEI scaffold. For PEI-based PNAs, NB remains close to the polymer scaffold. In 
contrast to NB in PEI-based PNAs, NB in PLL-based PNAs is attached to amines on the 
lysine side chains. As a result, NB in PLL-based PNAs may be further from the polymer 
scaffold. Therefore, the distance between dye molecules and the polymer scaffold may 
contribute to the fluorochromism of dyes.  
The hydrophobicity of the nanoassembly core environment controls both the drug 
loading of PNAs and fluorochromic properties of dyes. The addition of PAL to the 
polymer scaffold increases the drug loading of PNAs and the fluorescence intensity of 
both drug-loaded and empty PNAs. In addition, PAL causes the fluorescence of PNAs in 
acidic conditions to increase rather than decrease. A thorough comparison between 2PN 
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and 3PN indicates that the design, synthesis and chemical properties of nanoparticles are 
critical to the successful use of fluorochromic dyes for theranostics.  
The removal of amines from the polymer scaffold of PNAs decreased the 
fluorescence of NB and interfered with its fluorochromism. In comparison to 3PN with 
strong fluorescence in water, the fluorescence of 3P’N was weak and could not be 
detected by an IVIS or a plate reader. This result suggests that the PLL scaffold increases 
the water content of the PNA core compared to PEI and decreases NB fluorescence. In 
comparison to 3P’N, 3P’NAA had strong fluorescence but lacked fluorochromism. This 
observation suggests that the interactions between NB and the polymer scaffold in the 
core of PNAs contribute to fluorochromism. It should be noted that unexpected chemical 
reactions between AA and tertiary amines on NB in the PNA core could also prevent dye 
fluorochromism, but previous observations suggests that these reactions are not 
thermodynamically favorable (83).  
Halo-fluorochromic properties of molecules often depend on the ionization of 
specific chemical moieties resulting in fluorescence spectra shifts (84). The pKa values of 
these ionization processes can shift greatly depending on the solvent environment of the 
molecule (85). The addition of hydrophobic groups to the core of PNAs changed the 
halo-fluorochromic properties of 3PN compared to 2PN. While 2PN had decreased 
fluorescence intensity in acidic conditions, 3PN had increased fluorescence intensity. The 
interactions between NB and ionized moieties on PEI may cause this difference by 
shifting NB fluorescence peak wavelengths. Both drug-loaded and empty PNAs have 
similar fluorescence trends in response to acidity. This indicates that drug loading in the 
core of PNAs does not prevent NB from detecting changes in solvent acidity, and 
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suggests that PNAs have separable solvato- and halo-fluorochromic properties. However, 
the loading of ionizable drugs could affect the halo-fluorochromic properties of the 
PNAs. Therefore, the use of these PNAs should be avoided for drugs with pKa values 
between 6.0 and 7.4. 
The ionization of model drugs in the core of PNAs may contribute to the solvato-
fluorochromism of PNAs. Although empty 3PN demonstrated no halo-fluorochromism at 
500 nm Ex and 620 nm Em, carfilzomib-loaded 3PN had decreased fluorescence at pH 
6.0 and 5.0 compared to pH 7.4. The PubChem (NIH) and DrugBank (University of 
Alberta) databases report that the pKa of carfilzomib is 3.5; however, a literature analysis 
of the ionization behavior of N-substituted morpholine groups suggests that the pKa of 
carfilzomib is between 5.0 and 5.2 (86). Additionally, a European Medicines Agency 
report reports the pKa of carfilzomib to be 5.14 (87). Ionized carfilzomib in the 3PN core 
could decrease the fluorescence of 3PN and lower excitation wavelengths by decreasing 
the hydrophobicity within the nanoparticle core compared to unionized carfilzomib. 
However, additional work is needed to determine an accurate pKa value of carfilzomib in 
solution and in the nanoassembly core. 
Identifying experimental conditions to separate the effects of halo- and solvato-
fluorochromism in fluorescence measurements is necessary to evaluate the potential 
applications of fluorochromism for cancer theranostics. These results show that the 
fluorescence of 2PN and 3PN at low excitation and emission wavelengths is dependent 
on drug loading but not solvent acidity. This suggests that specific fluorescence 
excitation and emission conditions can detect drug loading and ignore solvent acidity. At 
high excitation and emission wavelengths, the fluorescence of 2PN and 3PN are 
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dependent on both drug loading and solvent acidity. Therefore, in order to measure the 
effects of solvent acidity in fluorescence measurements, empty PNAs can be used. It 
should be noted that the drug loading effects on fluorescence that are solely attributed to 
solvato-fluorochromism could be partially attributed to halo-fluorochromism if 
hydrophobic drug molecules alter the protonation behavior of NB. By measuring the 
activity of the nanoassembly core environment before and after drug loading and 
comparing activity changes to the halo-fluorochromic properties of PNAs, the specific 
effects of drug loading on both halo- and solvato-fluorochromism could be determined.  
2.4.3 Benefits of Solvato-Fluorochromism for Cancer Theranostics 
 Solvato-fluorochromism is critical to the design of nanoparticles for the detection 
of metastatic tumors. Non-fluorochromic dyes entrapped in nanoparticles allowed 
investigators to detect solid tumors, because the accumulation of dye-containing 
nanoparticles in solid tumors increased the fluorescence signals from solid tumors and 
overcame the background signals from free dyes and circulating nanoparticles (88). 
However, metastatic tumors are not expected to accumulate significant amounts of dye-
containing nanoparticles compared to solid tumors, and free dyes or circulating 
nanoparticles could interfere with fluorescence imaging (89). The results in this study 
show that NB-conjugated PNAs fluoresce stronger than free NB in water due to solvato-
fluorochromism. Because of this result, any potential fluorescence from free NB will not 
contribute significantly to overall fluorescence signals. Therefore, the development of 
nanoparticles that can minimize the fluorescence signals from free dyes and circulating 
nanoparticles, while also enhancing nanoparticle fluorescence in tumor tissue, may allow 
for the detection of metastatic tumors without interference from free dyes. 
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Solvato-fluorochromism can overcome the limitations of other fluorescence 
methods for detecting drug loading in nanoparticles. For example, florescence resonance 
energy transfer (FRET) has measured hydrophobic drug loading in nanoparticles in real 
time (90). FRET detection of drug loading requires specific energetic interactions 
between drugs and dyes in the nanoassembly core, which limits the potential 
combinations of drugs and dyes that can be used in these systems (91). Because the 
solvato-fluorochromic properties of dyes do not require hydrophobic drugs to have 
specific optical properties, fluorochromic PNAs have the potential to measure drug 
loading and release for various applications (92). However, the use of solvato-
fluorochromic dyes to measure drug release has some limitations. First, drugs that absorb 
and fluoresce light at the same wavelengths as fluorochromic PNAs may interfere with 
fluorescence measurements. Therefore, the scope of this approach must be narrowed to 
hydrophobic drugs without absorbance in the visible range of light (400-700 nm). 
Although this limits the potential applications of fluorochromism, many hydrophobic 
anticancer drugs do not absorb or fluoresce light in the visible range. Second, 
hydrophobic anticancer drugs that contain some hydrophilic moieties such as amines or 
carboxylate anions may draw water into the nanoparticle core and reduce the 
fluorescence signals of PNAs. Therefore, the chemical properties of hydrophobic drugs 
should be carefully considered to avoid drawing additional water into the PNA core. 
Although further feasibility tests are necessary in vivo, these results suggest that in situ 
determination of drug concentrations in metastatic tumors or other targeted sites might be 
possible by using fluorochromic nanoparticles. In combination with measurements of 
drug metabolism and clearance, this system has the potential to determine the ADME of a 
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drug in real time. Towards this goal, a method of normalizing fluorochromic signals with 
respect to drug carrier concentration is needed. 
2.4.4 Benefits of Halo-Fluorochromism for Cancer Theranostics 
 Fluorochromic dyes are often used to identify biological molecules in imaging 
assays. For example, acridine orange (AO) is a widely used dye to detect nucleic acids, 
because its Ex and Em maximum wavelengths change upon binding to DNA or RNA 
(93). In acidic conditions, AO also has a blue shift in excitation wavelength (94). Despite 
its imaging potential, AO cannot differentiate between metastatic tumors and normal 
tissue. NB has several advantages over fluorochromic dyes such as AO, such as the 
potential for dye conjugation to the core of PNAs and the enhanced halo-fluorochromism 
of NB following conjugation. These unique optical properties of NB allowed NB-
conjugated PNAs to provide real-time information on the amount of drugs remaining in 
the particles and solution acidity.  
PNAs entrapping fluorochromic dyes can improve the detection of metastatic 
tumors compared to traditional biomarker-based methods. Biomarker detection using 
dye-labelled antibodies or aptamers can be selective for cancer cells, but antibodies or 
aptamers may have a limited time window for imaging due to dye photobleaching (95). 
The photostability of NB has been reported in the literature (96), and the photostability of 
NB during conditions used for fluorescence detection are experimentally confirmed in 
chapter 4. In contrast to antibodies or aptamers with a limited time windows for imaging, 
nanoparticles circulating throughout the body for a prolonged period of time can extend 
the time window for clinicians to observe metastatic tumors (97). Therefore, PNAs may 
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be a beneficial tool for the sensitive detection of metastatic tumors during surgery or 
other treatments.  
Although the tissue pH of solid tumors has been measured, the detection of 
metastatic tumor tissue pH remains elusive. One of the obstacles to measuring metastatic 
tumor tissue pH is the rapid clearance and inconsistent optical properties of reporter 
molecules within the tumor tissue. In contrast to small molecules, dye-conjugated PNAs 
can accumulate in tumors and remain in tumor tissue for an extended period of time (98, 
99). Although PNAs could detect acidic conditions in vitro, further optimization of tissue 
pH detection conditions such as fluorescence signal normalization at multiple emission 
wavelengths may be needed to accurately quantify the tissue pH of the acidic tumor 
microenvironment. 
2.5  Conclusions 
 In this study, polymer nanoassemblies were synthesized by tethering hydrophilic 
polymer chains (PEG) onto cationic polymer scaffolds (PEI or PLL), followed by 
conjugation of fluorochromic molecules (NB), lipophilic chains (PAL) and amine end-
capping groups (AA) to the core of the nanoassemblies. NB was selected as a model 
fluorochromic dye because of its increased fluorescence in the PNA core compared to 
free dyes in solution and its potential for both halo- and solvato-fluorochromism. In 
comparison to 2PN with a hydrophilic core that quenched NB fluorescence, 3PN with a 
hydrophobic core showed strong fluorescence in acidic conditions or in the presence of 
the model hydrophobic anticancer drug (CFZ). In contrast to 3PN, 3P’N had weak 
fluorescence that could not be quantified, while 3P’NAA had fluorescence but lacked 
fluorochromism. These results suggest that interactions between dyes, hydrophobic drugs 
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and the polymer scaffold contribute to the fluorochromism of PNAs. The findings in this 
study suggest that further experiments with PNAs may validate their potential as 
diagnostic tools with the capability to deliver chemotherapeutic drugs to tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**Portions of Chapter 2 were previously published in (65). Reproduced with permission 
from Future Science Group: Therapeutic Delivery, Volume 6, Issue 10, 2015, Pages 
1221-1237, Figures 2-6, Methods, Results, Discussion and Conclusion. Copyright 2015 is 
given to the publication in which the material was originally published. 
Copyright (C) Derek Reichel 2017  
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3 DISTRIBUTION OF HALO-FLUOROCHROMIC POLYMER 
NANOASSEMBLIES IN NORMAL ORGANS AND SOLID TUMORS FOR THE 
DETECTION OF METASTATIC CANCER 
3.1 Introduction 
 Colorectal cancer (CRC) is the second most common cause of gender non-
specific cancer deaths for adults in the United States, but its treatment is commonly 
hindered by the lack of effective methods for the early and accurate detection of 
metastatic CRC (MCRC) (100). Although primary CRC tumors can kill patients by 
interfering with normal colon functions, metastasis accounts for 90% of CRC-related 
deaths (101). The primary site of CRC metastasis is the liver; however, liver metastatic 
CRC has the second shortest median survival time of all metastatic CRC (102). 
Unfortunately, clinically available detection methods cannot effectively distinguish small 
MCRC tumors infiltrating into the liver from healthy tissue with high accuracy. In 
comparison to primary CRC tumors that can be treated with surgery or chemotherapy, 
MCRC tumors are difficult to treat because they are surrounded by healthy cells (103). In 
addition, MCRC tumors often become resistant to chemotherapy unless they are treated 
early in their development because they contain heterogeneous cell sub-populations with 
high mutation rates (104). As MCRC tumors grow and expand, the delivery of ionizable 
drugs into MCRC tumors becomes poor due to the dense acidic tissue microenvironment 
decreasing the diffusion of ionized anticancer drugs through cancer cell membranes (58, 
59, 105). Small metastatic tumors may remain susceptible to clinically available 
micrometastatic tumor treatment methods such as neoadjuvant chemotherapy (106, 107). 
51 
Therefore, there is a need to detect small, underdeveloped MCRC tumors accurately 
before they grow too large to be treated effectively with surgery and chemotherapy. 
 Medical imaging has been used in the clinic for the non-invasive detection of 
solid tumors and tumor metastasis, but traditional imaging methods have failed to 
improve the treatment of MCRC because they cannot detect small metastatic tumors. 
Traditional medical imaging methods for tumor detection include magnetic resonance 
imaging (MRI), computerized tomography (CT), and intraoperative fluorescence imaging 
(108). MRI and CT identify structural abnormalities in normal tissue caused by tumors, 
but these methods may fail to detect small metastatic tumors that are smaller than the size 
detection limit. In order to decrease this size detection limit and detect small metastatic 
tumors, contrast agents have been developed to enhance MRI or CT signals in tumor 
tissues compared to normal tissue. Unfortunately, many contrast agents still fail to allow 
clinicians to detect small metastatic tumors that make little to no changes to tissue 
structure (109). Imaging artifacts also contribute to high false positive rates in MRI and 
CT. In contrast to MRI and CT, fluorescence imaging holds promise for the high-
resolution imaging of tumors (110). Unfortunately, most fluorescent dyes do not 
selectively accumulate in cancer cells (111). In addition, many fluorescent dyes have 
poor diagnostic properties such as low signal-to-noise ratios, high background signals, 
short half-life in tumor tissue, and rapid clearance from the blood (112). Delivery systems 
that can improve the diagnostic properties of fluorescent dyes hold promise to increase 
the sensitivity of fluorescence imaging for the detection of primary tumors and tumor 
metastasis (113). 
52 
 Nanoparticles entrapping fluorescent dyes may improve the diagnostic properties 
of fluorescent dyes and allow clinicians to detect CRC, but the effects of nanoparticle 
distribution on CRC detection are poorly understood. The accumulation of nanoparticles 
in the fenestrated vasculature surrounding primary tumors enhances fluorescence signals, 
but significant hepatic vasculature can also increase fluorescence signals in the liver 
(114). Distinguishing between fluorescence signals from primary tumors and healthy 
organs complicates tumor detection using fluorescence imaging. In addition, uneven 
diffusion of nanoparticles throughout tumor tissue due to heterogeneous sub-populations 
of cells with various cell densities and biological origins may cause clinicians to 
misidentify the size and shape of tumors (115). Heterogeneous sub-populations of cells 
create dense collagen meshes near tumor blood vessels with pore sizes of 50-100 nm 
(116, 117). Fluorescence signals from metastatic tumors may also be obscured by strong 
background fluorescence from the healthy tissue surrounding tumors. Nanoparticles 
entrapping halo-fluorochromic dyes can address these imaging limitations and detect 
small metastatic tumors by combining the indirect detection of abnormal tumor tissue 
with the direct monitoring of fluorescent dyes within tumors.  
 Based on this background, it is hypothesized that PNAs accumulate in the 
extracellular space of solid tumors and in the acidic interstitium between MCRC tumors 
and healthy cells in liver tissue (Figure 3.1). In order to test this hypothesis, the 
macroscopic and microscopic distributions of PNAs in tumor tissue were evaluated, and 
the distributions were compared to computational simulations of PNAs in metastatic 
tumors. Initially, the diffusion and opsonization of PNAs were evaluated using PNAs 
entrapping non-halo-fluorochromic dyes (IR820 and Alexa Fluor® 546). In addition, 
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cellular uptake was evaluated using halo-fluorochromic PNAs with various core 
environments. Patient-derived xenograft (PDX) models of primary CRC tumors and 
orthotopic liver MCRC tumor models were selected for this study. PDX tumor models 
reproduce the heterogeneity and microenvironment of tumors observed in the clinic 
(118), while orthotopic liver MCRC tumor models mimic metastatic tumors surrounded 
by healthy tissue in normal organs (119, 120). Orthotopic MCRC tumors also retain 
heterogeneous sub-populations of cancerous and healthy cells. Liver MCRC tumors were 
selected for this study because the liver is the primary site of CRC metastasis in patients 
(121). In addition, collaborators used a computational simulation based on a reaction-
diffusion system to model PNA distribution in a metastatic lesion. Modeling results were 
compared to fluorescence images of PNA accumulation in metastatic tumors. Key 
simulation parameters such as blood vessel density and tumor cell state (proliferating, 
hypoxic, necrotic) were calibrated from orthotopic liver MCRC tumor models (122-124). 
These simulations provide a quantitative method to evaluate the potential of halo-
fluorochromic PNAs for the early and accurate detection of metastatic tumors. By 
comparing the diffusion, cellular uptake, and aggregation of PNAs to the macroscopic 
and microscopic distribution of PNAs in solid CRC and liver MCRC tumors, the 
mechanism by which halo-fluorochromic PNAs detect MCRC tumors can be elucidated. 
Computational simulations can further validate the potential of halo-fluorochromic PNAs 
for the early and accurate detection of tumor metastasis. Results from this study will aid 
the development of halo-fluorochromic PNAs and other types of nanoparticles as useful 
tools for the early and accurate detection of MCRC tumors.   
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Figure 3.1. Graphical description of the halo-fluorochromic detection of acidic 
microenvironments (top), macroscopic and microscopic imaging of halo-fluorochromic 
PNAs in primary tumors or live MCRC tumors (middle), and computational simulations 
of PNAs in metastatic tumors (bottom). Simulations model a metastatic lesion (bottom 
left) containing blood vessels (black) and tumor with proliferating (red), hypoxic (blue) 
or necrotic (brown) regions. The model then predicts PNA distribution (bottom right, 
red)over time and quantifies PNA accumulation in each region.  
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3.2 Materials and Methods 
3.2.1  Materials and Cells 
α-Succinimidyloxysuccinyl-ω-methoxy-poly(ethylene glycol) (5 kDa, NHS-
activated PEG) was purchased from NOF America (White Plains, NY). Acetic anhydride, 
agarose, HEPES sodium salt, IR-820 sodium salt, NHS-activated Alexa Fluor® 546 dye 
(Alexa 546), palmitoyl chloride, poly(L-lysine hydrobromide) (30-70 kDa, PLL) and 
sucrose were purchased from Sigma Aldrich (St. Louis, MO). The chemical structure of 
IR-820 sodium salt is in figure 3.1. Diethyl ether, DMSO, THF, methanol, nuclear 
staining dye Hoechst 33342, pyridine, chamber slides, dialysis membrane with 3.5 or 100 
kDa MWCO, phosphate buffer solutions (50 mM, pH 7.4, 7.0 and 6.0) and preparative 
size exclusion columns (PD Minitrap, G-25, 3.5 ml) were purchased from Fisher 
Scientific (Waltham, MA). Aqueous ultramount permanent mounting medium was 
purchased from Dako (Carpinteria, CA). Optimal cutting temperature compound (OCT) 
was purchased from Andwin Scientific (Schaumburg, IL). Paraformaldehyde solution 
(4%) was purchased from Polysciences (Warrington, PA). Mouse EpCAM antibodies 
were purchased from LSBio (Seattle, WA), while mouse CD31 and donkey anti-mouse 
NL637-labelled IgG antibodies (secondary antibody) were purchased from R&D Systems 
(Minneapolis, MN). McCoy’s 5A (M5A) media, phosphate buffered saline (PBS) and 
0.05% trypsin/EDTA were purchased from GE Healthcare (Logan, UT). Fetal bovine 
serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA). Human 
CRC cell-lines (HT29 and HCT116) were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). Cells were cultured in M5A supplemented with 10% 
FBS in a humidified environment with 5% CO2 at 37 °C.  
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Figure 3.2. Chemical structure of IR-820 sodium salt. 
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3.2.2  Synthesis of Non-Halo-Fluorochromic PNAs 
PNAs were synthesized following Figure 3.3. The synthesis protocol and 
characterization of halo-fluorochromic PNAs is described in chapter 2. Non-halo-
fluorochromic PNAs are denoted as PEG-PLL-PAL-AA-IR-820 (3P’IR820) and PEG-
PLL-PAL-Alexa Fluor® 546 (3P’A546). Briefly, PLL (334.4 mg) was reacted with 
NHS-activated PEG (2.0 g) in 2:1:1 water:DMSO:pyridine at room temperature for 3 
days. PEG-PLL was purified by dialysis in water and collected after freeze drying. A 
portion of the PEG-PLL (1.0 g) was reacted with palmitoyl chloride (299 μl) at 40 °C in 
THF for 2 h. Pyridine (100 μl) was added to the reaction solution after 15 minutes to 
scavenge hydrochloric acid by-products. The product PEG-PLL-PAL was purified by 
ether precipitation and dialysis in water, and then collected after freeze drying. A portion 
of PEG-PLL-PAL (100.0 mg) was reacted with Alexa 546 (673.0 μg) at room 
temperature in DMSO overnight. The product 3P’A546 was purified using preparative 
size exclusion columns and collected after freeze drying. Another portion of the PEG-
PLL-PAL (200.0 mg) was reacted with IR-820 (542.4 mg) in methanol at 40 °C 
overnight. Pyridine (300 μl) was added to the reaction solution after 1 hour to scavenge 
hydrochloric acid by-products. The product PEG-PLL-PAL-IR-820 was purified by 
dialysis in water and collected after freeze drying. PEG-PLL-PAL-IR-820 (180.0 mg) 
was subsequently reacted with acetic anhydride (54.3 μl) at room temperature in DMSO 
to end-cap remaining primary amines on PLL. The final product 3P’IR820 was purified 
by dialysis in water and collected after freeze drying.  
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Figure 3.3. Synthesis protocol for halo-fluorochromic and non-halo-fluorochromic 
PNAs.  
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3.2.3 Physical and Optical Characterization of Non-Halo-Fluorochromic PNAs 
Chemical compositions of non-halo-fluorochromic PNAs were determined by 
proton NMR spectroscopy (Varian 400 MHz, d6-DMSO, referenced to TMS). In order to 
determine the dye conjugation of PNAs, the absorbance of dye-conjugated PNAs was 
compared to free dye standards using a plate reader (SpectraMax M5, Sunnyvale, CA). 
The size distribution and uniformity of PNAs were determined by GPC (Asahipak GF-
7M, PBS, 0.5 ml/min, 40 °C, calibrated using PEG standards). The diameter and surface 
charge of PNAs were determined by DLS (Zetasizer Nano ZS, Malvern, UK). The 
insensitivity of 3P’IR820 fluorescence to changes in drug loading and solvent pH was 
confirmed by measuring the fluorescence of PNAs (1 mg/ml) with and without 
carfilzomib loading at pH 7.4, 7.0, 6.0 and 5.0 using an IVIS (Ex 745 nm/Em 840 nm).  
3.2.4 Diffusion and Flux of PNAs in Tissue Mimics 
Agarose gels were prepared to mimic the pH and density of healthy and tumor 
tissues. These gels allowed for the direct measurement of PNA diffusion under controlled 
conditions (125). Briefly, agarose (0.5% or 1% w/v) was added to buffers (pH 7.4, 7.0 
and 6.0) and heated to prepare suspensions. Low gel density (0.5% w/v) creates pores 
mimicking extracellular space between healthy cells (200 to 500 nm), while high gel 
density (1.0% w/v) provides pores corresponding to the keratin mesh surrounding tumors 
(50 to 100 nm) (117). The acidity of gels represents healthy tissue (pH 7.4), tumor 
periphery (pH 7.0) and the tumor core (pH 6.0) (126). Agarose suspensions were then 
pipetted into 96 well plates (100 μl per well) and cooled at room temperature to create 
gels. Stock solutions of 3P’IR820 (1 mg/ml) and 3PN (10 mg/ml) were prepared in water. 
3P’IR820 solution (100 μl) was added to wells and allowed to diffuse into gels for 0.1, 
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0.5, 1, 3, 6 or 24 h at 37 °C. The solutions were removed from the wells and the 
absorbances of these gels were measured at 820 nm. The background signals of untreated 
wells were subtracted from the measurements and the corrected signal was normalized to 
absorbance of 100 μl of 3P’IR820 solution. In an attempt to mimic interarterial pressure 
forcing PNAs into liver stroma, diffusion experiments were repeated under an additional 
16 kPa (120 mm Hg) external pressure. The normalized absorbance changes of gels over 
time were fit to a linear regression. Flux values were calculated by dividing the slope 
values from the linear regressions by the well surface area and multiplying by the initial 
PNA concentration. In order to evaluate the effects of tissue diffusion on halo-
fluorochromic imaging, 3PN (100 μl, 10 mg/ml) was added to wells and allowed to 
diffuse into gels for 24 h at 37 °C. PNA solutions were removed from the wells and gels 
were imaged using an IVIS (Ex 640 nm/Em 700 nm). 
3.2.5 Opsonization and Aggregation of PNAs 
PNAs were exposed to anionic, cationic, physiological and serum-containing 
conditions that were previously reported in the literature to induce nanoparticle 
aggregation (127-130). Stock solutions of magnesium sulfate (Anionic, 1 M), calcium 
chloride (Cationic, 30 mM), McCoy’s 5A media (Physiological), and McCoy’s 5A media 
containing FBS (Serum-Containing, 50% v/v) were prepared. 3P’IR820 was dispersed in 
anionic, cationic, physiological and serum-containing solutions at 2 mg/ml and stored at 
37 °C for 24 hours. Absorbance changes indicating potential aggregation were measured 
at 0, 1, 3, 6 and 24 h. Absorbance values above 0.3 (650 nm) indicating 50% turbidity 
were defined as the aggregation threshold for PNAs. The diameter of PNAs in each 
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solution was also measured after 24 h using DLS and compared to initial diameter of 
PNAs in deionized water. 
3.2.6 Uptake of PNAs and Small Molecules in Cells 
HT29 cells were seeded in chamber slides at 15,000 cells per well. After 
overnight incubation of the chamber slides, the cells were treated with 2PN, 3PN or 
Mitotracker Green (MG) (1 mg/ml 2PN and 3PN, 200 nM MG) for 0.5, 1, 3, and 6 h. 
Cells were then placed on a heated stage maintained at 37 °C and imaged using a 
fluorescence microscope (Zeiss Axiovert 200M, Thornwood, NY). 2PN and 3PN were 
imaged using a Texas red filter (Ex 568 nm/Broad Spectum Em), while MG was imaged 
using a FITC filter (Ex 488 nm/Broad Spectrum Em). The background fluorescence of 
2PN, 3PN and MG was equalized in order to normalize the fluorescence signals over 
time for each treatment. The average intracellular and extracellular fluorescence for 2PN-
, 3PN- and MG-treated samples were calculated for each timepoint using ImageJ (NIH, 
Bethesda, MD). The fluorescence measurements were then converted to relative 
concentrations using a calibration curve of known concentration standards. The ratio of 
intracellular to extracellular PNA concentrations was defined as the uptake quotient (Q) 
in equation 3.1. Q is unitless. 
𝑄𝑄 = 𝐶𝐶𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝐶𝐶𝐸𝐸𝐸𝐸𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
    (3.1) 
To compare cellular uptake between PNAs, the cell experiments were repeated 
with 2PN and 3PN, but fluorescence images of cells were taken every 10 seconds for 0.5 
h following treatment. Kinetic parameters of cellular uptake were determined using a 
mathematical model based on previous reports (131). Briefly, a chamber with PNA 
concentration C1 and volume V1 was assumed to contain cells with intercellular PNA 
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concentration C2, volume V2 and surface area α2. In this derivation, the volume of cell 
media was assumed to be significantly greater than the volume of cytosol, and the surface 
ratio to volume ratio of cells was assumed to remain constant during measurements. 
Mass transfer equations describing PNA movement into (r12) and out of cells (r21) 
through the cell membrane can be written following equations 3.2 and 3.3, respectively. 
𝑟𝑟12 = 𝑘𝑘12(𝐶𝐶1 −
𝐶𝐶2
𝐾𝐾𝐸𝐸𝐸𝐸
)   (3.2) 
𝑟𝑟21 = 𝑘𝑘21(
𝐶𝐶2
𝐾𝐾𝐸𝐸𝐸𝐸
− 𝐶𝐶1)   (3.3) 
In equations 3.2 and 3.3, r12 and r21 have units of moles of PNA per square meter 
of cell surface area per minute, k12 and k21 have units of meters per minute, C1 has units of 
moles of PNA per cubic meter of cell media and C2 has units of moles of PNA per cubic 
meter of cytosol. In addition, KEQ is defined as a unitless cellular partition coefficient 
(C1eq/C2eq) that relates the media PNA concentration to the cytosol PNA concentration at 
equilibrium.  
Equations 3.2 and 3.3 were combined into equation 3.4, which describes the 
overall kinetic transfer of PNAs into and out of cells. 
𝑟𝑟𝐴𝐴 = −𝐾𝐾𝑀𝑀 �
𝐶𝐶2
𝐾𝐾𝐸𝐸𝐸𝐸
− 𝐶𝐶1�   (3.4) 
In equation 3.4, rA has units of moles of PNA per square meter of cell surface area 
per minute. KM is defined as an overall mass transfer coefficient accounting for both 
physical and biological processes contributing to nanoparticle uptake by cells. Similar to 
each rate constant, KM has units of meters per minute. 
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In addition to a kinetic equation describing uptake of PNAs, a mole balance 
describing changes in PNA concentrations in cells can be written as described in equation 
3.5. 
𝑑𝑑𝑑𝑑2
𝑑𝑑𝑑𝑑
= 𝑛𝑛12 − 𝑛𝑛21   (3.5) 
In equation 3.5, n12, n21, and dN2/dt have units of moles of PNA per minute. By 
assuming that the volume of cell media remains constant and that PNAs accumulate in 
cells only through mass transfer processes, we can convert equation 3.5 into terms of 
concentration using equations 3.6 and 3.7. 
𝑑𝑑𝑑𝑑2
𝑑𝑑𝑑𝑑
= 𝑉𝑉2 ∗
𝑑𝑑𝐶𝐶2
𝑑𝑑𝑑𝑑
    (3.6) 
 𝑛𝑛12 − 𝑛𝑛21 = 𝛼𝛼 ∗ 𝑟𝑟𝐴𝐴   (3.7) 
In equations 3.6 and 3.7, V2 has units of cubic meters and α has units of square 
meters. Equations 3.6 and 3.7 were substituted into equation 3.5 to yield equation 3.8.  
𝑉𝑉2 ∗
𝑑𝑑𝐶𝐶2
𝑑𝑑𝑑𝑑
= 𝛼𝛼 ∗ 𝑟𝑟𝐴𝐴   (3.8) 
Equation 3.4 was substituted into equation 3.8 to yield equation 3.9. 
𝑉𝑉2 ∗
𝑑𝑑𝐶𝐶2
𝑑𝑑𝑑𝑑
= −𝛼𝛼 ∗ 𝐾𝐾𝑀𝑀 �
𝐶𝐶2
𝐾𝐾𝐸𝐸𝐸𝐸
− 𝐶𝐶1�  (3.9) 
If extracellular PNA concentrations remain constant during uptake and M remains 
constant with respect to PNA concentrations, C1 is simplified to the initial extracellular 
PNA concentration C10 and equation 3.9 can be simplified to equation 3.10.  
𝑉𝑉2 ∗
𝑑𝑑𝐶𝐶2
𝑑𝑑𝑑𝑑
= −𝐾𝐾𝑀𝑀 ∗ 𝛼𝛼2 ∗ (
𝐶𝐶2
𝐾𝐾𝐸𝐸𝐸𝐸
− 𝐶𝐶10)  (3.10) 
Equation 3.10 can be rearranged to yield equation 3.11, which was solved for C2 
to yield equation 3.12, using the initial condition of no PNAs in the cytosol or on the cell 
membrane before treatment.  
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𝑑𝑑𝐶𝐶2
𝑑𝑑𝑑𝑑
= −𝐾𝐾𝑀𝑀∗𝛼𝛼2
𝐾𝐾𝐸𝐸𝐸𝐸∗𝑉𝑉2
∗ (𝐶𝐶2 − 𝐾𝐾𝐸𝐸𝐸𝐸 ∗ 𝐶𝐶10)  (3.11) 
𝐶𝐶2
𝐶𝐶1
0 = 𝐾𝐾𝐸𝐸𝐸𝐸 ∗ (1 − 𝑒𝑒
−𝐾𝐾𝑀𝑀∗𝛼𝛼2
𝐾𝐾𝐸𝐸𝐸𝐸∗𝑉𝑉2
∗𝑑𝑑
)   (3.12) 
As described earlier and repeated below in equation 3.13, KEQ was defined as the 
cellular partition coefficient. In addition, k was defined as the cellular uptake rate 
constant in equation 3.14. KEQ is unitless, while k has units of inverse minutes. In 
addition, because extracellular PNA concentrations are assumed to remain constant, the 
left side of equation 3.12 is equal to the uptake quotient.  These parameters are 
substituted into equation 3.12 and simplified to yield equation 3.15. The uptake 
coefficient-time profiles were fit to equation 3.7 using Prism 5.0 (Graphpad, La Jolla, 
CA). Because the concentration ratios are determined in equation 3.15 rather than the 
molar ratios, the phase volumes are not necessary to calculate uptake kinetics. 
𝐾𝐾𝐸𝐸𝐸𝐸 =
𝐶𝐶1
𝐸𝐸𝐸𝐸
𝐶𝐶1
𝐸𝐸𝐸𝐸    (3.13) 
𝑘𝑘 = −𝐾𝐾𝑀𝑀∗𝛼𝛼2
𝐾𝐾𝐸𝐸𝐸𝐸∗𝑉𝑉2
    (3.14) 
𝑄𝑄 = 𝐾𝐾𝐸𝐸𝐸𝐸 ∗ (1 − 𝑒𝑒𝑘𝑘∗𝑑𝑑)   (3.15)  
In order to compare the rate of cellular uptake between different PNAs, t95 was 
defined as the time for the uptake quotient (Q) to reach 95 percent of the cellular partition 
coefficient (KEQ) (equation 3.16). The t95 value has units of minutes. 
𝑡𝑡95 =
ln (20)
𝑘𝑘
    (3.16) 
3.2.7 Ex Vivo Imaging of Patient-Derived Xenograft Tumors from Mice using Non-
Halo-Fluorochromic PNAs 
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 NOD-scid gamma mice between 6 to 8 weeks old were purchased from the 
Jackson Laboratory (Bar Harbor, ME). All animal experiments were performed in 
accordance with the Institutional Animal Care and Use Committee (IACUC) and with 
approval from the Institutional Review Board of the University of Kentucky. A patient 
primary CRC tumor sample (F0) was collected, divided and implanted into a mouse 
flank. When these tumors (F1) grew to 1 cm3, the tumors were resected and divided into 
2 mm3 sections. The divided tumors were then implanted into mice (F2) for experiments. 
Mice bearing F2 tumors were dosed with 3P’A546 by tail vein injection (10 mg/kg). As a 
negative control, mice were also dosed with PBS. Mice were euthanized 1, 4, 8 and 24 
hours post-injection and lung, liver, kidney, spleen and PDX tumors were collected. The 
fluorescence of 3P’A546 in normal organs and tumors were quantified by IVIS. Density 
maps of PNA fluorescence in tissues were prepared using Living Image 3.1 (Caliper Life 
Sciences, Hopkinson, MA) and represented as a color gradient centered at the maximum 
fluorescence intensity. Additionally, tumor tissue samples were fixed in 4% 
paraformaldehyde containing 10% sucrose at 4°C, embedded in OCT on dry ice, 
sectioned at 10 μm thickness, and then dried overnight in the dark. Tumor tissue samples 
were then washed in PBS at room temperature, stained with Hoechst 33342 (500 ng/ml, 
PBS) and mounted in aqueous permanent mounting medium overnight. Additionally, 
tumor tissue samples were also treated with either EpCAM or CD31 primary antibodies 
to identify CRC cells or blood vessels, respectively. Primary antibody-treated samples 
were then treated with dye-labelled secondary antibodies for fluorescence imaging. 
Stained tissue slides were imaged by confocal microscopy at 20x magnification 
(Olympus FV1000, Tokyo, Japan). 
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3.2.8 Ex Vivo Imaging of Livers from Mice with Liver Metastatic Colorectal Cancer 
using Non-Halo-Fluorochromic and Halo-Fluorochromic PNAs 
Male athymic NCr nude mice between 6 to 8 weeks old were purchased from 
Taconic (Hudson, NY). Orthotopic liver MCRC tumors were established in these mice. 
Briefly, mice were injected with HCT 116 cells expressing green fluorescent protein 
(GFP) into the spleen capsule and allowed to develop MCRC tumors for 6 weeks. The 
establishment of liver MCRC tumors was confirmed by measuring the fluorescence of 
GFP corresponding to cancer cells in liver tissue. In order to maximize the fluorescence 
signals from normal organs without saturating the IVIS fluorescence detector, tumor-free 
mice were injected with 3P’A546 through the tail vein at varying doses (0, 5, 10 and 20 
mg/kg). Twelve hours after injection, mice were euthanized to collect organs for imaging 
by IVIS (Ex 535 nm/Em 580 nm). Based on the measured fluorescence intensities of 
livers from tumor-free mice, mice bearing liver MCRC tumors were injected with 
3P’A546 (10 mg/kg) through the tail vein and euthanized after 12 h. Mice bearing MCRC 
tumors were also injected with either 3PN (10 mg/kg) or PBS through the tail vein and 
euthanized after 6 h. The liver, kidney and lungs were collected from these mice for 
macroscopic imaging as described above. For microscopic imaging, liver tissue and liver 
MCRC tumor samples were collected from mice treated with 3P’A546 and fixed as 
described in the previous section. Tissue samples were stained with Hoechst 33342 (500 
ng/ml, PBS) to visualize cell nuclei, and then stained with CD31 primary antibodies to 
identify blood vessels. Primary antibody-treated tissue samples were then stained with 
dye-labelled secondary antibodies for fluorescence imaging. Stained tissue slides were 
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imaged by confocal microscopy at 20x magnification as described in the previous 
section.  
3.2.9 Quantification of Fluorescence Signals in Microscopic Fluorescence Images of 
Metastatic Tumors 
 Fluorescence signals corresponding to cell nuclei (DAPI), tumor vasculature 
(CD31) and PNAs were quantified from microscopic liver MCRC images. First, the 
fluorescence signals from merged images were split by channel to isolate nuclei, 
vasculature and PNA signals.  To account for differences in fluorescence signal strength 
between dyes, dye-labelled antibodies and PNAs, the fluorescence signals from each 
channel were normalized by converting the fluorescence intensities to binary signals 
using ImageJ. Next, regions of interest (80x80 μm) corresponding to metastatic tumor 
foci were selected and the total fluorescence per unit area was quantified in these regions. 
Fluorescence values per unit area were used to estimate cancer cell and vasculature 
density in metastatic tumors for computational simulations. 
3.2.10 Computational Simulations of PNA Distribution in Metastatic Tumors 
A computational model was used by Frieboes et al. to describe PNA distribution 
in MCRC tumors as a function of the surrounding tissue vascularization. Frieboes 
describes the model in detail in previous publications (124, 132-136). Briefly, the model 
represents viable, hypoxic, and necrotic tissue regions of a tumor in a two dimensional 
Cartesian coordinate system, and it simulates a small lesion (initial diameter ~50 μm) in 
the center of a pre-existing vascular capillary grid from healthy tissue. Mass conservation 
equations describe tissue growth (proliferation as a function of cells cycling) and tissue 
death via necrosis as a function of hypoxia. Hypoxia induces the release of tumor 
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angiogenic factors such as Vascular Endothelial Growth Factor (VEGF), which causes 
neovascularization to supply the tumor with sufficient nutrients for growth. The tumor 
growth equations are combined with the diffusion of PNAs, oxygen, and cell nutrients to 
a reaction-diffusion equation. The rate constants for proliferation and death depend on the 
availability of oxygen, nutrients, and drug, and are thus spatio-temporally heterogeneous.  
 The tumor growth component of the computational model is based on (137). 
Briefly, the tumor tissue and its boundary are denoted by Ω and Σ, respectively. The 
tissue typically has a proliferating region ΩP (100-200 μm thickness) in which cells have 
sufficient oxygen and nutrients, a hypoxic region ΩH in which oxygen and nutrients are 
sufficient for survival but not for proliferation, and a necrotic region ΩN in which oxygen 
and nutrients are insufficient for survival. The non-dimensionalized tumor growth 
velocity is implemented via a generalized Darcy’s law in equation 3.17 (137). 
 𝒗𝒗𝐶𝐶 = −𝜇𝜇∇𝑃𝑃 + χ𝐸𝐸∇𝐸𝐸  (3.17) 
In equation 3.17, μ is cell-mobility representing the net effects of cell-cell and 
cell-matrix adhesion, P is oncotic pressure, χE is haptotaxis, and E is extra-cellular matrix 
(ECM) density. Definitions for χE and E are in (137). By assuming that the cell density is 
constant in the proliferating region, the overall tumor growth can be associated with the 
rate of volume change in equation 3.18. 
∇ · 𝒗𝒗𝐶𝐶 = 𝜆𝜆𝑃𝑃   (3.18) 
In equation 3.18, λP is the non-dimensional net proliferation rate as further 
detailed below.  
The angiogenesis component of the model simulates the lesion by (138) and is 
based on previous work (136, 139). As a tumor grows in the dynamic, vascularized tissue 
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environment, tumor cells have varying access to molecules diffusing from the 
vasculature, depending on the tissue pressure and the distance from the nearest blood 
vessels.  
The diffusive transport of oxygen σ through tumor tissue is simulated from the 
extravasation location of molecules from the tumor blood vessels. Oxygen is supplied 
from the neo- and pre-existing vessels with extravasation rates λevσ = λneo σ and λev σ = λpre σ, 
respectively, diffuses with a diffusion coefficient Dσ, is taken up by both normal cells 
(with a rate λtissue σ) and tumor cells (λtumor σ in the proliferating region and qs in the 
hypoxic region), and decays (with a rate λN σ) in the necrotic region. Oxygen is consumed 
in tumor tissue (with a rate λP) depending on the tumor region. Assuming steady-state 
conditions, the formulation is in equation 3.19 and 3.20, which was derived based on 
previous reports (133, 135, 137). 
0 = ∇ · (𝐷𝐷𝜎𝜎∇𝜎𝜎) + 𝜆𝜆𝑒𝑒𝑒𝑒𝜎𝜎 (𝒙𝒙, 𝑡𝑡,𝟏𝟏𝑒𝑒𝑒𝑒𝑣𝑣𝑣𝑣𝑒𝑒𝑣𝑣 ,𝑝𝑝𝑖𝑖 ,𝜎𝜎, ℎ)− 𝜆𝜆𝜎𝜎(𝜎𝜎)𝜎𝜎  (3.19) 
𝜆𝜆𝑃𝑃 = �
𝜆𝜆𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑒𝑒𝜎𝜎    outside Ω
𝜆𝜆𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑟𝑟𝜎𝜎            in Ω𝑃𝑃
𝑞𝑞𝜎𝜎(𝜎𝜎)          in  Ω𝐻𝐻
𝜆𝜆𝑁𝑁𝜎𝜎                 in Ω𝑁𝑁 
  (3.20) 
In equation 3.19, x is position in space, t is time, 1vessel is the characteristic 
function for the vessels (equals 1 at vessel locations and 0 otherwise), pi is the interstitial 
pressure, and h is the hematocrit in the vessel network which is related to oxygen 
extravasation (following reference (137)). The extravasation of oxygen is modulated by 
the extravascular interstitial pressure pi scaled by the effective pressure pe, with kpi being 
the weight of the convective transport component of molecules (133). This process is 
described in equation 3.21. 
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𝜆𝜆𝑒𝑒𝑒𝑒
𝜎𝜎 = 𝜆𝜆�𝑒𝑒𝑒𝑒
𝜎𝜎 𝟏𝟏𝑒𝑒𝑒𝑒𝑡𝑡𝑡𝑡𝑒𝑒𝑣𝑣(𝐱𝐱, t) �
ℎ
𝐻𝐻�𝐷𝐷
− ℎ�𝑡𝑡𝑡𝑡𝑛𝑛� + �1 − 𝑘𝑘𝑝𝑝𝑡𝑡
𝑝𝑝𝑡𝑡
𝑝𝑝𝑒𝑒
� (1 − 𝜎𝜎)(3.21) 
In equation 3.21, the constants 𝐻𝐻�𝐷𝐷 and ℎ�𝑚𝑚𝑖𝑖𝑚𝑚 represent the normal and minimum 
blood hematocrit levels required for oxygen extravasation, respectively, and ?̅?𝜆𝑒𝑒𝑒𝑒𝜎𝜎  is the 
constant transfer rate from both pre-existing and tumor-induced blood vessels. The 
oxygen transport parameters are calibrated so that the growth rate of an avascular 
spheroid matches the experimentally observed rates (134). 
The acidity of the tumor microenvironment is modeled as a first order 
approximation that is proportional to the release of tumor angiogenic factors (TAF) from 
hypoxic cells within the tumor. The maximum TAF value represents a pH of 5, and the 
absence of TAF represents physiological conditions (pH 7.4). TAFs are produced by 
hypoxic tumor cells at rate ?̅?𝜆𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑, diffuse into the tissue with a constant diffusion 
coefficient 𝐷𝐷𝑇𝑇, are taken up by endothelial cells with a rate ?̅?𝜆𝑏𝑏𝑖𝑖𝑚𝑚𝑑𝑑𝑖𝑖𝑚𝑚𝑏𝑏𝑇𝑇 , and decay 
exponentially with a rate ?̅?𝜆𝑑𝑑𝑒𝑒𝑑𝑑𝑑𝑑𝑑𝑑𝑇𝑇  [33]. This process is described in equation 3.22. 
0 = ∇ ∙ (𝐷𝐷𝑇𝑇∇𝑇𝑇) + ?̅?𝜆𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑𝑇𝑇 (1 − 𝑇𝑇)𝟏𝟏Ω𝐻𝐻 + ?̅?𝜆𝑑𝑑𝑒𝑒𝑑𝑑𝑑𝑑𝑑𝑑
𝑇𝑇 𝑇𝑇 
−?̅?𝜆𝑏𝑏𝑖𝑖𝑚𝑚𝑑𝑑𝑖𝑖𝑚𝑚𝑏𝑏𝑇𝑇 𝟏𝟏𝑒𝑒𝑒𝑒𝑣𝑣𝑣𝑣𝑒𝑒𝑣𝑣   (3.22) 
The transport of PNAs s through tumor tissue, like oxygen, is also simulated from 
the location of extravasation from the vessels. PNAs are simulated to be injected 
systemically, flowing from the lower left to upper right of the vascularized tumor system.  
PNAs are taken up both by both normal and tumor cells with a rate . The 
formulation is described in equation 3.23. 
0 = ∇ ∙ (𝐷𝐷𝑣𝑣∇s) + 𝜆𝜆𝑒𝑒𝑒𝑒𝑣𝑣 (𝒙𝒙, 𝑡𝑡,𝟏𝟏𝑒𝑒𝑒𝑒𝑣𝑣𝑣𝑣𝑒𝑒𝑣𝑣,𝑝𝑝𝑖𝑖, 𝑡𝑡) − ?̅?𝜆𝑢𝑢𝑝𝑝𝑑𝑑𝑑𝑑𝑘𝑘𝑒𝑒𝑣𝑣  (3.22)  
s
uptakeλ
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Assuming a constant transfer rate from both pre-existing and tumor-induced 
vessels, the PNA extravasation is described in equation 3.23. 
𝜆𝜆𝑒𝑒𝑒𝑒𝑣𝑣 = ?̅?𝜆𝑒𝑒𝑒𝑒𝑣𝑣 𝟏𝟏𝑒𝑒𝑒𝑒𝑣𝑣𝑣𝑣𝑒𝑒𝑣𝑣(x, t)(1 − 𝑘𝑘𝑝𝑝𝑖𝑖
𝑝𝑝𝑖𝑖
𝑝𝑝𝐼𝐼
)(𝐶𝐶𝐼𝐼
𝑠𝑠
𝐶𝐶̅𝑠𝑠
− s) (3.23) 
In this equation, the diffusion in tumor tissue is assumed to be modulated by the 
interstitial pressure (133). The diffusivity is assumed to be similar to previous diffusion 
measurements for nanoparticles (140).The initial PNA concentration in the vasculature is 
𝐶𝐶̅𝑣𝑣, with an extravasation described in equation 3.24. 
𝐶𝐶𝑑𝑑𝑣𝑣 = 𝐶𝐶̅𝑣𝑣𝑒𝑒−𝑑𝑑/𝜏𝜏   (3.24) 
Equation 3.24 assumes first order kinetics, i.e., the extravasation is concentration 
dependent. The PNA half-life (dependent on τ) is assumed to be proportional to the 
clearance rate of drug released from them, as previously measured (134).   
The model parameters associated with oxygen uptake and transfer rates were 
determined from the literature (141). In addition, the diffusivity, mass transfer rate and 
clearance of PNAs were estimated based on previous experiments (123, 142). The tumor 
proliferation rate, necrosis threshold and hypoxia threshold were calibrated based on 
growth profiles of liver MCRC tumors. 
3.2.11 Statistics 
All values in figures are reported as mean±standard deviation for three 
measurements unless otherwise noted. Groups of multiple measurements were compared 
by one-way ANOVA with Bonferroni’s post-test correction, while pairs of measurements 
were compared by Student’s t test unless described otherwise. Statistical significance in 
figures and tables is represented with * (p<0.05), ** (p<0.01) or *** (p<0.001). 
 
s
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3.3 Results 
3.3.1 Fluorochromism Does Not Affect the Physicochemical Properties of PNAs 
The synthesis and characterization of 2PN and 3PN was described in chapter 2. 
Proton NMR indicated attachment of PEG (3.51 ppm, s, relative area 1.000), PAL (0.83 
ppm, d, relative area 0.002; 1.23 ppm, s, relative area 0.027; 1.46 ppm, s, relative area 
0.009) and AA (1.78 ppm, s, relative area 0.024) to PLL (2.23 ppm, m, relative area 
0.0013; 2.60 ppm, s, relative area 0.0005; 2.68 ppm, s, relative area 0.0008; 2.97 ppm, s, 
relative area 0.0009; 3.24 ppm, s, relative area 0.0114; 3.68 ppm, s, relative area 0.027; 
4.09 ppm, s, relative area 0.040; 7.78 ppm, s, relative area 0.009). The size and chemical 
purity of 3P’A546 and 3P’IR820 were confirmed by GPC in Figure 3.4. 3P’A546 and 
3P’IR820 had 1% molar substitution of Alexa Fluor® 546 and 5% molar substitution of 
IR820, respectively. Table 3.1 summarizes the diameters, surface charges and chemical 
properties of non-halo-fluorochromic PNAs. Figure 3.5 shows the fluorescence of 
3P’IR820 at various pH values and with and without drug loading in order to confirm 
non-halo-fluorochromism. Changes in pH did not consistently alter the fluorescence of 
3P’IR820, but the fluorescence of drug-loaded 3P’IR820 slightly decreased at pH 7.0 and 
6.0 compared to pH 7.4. Drug loading increased the fluorescence of PNAs by about 30% 
compared to empty PNAs.  
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Figure 3.4. Gel permeation chromatographs of 3P’A546 (A) and 3P’IR820 (B). 
Chromatographs were measured by UV-visible absorbance detector at 546 nm (A) or 820 
nm (B).   
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Table 3.1. Physicochemical properties of 3P’A546 and 3P’IR820. Characterization 
information for 2PN and 3PN are in Table 2.1 of Chapter 2. 
PNA Diameter (nm) Zeta potential (mV) Polydispersity Index (PDI) (unitless) 
3P’A546 23.2±1.0** -0.8±0.4 0.31±0.02 
3P’IR820 18.8±0.3** 0.3±0.7 0.29±0.02 
PNA 
PEG Substitution 
(mol/mol primary 
amine on scaffold) (%) 
PAL Substitution 
(mol/mol primary 
amine on scaffold) (%) 
Dye Substitution 
(mol/mol primary 
amine on scaffold) (%) 
3P’A546 24.0±0.6 37.0±0.9 1.0±0.1*** 
3P’IR820 24.0±0.6 37.0±0.9 5.0±0.1*** 
Diameter, zeta potential PDI and dye substitution are reported as mean±SD (n=3). PEG 
and PAL substitution are reported as measurement±SE for NMR measurement (n=1). 
Statistical significance is determined with a Student’s t test as described in the methods 
section. 
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Figure 3.5. Fluorescence properties of 3P’IR820 measured by IVIS (A). The fluorescence 
of empty (B) and drug-loaded 3P’IR820 (C) were quantified from IVIS images.   
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3.3.2 PNAs Diffuse into Gels Mimicking Tissue Conditions and Fluoresce in Acidic 
Environments 
Figure 3.6 describes the flux of 3P’IR820 into agarose gel tissue mimics with and 
without 120 mmHg additional external pressure. The calculated flux for PNAs in each gel 
density, pH, and pressure condition are located in Table 3.2. The flux of 3P’IR820 
decreased by about 40 % in high density gels (1.0%) compared to low density gels 
(0.5%). Decreases in gel pH did not consistently affect the flux of PNAs, but the flux of 
PNAs was greater for pressurized 1% gels at pH 7.0 compared to pH 7.4 or 6.0. External 
pressure decreased the flux of 3P’IR820 slightly, possibly due to the compression of the 
gel disrupting pores near the top of the gel. To determine the effects of diffusion on the 
halo-fluorochromic imaging of PNAs, gels were treated with 3PN for 24 h. Figure 3.7 
shows the fluorescence of halo-fluorochromic 3PN after diffusion into tissue mimics. 
Fluorescence images confirm PNA diffusion and distribution in the gel mimics. For each 
gel density, the fluorescence increased in order of pH 6.0>7.0>7.4. The fluorescence of 
PNAs in 0.5% gels was slightly greater than the fluorescence in 1.0% gels at varying pH 
values, except pH 6.0 where 3PN showed greater fluorescence in 1.0% gel than 0.5% gel. 
The fluorescence of halo-fluorochromic PNAs in 1.0% gel at pH 6.0 is greater than 
expected, based on fluorescence trends due to changes in pH and gel density. 
Imperfections on the surfaces of gel surfaces in the pH 6.0 gels with 1.0% gel density, 
perhaps due to air bubbles at the surface of the gels after solidification, may increase the 
observed fluorescence signal of PNAs in acidic gels, due to reflections of fluorescence 
signals during imaging amplifying signals. However, the exact mechanism of increased 
fluorescence at low pH and high gel density is unknown. Future studies are needed to 
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elucidate the effects of gel density and acidity on fluorescence signals of dyes diffused 
into agarose in gels. In addition, the halo-fluorochromism of PNAs appears to be greater 
in gels than in solution, as measured in chapter 2. Differences in the observed 
fluorescence behavior of 3PN may be due to the exclusion of the pH 5.0 measurement, 
which had much greater fluorescence than the other pH values in solution. As a result, the 
fluorescence of 3PN in gels can more accurately elucidate subtle differences in 
fluorescence signals due to increased acidity. 
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Figure 3.6. Diffusion of PNAs into gels mimicking tissue conditions. The pressurized 
condition is 120 mm Hg as described in the methods section.  
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Table 3.2. Calculated flux values for PNAs in gels with and without additional external 
pressure. 
  Flux (kg/(s*cm2))*1010 
Additional 
Pressure 
(mm Hg) 
Gel %*** pH 7.4 pH 7.0 pH 6.0 
0 
(Atmospheric) 
0.5 9.76 (9.01-10.47) 10.55 (9.05-12.06) 10.08 (9.01-11.15) 
1.0 7.63 (6.95-8.30) 7.12 (6.31-7.94) 5.97 (5.11-6.83) 
Additional 
Pressure 
(mm Hg) 
Gel %*** pH 7.4** pH 7.0** pH 6.0** 
120 
(Pressurized) 
0.5 8.23 (7.05-9.41) 9.31 (8.36-10.25) 7.73 (6.14-9.32) 
1.0 4.35 (3.45-5.24) 7.18 (6.27-8.09) 4.66 (3.81-5.51) 
Flux values are reported as mean with 95% CI in parenthesis. Statistical significance is 
determined for gel density and pH at each pressure by two-way ANOVA with 
Bonferroni’s post-test correction.  
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Figure 3.7. Fluorescence of 3PN that has diffused into gels for 24 hours (A). 
Fluorescence signal was quantified by IVIS (B).  
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3.3.3 Ionic and Serum-Containing Conditions Do Not Induce the Opsonization or 
Aggregation of PNAs 
 Figure 3.8A describes the changes in the absorbance of PNA solutions for up to 
24 h in aggregating conditions. The absorbance of PNAs decreased after 1 hour but 
slightly increased up to 24 h in cationic, physiological and serum-containing conditions. 
However, the absorbance of PNAs in anionic solutions slightly decreased for 24 h after 
treatment. No precipitation was observed in the samples over 24 h. Because the 
absorbance of PNAs in solution was below 0.3 for all time points (black dotted line), 
PNAs did not aggregate. Figure 3.8B shows the diameters of PNAs in aggregating 
conditions after 24 h. Changes in PNA diameters are not statistically significant. These 
results confirm that PNAs do not significantly opsonize for up to 24 h in aggregating 
conditions.  
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Figure 3.8. Absorbance (A) and diameter (B) changes of PNAs stored in aggregating 
conditions for 24 hours.  
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3.3.4 Most Nanoassemblies Remain in the Cell Media During In Vitro Cellular Uptake 
Measurements 
Figures 3.9A-C describe the uptake of 2PN, 3PN and MG in HT29 cells from 0.5-
6 h post-treatment. Uptake quotients of 2PN, 3PN and MG were calculated from 
fluorescence images (Table 3.3). Because uptake quotients (Q) are defined as the ratio of 
intracellular to extracellular PNA concentrations, a low Q value (<1) indicates a high 
concentration of PNAs in the extracellular space relative to cells, while a high Q value 
(>1) indicates a high concentration of PNAs in cells relative to the extracellular space. 
Low values of Q for PNA uptake up to 6 h post-treatment indicate that most PNAs 
remain in the cell media rather than accumulating inside of cancer cells. In contrast to 
PNA uptake quotients, MG uptake quotients increased up to 6 h post-treatment. The high 
values of MG uptake quotients suggest that MG accumulates inside of cancer cells. 
Figure 3.9D shows the changes in uptake quotient over time for 2PN, 3PN and MG. 
Time-dependent differences in uptake quotient for 2PN or 3PN were not statistically 
significant, but time-dependent differences for MG were significant. Treatment-
dependent differences between uptake quotients of PNAs and MG are not statistically 
significant at 0.5 h post-treatment, but they were statistically significant between 1-6 h 
post-treatment. In addition, Figure 3.9E shows uptake quotients over time of 2PN and 
3PN from 0 to 0.5 h post-treatment. Kinetic parameters from a mathematical model of 
nanoparticle uptake in Figure 3.8E are in Table 3.4. 3PN had a larger cellular partition 
coefficient (KEQ) and a larger rate constant (k) than 2PN; however, both 2PN and 3PN 
had low cellular uptake quotients (Q) compared to small molecules. Cellular partition 
coefficients of 2PN and 3PN indicate that the intracellular concentrations of 2PN and 
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3PN are 25% and 40% of their extracellular concentrations, respectively. Small t95 values 
for both 2PN and 3PN suggest that PNAs are taken up in cells by active processes such as 
endocytosis, but that processes such as exocytosis may remove PNAs from the cytosol 
and maintain low cellular partition coefficients over time. Rheiner et al. previously 
confirmed that cellular uptake of PNAs was performed by endocytosis (76). All PNAs 
showed low cellular uptake under in vitro conditions based on concentration ratios. Based 
on estimations of molar ratios of PNA uptake accounting for intracellular volume, 
extracellular volume and measured cellular partition coefficients (KEQ) of cells in 
chamber slides, molar ratios of PNA uptake in cells on chamber slides were less than 
0.01. A further analysis of PNA uptake in metastatic tumors or solid tumors is in the 
discussion section.   
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Figure 3.9. Microscopic fluorescence imaging of 2PN (A), 3PN (B) and MG (C) uptake 
into HT29 cells. Uptake of PNAs and MG were compared up to 6 h of treatment (D). 
Uptake of 2PN and 3PN was compared up to 0.5 h of treatment (E). 
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Table 3.3.  Uptake quotients of cells treated with 2PN, 3PN and MG. 
 Time (h) 
Treatment 0.5 1 3 6 
2PN 0.37±0.11 0.22±0.12 0.26±0.10 0.27±0.08 
3PN 0.33±0.10 0.39±0.11 0.38±0.11 0.40±0.07 
MG 0.11±0.12 1.33±0.14*** 2.37±0.31*** 12.26±1.92*** 
Uptake quotients are reported as mean±SD (n=3). Differences in uptake quotients 
between treatments at each timepoint were compared by a one-way ANOVA with 
Bonferroni’s post-test correction. Statistical significance is reported as described in the 
methods section. 
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Table 3.4. Kinetic parameters of PNA uptake from a first order association model.  
PNA KEQ (unitless) k (min-1) t95 (min) 
2PN 0.26 (0.25-0.26)*** 0.23 (0.20-0.25)*** 13.2 (11.8-15.0)*** 
3PN 0.41 (0.40-0.41)*** 0.46 (0.44-0.47)*** 6.6 (6.4-6.8)*** 
Kinetic parameters are reported as mean with 95% CI in parentheses. Differences in 
kinetic parameters between each model were compared by an extra sum of squares F 
test. Statistical significance is reported as described in the methods section. 
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3.3.5 PNAs Accumulate Throughout Cancer Cells in Solid Tumors 
Figure 3.10 shows fluorescence imaging of tumors, livers, spleens, kidneys and 
lungs from mice bearing PDX tumors. Weak fluorescence signals can be observed in 
PDX tumors at 1 hour post-injection, but the signal increases up to 24 hours post-
injection. In contrast to PDX tumors, the fluorescence signals in normal organs are 
minimal. Figure 3.11A shows microscopic fluorescence imaging of PDX tumors from 
mice treated with 3P’A546. Weak fluorescence can be observed at 4 hours post-injection, 
but the fluorescence signal increases up to 24 hours post-injection. The fluorescence of 
PNAs is near the fluorescence of nuclei in all images, suggesting that PNAs accumulate 
in PDX tumor cells. Differences between the measured cellular uptake in Figures 3.9 and 
3.11A may be due to biological differences between cancer cells and patient-derived 
tumor cells, extracellular PNA concentrations, exposure times or removal of extracellular 
PNA signal due to sample preparation. Figure 3.11B shows microscopic fluorescence 
imaging of PNAs and EpCAM antibodies, which indicates the colocalization of PNAs 
with cancer cells. The fluorescence of PNAs remains near the fluorescence of EpCAM, 
suggesting that PNAs accumulate in EpCAM-expressing CRC cells rather than other 
tumor-associated cells such as macrophages. Figure 3.11C show microscopic 
fluorescence imaging of PNAs and CD31 antibodies, which indicates the colocalization 
of PNAs and blood vessels in tumors. Fluorescence of PNAs does not colocalize with 
CD31 fluorescence, suggesting that PNAs diffuse out of blood vessels and enter the 
interstitium of tumors. Figure 3.12 shows digitally zoomed versions of the microscopic 
fluorescence images in Figure 3.11. 
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Figure 3.10. Macroscopic fluorescence imaging of PDX tumors and organs from mice 
treated with 3P’A546 (10 mg/kg). 
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Figure 3.11. Microscopic fluorescence imaging (20x) of PNA uptake in PDX tumors over 
24 hours (A). Fluorescence images at 8 hours were also taken with EpCAM (B) or CD31 
(C) staining. In all images, blue is the cell nucleus, red is PNAs and green is EpCAM or 
CD31. The arrows in (C) indicate blood vessels.  
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Figure 3.12. Digitally zoomed microscopic fluorescence imaging (80x) of PDX tumors. In 
all images, blue is the cell nucleus, red is PNAs and green is either EpCAM or CD31. 
The arrows in (B) and (C) indicate cancer cells and blood vessels, respectively. 
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3.3.6 Halo-Fluorochromic PNAs Enable the Detection of Liver Metastasis and the 
Reduction of Background Signals from Healthy Tissue 
Figure 3.13 shows a fluorescence signal optimization of 3P’A546 in liver. The 
fluorescence of the liver increased with increasing doses of PNAs, but the fluorescence 
signal was not evenly distributed throughout the liver receiving the 20 mg/kg dose. Based 
on these measurements, a dose of 10 mg/kg was selected to maintain a consistent PNA 
concentration throughout liver tissue. Figure 3.14A shows the fluorescence of liver, 
kidney and lungs from mice bearing liver MCRC tumors that were treated with 3P’A546. 
The presence and location of metastatic tumors in the livers of these mice was confirmed 
by brightfield and GFP imaging of the liver. PNAs fluoresce throughout the liver, kidney 
and lungs. In addition, fluorescence is observed in both healthy tissue and MCRC tumors 
in the liver. Figure 3.14B shows the fluorescence of liver from either healthy mice or 
mice with liver MCRC tumors that were treated with halo-fluorochromic 3PN. The GFP 
signal in liver confirms that MCRC tumors were successfully established in mice. No 
fluorescence signal is observed in healthy mice treated with 3PN, suggesting that halo-
fluorochromism of PNAs reduces fluorescence signals from PNAs in in healthy tissue. In 
mice bearing liver MCRC tumors, the halo-fluorochromic signal from 3PN colocalizes 
with GFP, but there are differences between the shapes of each signal. Figure 3.15 shows 
microscopic fluorescence images of the boundary between the healthy liver and 
metastatic tumors from mice treated with either PBS or 3P’A546. The fluorescence of 
3P’A546 is stronger in liver tissue than in metastatic tumors. Figure 3.16 shows 
microscopic imaging of healthy liver and MCRC tumor tissues from mice treated with 
either PBS or 3P’A546.  Hoechst staining indicates that nuclei are less dense in healthy 
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liver tissue compared to MCRC tumors. In addition, the nuclei in liver tissue are larger 
than the nuclei in metastatic tumors. CD31 staining indicates that the number of blood 
vessels per unit area is greater in liver tissue than in MCRC tumors, and that the 
distribution of blood vessels in the healthy liver is more homogeneous than in metastatic 
tumors. Differences in blood vessel density suggest that MCRC tumors are less perfused 
with blood than healthy liver tissue. Weak fluorescence signal corresponding to 3P’A546 
throughout liver tissue suggests that PNAs accumulate throughout liver tissue. Figure 
3.17 shows digitally zoomed microscopic imaging of PNAs in healthy liver and liver 
MCRC tumors. Although most PNAs are evenly distributed throughout tissue samples, 
some PNAs fluoresce in small circles near outside edges of CD31 fluorescence. The 
exact cause of these spots is unknown. It should be noted that these small circles are 
difficult to observe in large microscopic images and do not significantly contribute to 
overall fluorescence signals in liver tissue. In addition, weak fluorescence of 3P’A546 is 
observed in the space near blood vessels surrounding colonies of cancer cells in 
metastatic tumors, but the fluorescence signal decreases near center of metastatic cancer 
cell colonies. The fluorescence signal of 3P’A546 in microscopic images is weaker than 
the fluorescence signal from macroscopic images, suggesting that the fixing and staining 
methods used to prepare tissue samples may extract extracellular PNAs from tissue 
samples and decrease fluorescence signals.  
94 
 
 
 
 
 
 
Figure 3.13. Macroscopic fluorescence imaging of liver, spleen, kidney and lung from 
mice treated with 3P’A546 at various doses.   
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Figure 3.14. Macroscopic fluorescence imaging of non-halo-fluorochromic and halo-
fluorochromic PNAs (10 mg/kg for each) in healthy liver and liver metastatic tumors. 
Fluorescence images of liver, kidney and lung tissue from mice bearing orthotopic liver 
MCRC tumors treated with 3P’A546 (A). Fluorescence imaging of liver from healthy 
mice or mice bearing orthotopic liver MCRC tumors treated with 3PN (B). 
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Figure 3.15. Microscopic fluorescence imaging (20x) of 3P’A546 at the boundary of 
healthy liver and metastatic tumors (10 mg/kg). In all images, blue is the cell nucleus, red 
is PNAs and green is CD31. 
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Figure 3.16. Microscopic fluorescence imaging (20x) of 3P’A546 in healthy liver or 
metastatic tumors (10 mg/kg). In all images, blue is the cell nucleus, red is PNAs and 
green is CD31.   
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Figure 3.17. Digitally zoomed microscopic fluorescence imaging of healthy liver and 
metastatic tumors. Blue corresponds to nucleus, green corresponds to CD31 and red 
corresponds to 3P’A546.  
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3.3.7 Computational Simulations of PNA Accumulation in Metastatic Tumors 
Figure 3.18 shows the distribution and accumulation of PNAs in metastatic CRC 
tumors after systemic, intravenous bolus injection simulated by Frieboes et al. for low, 
medium and high tissue vascularization densities. Physical parameters for PNAs and 
biological parameters for tumors are in Table 3.5. The computational model is based on 
previous results (122), and it builds on computational modeling of a reaction-diffusion-
controlled reactor simulating a metastatic tumor (123, 124, 132). PNA concentrations in 
the blood, indicated by the tumor blood vessels, decrease over time as PNAs are cleared 
from the plasma. Most PNAs remain in the extracellular matrix surrounding the lesion 
and the tumor tissue adjacent to it. As the vascular density increases, the PNAs 
accumulate at higher concentrations in the periphery of the metastatic tumors. The figure 
also indicates that PNA accumulation near the metastatic tumors is projected to decline to 
about half of its initial value 12 h post-treatment. In order to quantify PNA accumulation 
in various regions of the metastatic lesion, the uptake profiles of PNAs were also 
simulated.  
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Table 3.5. Parameters for the computational model of PNA distribution in metastatic 
tumors.  
Parameter Value Reference 
CRC Tumor proliferation rate 1 day-1 Measured (134) 
CRC in liver tumor necrosis threshold 0.515 Calibrated 
CRC in liver tumor hypoxic threshold 0.575 Calibrated 
Oxygen diffusivity 1 (*) (136) 
Oxygen transfer rate from vasculature 5 (*) (136) 
Oxygen uptake rate by proliferating tumor cells 1.5 (*) (136) 
Oxygen uptake rate by hypoxic tumor cells 1.3 (*) (136) 
Oxygen uptake rate by tumor microenvironment 0.12 (*) (136) 
Oxygen decay rate 0.35 (*) (136) 
PNA diffusivity 0.3 (*) Estimated (140) 
PNA transfer rate from vasculature 5 (*) Estimated (140) 
PNA uptake rate by tumor cells 1.5 (*) Estimated (140) 
PNA plasma clearance half life 14.4 h Estimated (142) 
The parameters denoted with (*) were rescaled by the characteristic length (1 cm), the 
characteristic time (1 s) or oxygen diffusivity (1*10-5 cm2/s) as described in previous 
work (143).  
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Figure 3.18. Computational simulations of PNA distribution in metastatic tumors. Images 
on the left represent metastatic tumors with tumor vessels (brown), proliferating (red), 
hypoxic (blue) and necrotic region (brown). Images in center and right represent PNA 
distribution in the tumors on the left of each row. 
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Figure 3.19 describes PNA accumulation based on vasculature surface area (µm2, 
based on vessel length x circumference) for up to 60 h following treatment. One day (24 
h) after treatment, the total PNA concentration has decreased by 75%, 80%, and 90% for 
the low, medium and high vascularization cases compared to the initial total PNA 
concentration, which reflects increasing PNA washout with a higher number of blood 
vessels. The total PNA concentration has the largest peak for the case of medium 
vascularization (0.20), while the peak concentration is reached in the hypoxic tissue for 
the high vascularization case (0.057).  Figure 3.20 quantifies the simulated PNA 
accumulation per vasculature surface area at 1.8 and 12 h post-treatment as a function of 
the degree of vascularization and the tumor region (proliferating, hypoxic, necrotic, and 
blood vessels).  At 1.8 h post-treatment, the PNA concentration is 10x, 7.8x, and 7.5x 
higher in the proliferating regions than in the hypoxic regions for the low, medium, and 
high vascularization conditions, respectively.  By 12 h, these concentrations become 
more comparable (1.8x, 2x, and 1.2x, respectively), with PNA accumulation decreasing 
by 75% in the proliferating regions, by 50% in the tumor blood vessels, while also 
increasing by 100% in the hypoxic tissue regardless of vascular density.  In all cases, the 
accumulation of PNAs in the necrotic regions of tumors is negligible. These 
computational modeling results suggest that although a higher number of PNAs is 
projected to be initially taken up by the proliferating regions, accumulation in the hypoxic 
(and more acidic) tissue of the lesion is expected to increase and remain steady for 
several hours.  Further, this accumulation is projected to be mostly independent of the 
degree of vascularization of the tissue surrounding the lesion. 
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Figure 3.19. Distribution-time profiles of PNAs in simulated metastatic tumors with low, 
medium and high vascularization.  
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Figure 3.20. Distribution Profiles of PNAs in simulated metastatic tumors at 1.8 and 12 
hours post-treatment. 
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3.4 Discussion 
3.4.1 PNAs Sustain Fluorescent Dye Concentrations in Tumors  
 The successful treatment of CRC depends on the effective detection of small 
MCRC tumors. Traditional CRC detection methods cannot identify small MCRC tumors 
that rarely affect the structure and morphology of the surrounding tissues (144). As a 
result, MCRC tumors cannot be easily detected until they become too large to effectively 
treat with chemotherapy due to acquired drug resistance (145). Fluorescent dyes are often 
used to identify small tumors by visualizing cancer cells, but their clinical applications 
have been limited by low signal-to-noise ratios and short half-lives in vivo (146). In order 
to overcome these limitations, small molecule fluorescent dyes are often entrapped in 
nanoparticles. In previous studies, nanoparticles entrapping fluorescent dyes increased 
the strength and duration of fluorescence signals from solid tumors, which allowed for 
the fluorescence imaging-guided detection of tumors (46). 
Despite their benefits for fluorescence imaging, fluorescent nanoparticles can 
hinder the detection of metastatic tumors by increasing background signals in healthy 
organs, such as the liver, lung, spleen, or kidney (147, 148). In order to reduce 
background fluorescence signals and identify MCRC tumors more accurately and earlier 
in their development, PNAs entrapping halo-fluorochromic dyes were developed. 
Although halo-fluorochromic PNAs detected liver MCRC tumors in preliminary studies, 
their fluorescence signals did not perfectly correspond to liver MCRC tumors. Halo-
fluorochromic PNAs could emit fluorescence only in some sections of acidic tumor 
tissue, due to the altered distribution patterns of PNAs in MCRC tumors compared to the 
liver (149). Therefore, it was hypothesized that halo-fluorochromic PNAs accumulate in 
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the acidic interstitium between MCRC tumors and healthy liver tissue. To test this 
hypothesis, the effects of physical and biological factors related to MCRC tumor 
detection, such as tissue diffusion, cell interactions, and opsonization, were elucidated. 
The effects of these factors were observed in fluorescence images of PNA distribution in 
solid tumors, healthy liver tissue and liver MCRC tumors. In addition, fluorescence 
images were compared to computational simulations of PNAs in metastatic lesions. 
3.4.2 Physicochemical Properties of PNAs Predict Their In Vivo Distribution Profiles 
 Although PNAs accumulated throughout liver tissue with MCRC tumors, the 
diffusion rate of PNAs into tissue was difficult to measure accurately due to fluctuations 
in tissue density, interstitial space volume, and tissue pH. To accurately measure tissue 
diffusion rates for PNAs, agarose gel tissue mimics with controllable mass transport 
properties such as density and pH were prepared. As described in the methods section, 
the gel densities in this study mimic the extracellular space between healthy cells (0.5% 
w/v) and the keratin mesh surrounding tumors (1.0% w/v). In addition, the pH of gels 
was selected to mimic healthy tissue (pH 7.4) and acidic tumor tissue (pH 7.0 and 6.0). 
These gels simulate a variety of conditions representative of healthy and tumor tissues. 
Mass transport properties of agarose gels have been well studied for physical separation 
methods such as electrophoresis and gel blotting. Unlike ionizable molecules that alter 
their diffusion rates into agarose gels as a function of pH, PNAs lacking surface charge 
had consistent flux into agarose gels between pH 7.4 and 6. Although there were small 
pH-dependent variations in flux, these variations did not represent an overall trend. High 
gel density reduced PNA flux by about 40% compared to low gel density. Although the 
pores in both gels are large enough (50 to 500 nm) for 30 nm PNAs to enter, smaller 
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pores may increase the interactions between pore walls and PNAs and slow long-range 
diffusion. Therefore, although gel pores should allow PNAs to freely diffuse into tissue 
mimics, the experimental data demonstrate a clear correlation between tissue density and 
PNA transport.  
Despite these findings, it should be acknowledged that gel mimics have physical 
and chemical limitations in accurately reproducing tissue conditions. For example, gel 
mimics lack lipids and proteins that can affect pore structure and PNA interactions during 
diffusion (150). In addition, tumors have high interstitial tissue pressure due to disrupted 
lymphatic drainage that can further influence PNA transport into MCRC tumors (151). 
Previous studies show that high intratumoral pressure limits the diffusion of small 
molecules and nanoparticles into solid tumors (152, 153). A simple pressurized system 
was developed to attempt to investigate the effects of pressure on diffusion; however, 
because the system pressurized gels from all sides, rather than creating a pressure 
gradient through the gel, the system was unlikely to accurately mimic in vivo pressure 
conditions. In addition, this system did not account for blood flow, which can increase 
nanoparticle transport out of the blood vessels and into interstitial space surrounding 
tumors (154, 155). Regardless, pressurized conditions increased short-term entry of 
PNAs into tissue mimics (<0.5 h) but failed to further enhance PNA diffusion (> 0.5 h). 
This increase may be due to the deformation of gels near the surface increasing the entry 
of PNAs into the surface. Future work is needed to develop a robust system that 
accurately mimics the flow conditions in tumor vasculature and the pressure conditions in 
solid tumors in order to further investigate nanoparticle transport into gel mimics. 
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The diffusion of molecules into gel mimics is expected to follow Fick’s second 
law of diffusion. Mathematically, this indicates that the concentration-time data should fit 
to an unsteady state first order diffusion equation with a constant concentration and a zero 
concentration boundary condition. The analytical solution of this equation indicates that 
concentration-distance profiles at each timepoint follow an error function distribution, 
and total mass-time profiles in gels would follow an exponential function. Preliminary 
diffusion experiments using the small molecule NB followed this expected behavior; 
however, mass-time plots from 3P’IR820 yielded linear equations with respect to time. 
As a result, the flux of PNAs into gels could be determined by the slope of a linear 
regression of the mass-time profiles. This unexpected result indicates that there are 
fundamental differences between small molecule and nanoparticle diffusion into gels, and 
that an unsteady state first order diffusion model may not be appropriate to model 
nanoparticle diffusion in gel mimics. Small molecules have small hydrodynamic 
diameters (< 1 nm) compared to PNAs (~30 nm), so small molecules can diffuse 
unimpeded through gel pores (50-500 nm) compared to small molecules (156). 
Interactions between PNAs and the walls of pores in tissue mimics may change their 
diffusion behavior from expected profiles (157). In addition, non-linearity of PNA 
absorbance due to the heterogeneous distribution of PNAs in gels could increase the 
absorbance of PNAs diffused into gels at later timepoints and artificially increase 
measured flux rates. Therefore, the physical properties of PNAs and other nanoparticles 
related to pore interactions should be carefully considered in addition to their diffusivity 
in solution in order to increase the in vivo diffusion of nanoparticles. 
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The opsonization and aggregation of nanoparticles can reduce their tumor 
accumulation, decrease their half-life in blood and increase the interactions between 
PNAs and immune cells (158, 159). PNAs showed negligible opsonization and 
aggregation in vitro, which indicates that the PEG shell shields dyes from 
macromolecules in solution and allows dyes to detect the tumor microenvironment. 
However, fluorescence imaging of halo-fluorochromic PNAs shows that the PEG shell 
does not prevent the diffusion of small acidic molecules into the PNA core allowing the 
detection of the acidic environment. Taken together, these results suggest that PNAs with 
minimal opsonization allow fluorescent dyes to remain in the blood and detect acidic 
tumors or tumor metastasis. 
The accumulation of halo-fluorochromic PNAs in the cytosol or in the endosomes 
of cancer cells can prevent the detection of the acidic extracellular tumor 
microenvironment. In vitro cellular uptake measurements indicated that only a small 
fraction of PNAs by mole or mass entered cells, but these conditions had fewer cells and 
greater extracellular volume than solid tumors. The molar ratio of PNA uptake in cells of 
tumors at equilibrium is calculated following equation 3.25. 
𝑑𝑑𝑖𝑖𝐼𝐼𝐼𝐼
𝐸𝐸𝐸𝐸
𝑑𝑑𝐼𝐼𝐸𝐸𝐼𝐼
𝐸𝐸𝐸𝐸 = 𝐾𝐾𝐸𝐸𝐸𝐸 ∗
𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼∗𝑑𝑑𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼∗𝜌𝜌𝐼𝐼𝐼𝐼𝑡𝑡𝑡𝑡𝐼𝐼∗𝑉𝑉𝐼𝐼𝐼𝐼𝑡𝑡𝑡𝑡𝐼𝐼
𝑉𝑉𝐼𝐼𝐸𝐸𝐼𝐼∗𝑉𝑉𝐼𝐼𝐼𝐼𝑡𝑡𝑡𝑡𝐼𝐼
  (3.25) 
In equation 3.25, KEQ and Vext are unitless, Vcell has units of cm3 per cell, Ncell has 
units of cells per g of tumor tissue, ρtumor has units of g per cm3, and Vtumor has units of 
cm3. If the spatial properties of tumors are assumed to be independent of volume, then the 
results are independent of Vtumor. Experimental measurements by Park et al. indicated that 
solid xenograft tumors have a density (ρtumor) of 0.79 g/cm3 (160). Solid tumors are often 
assumed to contain 109 cells per gram of tumor tissue (Ncell), but it should be noted that 
110 
this value has been challenged for some types of tumors (161). In addition, Vestvik et al. 
estimated the extracellular fluid volume ratio (Vext) of human melanoma xenograft tumors 
to be between 7.1 to 27.1% based on the cell type (162). Table 3.6 contains calculated 
molar ratios of 2PN and 3PN uptake for solid tumors with the extracellular fluid volume 
ratios 7.1, 17.1 and 21.7%. After accounting for the decreased extracellular space and 
increased cell density in tumors, the estimated in vivo molar ratio of PNAs in cells is 
greater than the in vitro measured ratio. In order for this calculation to be valid, it is 
assumed that the biological factors affecting KEQ, such as a constant surface area-to-
volume ratio of cancer cells and the homogeneous distribution of PNAs in the interstitial 
fluid surrounding cancer cells, remain consistent from in vitro conditions to in vivo 
conditions. The decreased surface area-to-volume ratios of cancer cells and the 
heterogeneous distribution of PNAs in solid tumors may significantly reduce the 
measured equilibrium constant in vivo. 
  
111 
Table 3.6. Calculated molar ratios of PNA uptake using the spatial properties of solid 
tumors.  
 Extracellular Fluid Volume Ratio (%) 
PNA 7.1 17.1 27.1 
2PN 5,800 (5,600-6,000) 2,400 (2,300-2,500) 1,500 (1,400-1,600) 
3PN 9,100 (8,900-9,300) 3,800 (3,700-3,900) 2,400 (2,300-2,500) 
Calculated molar ratios are reported as mean with 95% CI in parentheses. The 
confidence intervals contain errors that were propagated from the equilibrium constant 
in equation 3.25. Because these values are calculated estimations and not measured 
values, they were not compared statistically. 
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The accumulation of halo-fluorochromic PNAs in acidic endosomes or lysosomes 
could interfere with the detection of the acidic tumor microenvironment. Fluorescence 
signals of halo-fluorochromic PNAs were not observed in healthy tissue, suggesting that 
fluorescence signals from PNAs in endosomes or lysosomes of healthy cells is not 
sufficient to detect halo-fluorochromic PNAs. Videos of live cell uptake of 3PN showed 
small circular spots traveling through cells, suggesting that some PNAs were present in 
endosomes. However, these endosomes quickly disappeared, suggesting that 3PN can 
escape endosomes and enter the cytosol. Fluorescence imaging of cells stained with 
lysosome-sensitive dyes indicated that PNAs with a hydrophobic core environment 
escaped endosomes and entered the cytosol (76). However, it should be noted that some 
PNAs (~10% of intracellular fluorescence) remained in endosomes, and the fluorescence 
of PNAs in endosomes or lysosomes may contribute to the overall fluorescence signals of 
halo-fluorochromic PNAs in tumors. 
It is often assumed that nanoparticle uptake by cells depends on interactions 
between the nanoparticle shell and the surface of the cell membrane. Intracellular uptake 
of PNAs reached equilibrium within 0.5 h of initial treatment, but small molecules that 
diffuse through the cell membrane accumulate in cells up to 24 hours post-treatment. 
Surprisingly, hydrophobic core modifications slightly increased the uptake of PNAs 
despite the PEG shell, suggesting that the core of PNAs can weakly interact with the cell 
membrane through hydrophobic interactions and slightly increase cellular uptake.  
Differences in cellular uptake mechanisms between samples can contribute to 
differences in uptake behavior. First, MG and PNAs had distinct cellular uptake profiles 
up to 6 hours post-treatment. Although PNAs remained outside of cells and quickly 
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reached equilibrium with the surrounding environment, MG continued to accumulate 
inside cells up to 6 h post-treatment. MG is a cell membrane-permeable dye that initially 
accumulates in mitochondria of cells due to mitochondrial membrane potential (163). 
Due to its lipophilicity at physiological pH, MG can enter cells by diffusion through the 
cell membrane. Because PNAs are large and contain a hydrophilic shell, they are unlikely 
to diffuse through the cell membrane. Previous studies indicate that PNAs enter cells 
through energetic processes such as endocytosis (76). However, differences in 
equilibrium constants and rate constants were observed between the uptake of 2PN and 
3PN, which should contain similar hydrophilic shells due to PEG substitution. 
Differences between the diameters of 2PN (~25 nm) and 3PN (~35 nm) could slightly 
increase the uptake of 3PN compared to 2PN. In addition, increased adsorption of 3PN to 
the cellular membrane could contribute to increased apparent uptake. Simulated 
illumination methods such as the ApoTome were considered for more sensitive imaging 
of the cell membrane, but poor spatial resolution of cells imaged by these methods 
compared to confocal microscopy limited their application for cell membrane imaging 
(164). In future studies, confocal microscopy of single live cells treated with PNAs could 
elucidate the differences in spatial distribution between 2PN and 3PN and indicate if 
differences in cellular uptake are due to extracellular membrane accumulation or 
intracellular cytosol accumulation.  
3.4.3 Computational Simulations of PNA Accumulation in Metastatic Tumors 
Overcome the Limitations of Microscopic Fluorescence Imaging 
 Clinicians typically use microscopic fluorescence images of patient tissues from 
biopsy samples to identify tumors and determine effective treatment regimens. 
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Macroscopic fluorescence imaging indicated that PNAs accumulate in PDX tumors and 
liver bearing MCRC tumors, but microscopic fluorescence images had decreased 
fluorescence compared to macroscopic images. Macroscopic fluorescence images of 
normal organs and tumors are taken immediately after collection, but microscopic images 
require significant sample preparation prior to imaging. For example, tissue samples in 
this study were washed, stained, treated and fixed to microscope slides prior to imaging. 
Tissue washing may extract water-soluble PNAs from the extracellular space and 
decrease fluorescence signals, but the cell membrane may prevent the extraction of PNAs 
from the cytosol (165). Therefore, microscopic fluorescence imaging may underestimate 
extracellular PNA concentrations in tissues. It should be noted that differences in 
detection method sensitivity could also contribute to changes in fluorescence signals 
between macroscopic and microscopic images. Specifically, increased sensitivity of the 
IVIS compared to the fluorescence microscope could increase fluorescence signals in 
macroscopic images compared to microscopic images. However, the fluorescence of NB-
labelled PNAs was stronger under a fluorescence microscope than under an IVIS, and 
decreased concentrations of 3PN had to be used in cellular uptake experiments compared 
to the IVIS characterization experiments in chapter 2. In order to investigate changes in 
extracellular PNA concentrations following tissue sample preparation, computational 
simulations of metastatic tumors were used to predict PNA accumulation in these tumors.    
Computational simulations of PNA distribution in metastatic tumors were used to 
quantitatively assess the potential for the early and accurate detection of tumor 
metastasis. These simulations indicate that PNAs are expected to readily accumulate near 
the perimeter and within tumor metastases. This accumulation is projected to remain 
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steady within hypoxic (more acidic) tumor regions.  This is consistent with the 
experimental results showing that PNAs near the perimeter of tumors can increase 
fluorescence and help identify the acidic environment of metastatic tumors. In the 
simulation, the uptake rate of PNAs by cancer cells was assumed to be equal to the 
uptake rate of oxygen. This assumes the highest expected value for the uptake of 
nanoparticles without receptor-targeting ligands. Decreased uptake parameters of PNAs 
would increase extracellular concentrations of PNAs and increase the predicted 
accumulation of PNAs in the hypoxic and necrotic regions of metastatic lesions. In the 
future, the computational simulations could be improved by calculating uptake 
parameters for PNAs in proliferating, hypoxic or necrotic regions of metastatic tumors 
and determining the effects of extracellular pH, oxygen concentrations and angiogenesis 
on PNA uptake parameters. 
3.4.4 Mechanism for the Halo-Fluorochromic Detection of Liver Metastatic Tumors 
 Determining a mechanism for the halo-fluorochromic detection of liver MCRC 
holds promise to improve the future detection of small MCRC tumor foci. The results 
from this study suggest that PNAs diffuse throughout healthy and tumor tissue, and that 
some PNAs remain outside of cancer cells. Macroscopic imaging implies that halo-
fluorochromic PNAs accumulate in acidic MCRC tumor tissue and fluoresce in the 
interstitial space between liver cells and tumors. However, microscopic imaging showed 
only small amounts of PNAs accumulating in interstitial space, probably because PNAs 
outside of cells were extracted during sample preparation for microscopic imaging. 
Nevertheless, non-halo-fluorochromic PNAs accumulated throughout liver tissue and 
failed to identify MCRC tumors, while halo-fluorochromic PNAs fluoresce strongly in 
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acidic microenvironments and identify MCRC tumors. Although some PNAs are taken 
up by Kupffer cells in the liver, their influence on overall images would be relatively 
small. Future studies should focus on determining the minimum size of MCRC tumor 
foci that halo-fluorochromic PNAs can detect effectively. 
3.5 Conclusions 
Halo-fluorochromic PNAs were developed as a tool for the early and accurate 
detection of liver MCRC tumors by imaging the periphery of acidic tumor tissues while 
minimizing signals from liver stroma. PNAs entrapping halo-fluorochromic dyes showed 
low opsonization, cellular uptake, and tissue diffusion, which allowed PNAs to enter the 
extracellular space of the liver. Macroscopic and microscopic imaging of PDX tumors 
showed that PNAs accumulate throughout primary tumors. Non-halo-fluorochromic 
PNAs diffuse through the healthy liver and hinder the detection of liver MCRC tumors, 
but halo-fluorochromic PNAs emit fluorescence mainly near acidic tumors and reduce 
background fluorescence signals from healthy liver. Computational simulations were 
used to evaluate halo-fluorochromic PNA detection of small metastatic CRC tumors early 
in development that cannot be detected by traditional imaging methods. These results 
suggest that halo-fluorochromic PNAs may detect MCRC tumors more effectively than 
small molecule dyes or nanoparticles modified with traditional dyes.  
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4 SOLVATO-FLUOROCHROMIC METHODS AS AN APPROACH TO 
OVERCOME THE LIMITATIONS OF CHROMATOGRAPHY-BASED METHODS 
FOR DIALYSIS-BASED DRUG RELEASE MEASUREMENTS 
4.1  Introduction 
PNAs can serve as nanoscale carriers delivering anticancer drugs to solid tumors, 
and they can increase drug accumulation in tumor cells by fine-tuning drug release rates 
within the interstitial and intercellular spaces of tumors (134, 142, 166-172). Drug release 
rates from PNAs have been controlled by modulating their polymer composition, particle 
stability, and chemical interactions with drug molecules (173-175). The antitumor 
activity of PNAs was expected to change as a function of their drug release rates (176-
183). However, in vivo drug release rates from PNAs were difficult to predict from in 
vitro measurements because of complicated interactions between nanoassemblies and 
released drugs in vitro (184, 185). 
Dialysis-based methods are often used to determine in vitro drug release rates for 
PNAs and other nanoparticle drug carriers (186-191). Under typical experimental 
conditions, drug-loaded nanoparticles are added into a dialysis cassette to release drugs 
over time, and released drugs diffuse through the dialysis membrane into a large volume 
of buffer solution (dialysis sink). Analytical methods such as HPLC or light spectroscopy 
are then used to quantify the drug remaining inside the dialysis solution and predict drug 
release patterns. However, these analytical methods cannot distinguish between released 
drugs from the nanoparticle carrier and entrapped drugs within the dialysis cassette. To 
address this issue, investigators have modified traditional dialysis methods for measuring 
nanoparticle drug release to use tangential flow, ultrafiltration, electrodialysis, surfactants 
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or organic solvents. These modifications attempt to either facilitate released drug 
diffusion through the dialysis membrane into the dialysis sink or to sequester released 
drugs within the dialysis cassette and improve sink conditions (192-198). In addition, 
computational modeling has corrected for in vitro interactions between PNAs and 
released drugs in the dialysis cassette (199, 200).  
Despite these efforts, the accuracy of drug release rates predicted by both 
traditional and modified dialysis methods remains questionable. Drug release profiles 
from dialysis-based methods are often fit to simple exponential models, which predict 
drug release rates based on four main assumptions: 1) all drug in the dialysis cassette is 
encapsulated in nanoparticles, 2) nanoparticles and dialysis membranes do not interact 
with released drug, 3) released drug is quickly removed from the dialysis cassette, and 4) 
released drug in the dialysis cassette does not affect the release rate of drug-loaded 
nanoparticles. Unfortunately, environmental factors such as molecular interactions and 
complicated mass transfer effects can invalidate some, if not all, of these assumptions. 
Drug binding to nanoparticles after release from the hydrophobic core can cause 
unrealistically slow drug release rates (64). In addition, drug adsorption to dialysis 
membranes can alter measured drug release rates. The adsorption of released drugs in the 
dialysis solution to the dialysis membrane can remove released drugs from the dialysis 
solution and increase the accuracy of chromatography-based drug release measurements, 
but rapid drug adsorption to the dialysis membranes followed by slow desorption of drug 
into the dialysis solution could also cause unrealistically slow drug release profiles (177, 
184). The slow diffusion of hydrophobic drugs out of the dialysis cassette can also 
increase the residence time of released drugs inside the cassette. As a result, a measured 
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in vitro drug release rate is often different from its corresponding in vivo release rate. 
Computational models cannot easily compensate for these modeling errors unless the 
specific contributions from encapsulated drug, bound drug, and released drug inside a 
dialysis cassette to the overall drug release rate can be measured. The isolation of these 
various drug species during drug release measurements from nanoparticle drug carriers 
remains challenging. Therefore, there is a critical need to develop a novel method to 
measure drug release profiles of nanoparticles and predict drug release rates in a facile 
and accurate manner.  
Based on this background, this study developed and evaluated a novel method to 
determine drug release rates from PNAs and potentially other types of nanoparticles with 
improved convenience and accuracy compared to traditional chromatography-based 
methods. This method employs solvato-fluorochromism (SFC), which was shown in 
chapter 2 and in the literature to be useful for analyzing the hydrophobicity of the PNA 
core and determining drug entrapment (201). Because the fluorescence of NB is 
quenched in water, potential interactions between free NB and released drug in solution 
should not interfere with fluorescence measurements. In addition, because SFC occurs 
over a short distance, NB in the core of PNAs should not interact with released drug. 
Therefore, in comparison to chromatographic methods that cannot distinguish various 
drug species in dialysis cassettes, SFC-based methods are expected to elucidate molecular 
interactions specifically between nanoparticles and drugs entrapped in the nanoparticle 
core.  
In this study, HPLC- and SFC-based methods were compared to determine drug 
release rates from NB-conjugated PNAs in dialysis cassettes with varying core conditions 
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that modulate drug entrapment and release (Figure 4.1). NB-conjugated PNAs with an 
ionic or hydrophobic core were synthesized as described in chapter 2 and reported in the 
literature (201). Carfilzomib (CFZ) and docetaxel (DOC) were used as clinically relevant 
model anticancer drugs with well-studied physicochemical and biological properties. To 
evaluate drug diffusion effects on drug release measurements, hydrophobic excipients 
(palmitate and deoxycholate) were added to PNAs to force entrapped drugs into the 
center of the nanoparticle core. Mathematical modeling was also used to elucidate the 
effects of drug binding and diffusion on each measurement method. Therefore, the goal 
of this study was to compare HPLC- and SFC-based methods for measuring drug release 
from dialysis cassettes and to evaluate the potential of the SFC method for the 
determination of drug release rates from nanoparticles.  
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Figure 4.1. Graphical description of solvato-fluorochromism (A) as a fluorescence-based 
drug release measurement method to overcome the limitations of HPLC-based drug 
release methods (B) and measure drug release (C). 
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4.2 Materials and Methods 
4.2.1 Materials 
2PN and 3PN PNAs were prepared as described in chapter 2. Palmitic acid (PAL) 
and deoxycholic acid (DOCA) were purchased from Sigma Aldrich (St. Louis, MO). 
Dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), McCoy’s 5A cell media, 
ethanol, and dialysis cassettes with a 10 kDa MWCO were purchased from Fisher 
Scientific (Waltham, MA). CFZ and DOC were purchased from LC Laboratories 
(Woburn, MA). 
4.2.2 Drug Loading of Unstabilized and Excipient-Stabilized PNAs 
Stock solutions of PNAs (2PN and 3PN, 100 mg/ml), drugs (CFZ and DOC, 1 
mg/ml), and excipients (PAL and DOCA, 100 mg/ml) were prepared in ethanol. PNA 
(100 μl) and drug solutions (1 ml) were mixed in a round bottom flask and evaporated at 
reduced pressure to create a thin film. These thin films were reconstituted in water and 
centrifuged at 1000 RPM for 1 minute to remove free drug, excess excipients, and other 
insoluble impurities. Drug-loaded PNAs in the supernatant were collected after freeze 
drying and stored at -20 °C. In addition, excipient-stabilized PNAs were prepared by 
adding excipient (20 μl), PNA (100 μl) and drug solutions (1 ml) into a round bottom 
flask and repeating this procedure. Drug concentrations in drug-loaded PNA solutions 
were determined by HPLC (Agilent Eclipse XDB-C18 column, 40 °C, 1 ml/min mobile 
phase) for CFZ (55:45 ACN/water with 0.1% formic acid, 200 nm, 2.01 min elution) and 
DOC (65:35 ACN/water with 0.1% formic acid, 230 nm, 2.65 min elution). Drug peaks 
in each sample were compared to calibration curves of known concentration drug 
standards. The drug loading efficiency and encapsulation efficiency were defined as the 
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weight ratio of drug to drug-loaded PNAs and the weight ratio of drug in PNAs to total 
drug added, respectively. In addition, the molar drug loading efficiency was calculated as 
the molar ratio of drug to drug-loaded PNAs. 
4.2.3 HPLC-Based and Solvato-Fluorochromic Drug Release Measurements 
Drug-loaded PNAs were dispersed at 10 mg/ml in PBS, and the solutions (1 ml) 
were dialyzed into 1 l of PBS at 37 °C. Aliquots (100 μl) from within the dialysis 
cassettes were removed after 0, 1, 3, 6, 24 and 48 hours, and drug concentrations were 
quantified by HPLC as described in the previous section. For the SFC method, drug-
loaded PNAs were dispersed at 10 mg/ml in PBS, and the solutions (1 ml) were dialyzed 
into 1 l of PBS at 37 °C. Aliquots (100 μl) from within the dialysis cassettes were 
removed after 0, 1, 3, 6, 24 and 48 hours, and drug concentrations were quantified as 
described below. In order to optimize the SFC method for measuring drug release 
profiles, fluorescence emission spectra of drug-loaded and empty PNAs were initially 
measured using several excitation wavelengths. From these spectra, excitation conditions 
for fluorescence spectra for 2PN (610 nm) and 3PN (580 nm) were selected for 
measurement using a plate reader (Spectramax M5, Sunnyvale, CA). These fluorescence 
spectra identified optimal excitation and emission wavelengths for analyzing 2PN (Ex 
610 nm/Em 670 nm) and 3PN (Ex 580 nm/Em 630 nm) drug release profiles. 
Fluorescence measurements were converted to normalized drug concentrations. Briefly, 
the fluorescence of empty PNAs was subtracted from the fluorescence of each SFC 
measurement, and the fluorescence was normalized to the initial fluorescence of each 
drug-loaded PNA. Drug release profiles from dialysis-based and SFC-based methods 
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were fitted to first order release kinetics models using Prism 5 (Graphpad, La Jolla, CA). 
Equation 4.1 below describes a first order kinetic model for drug release. 
𝐶𝐶
𝐶𝐶0
= 100 ∗ 𝑒𝑒−𝑘𝑘∗𝑑𝑑   (4.1) 
In equation 4.1, C/C0 is the percent drug concentration in samples at time t 
relative to the initial drug concentration, and k is the rate constant. The time t has units of 
hours, while the rate constant has units of inverse hours. C/C0 is unitless. The drug 
release half-life t1/2 was defined in equation 4.2 as the time for drug in samples to reach 
50% of the initial concentration. 
𝑡𝑡1/2 =
ln (2)
𝑘𝑘
    (4.2) 
The drug release half-life has units of hours. 
4.2.4 Free and Spiked Drug Release Measurements using HPLC-based and Solvato-
Fluorochromic Methods 
The release of free CFZ (1 or 0.5 mg/ml CFZ), free CFZ (1 mg/ml) spiked into 
2PN solution (10 or 5 mg/ml) and drug-loaded 2PN (10 or 5 mg/ml) was measured using 
both the HPLC and the SFC method. Briefly, CFZ was dissolved in DMSO at 100 mg/ml 
to prepare a stock solution. For free drug release experiments, either 10 or 5 μl of drug 
solution was added to 990 or 995 μl of PBS, respectively. For spiked drug release 
experiments, 10 μl of drug solution was added to 990 μl of 2PN solution (5 or 10 mg/ml 
in PBS). CFZ-loaded 2PN was also dispersed in PBS at 5 or 10 mg/ml for drug-loaded 
PNA release experiments. Each colloidal solution (1 ml) was dialyzed into 1 l of PBS at 
37 °C under sink conditions. Drugs remaining in PNAs were quantified using both the 
HPLC-based and SFC methods. As a negative control for the effects of organic solvents 
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on the SFC method, SFC measurements were repeated while adding blank DMSO (10 μl) 
to 990 μl 2PN solution (5 or 10 mg/ml PBS).  
4.2.5 Mechanistic Modeling of Drug Release from PNAs 
A mechanistic model of drug release kinetics from PNAs was derived to account 
for weak drug binding to the shell of PNAs and drug diffusion through the dialysis 
membrane. The mechanistic model was based on previous studies of drug release kinetics 
from polymer micelles (184). Mass balances were written for released drug (MR) and 
total drug remaining (MT) in dialysis cassettes in equations 4.3 and 4.4. Encapsulated 
drug in the core of PNAs was defined as ME, while drug that is weakly bound to PNAs 
and released drug in the dialysis solution were defined as MR,P and MR,W, respectively. 
𝑀𝑀𝑅𝑅 = 𝑀𝑀𝑅𝑅,𝑃𝑃 + 𝑀𝑀𝑅𝑅,𝑊𝑊   (4.3) 
𝑀𝑀𝑇𝑇 = 𝑀𝑀𝐸𝐸 + 𝑀𝑀𝑅𝑅,𝑃𝑃 + 𝑀𝑀𝑅𝑅,𝑊𝑊   (4.4) 
In equations 4.3 and 4.4, all mass values have units of micrograms. 
Equation 4.4 was divided by the total volume of the dialysis cassette (VT) in order 
to convert total mass to total concentration. Equation 4.5 describes total drug 
concentration in terms of volume. 
𝐶𝐶𝑇𝑇 =
𝑀𝑀𝑅𝑅,𝑊𝑊+𝑀𝑀𝐸𝐸+𝑀𝑀𝑅𝑅,𝑃𝑃
𝑉𝑉𝑇𝑇
   (4.5) 
In equation 4.5, VT has units of milliliters, while CT has units of micrograms per 
milliliter in the dialysis cassette. The total volume is assumed to be equal to the volume 
of the solution (VW) plus the volume of the PNAs (VP). 
In order to convert equation 4.5 into concentration terms for each species, the 
mass of each species is converted to the product of its concentration and its species 
volume in equation 4.6.  
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𝐶𝐶𝑇𝑇 =
�𝐶𝐶𝑅𝑅,𝑊𝑊∗𝑉𝑉𝑊𝑊�+(𝐶𝐶𝐸𝐸∗𝑉𝑉𝑃𝑃)+(𝐶𝐶𝑅𝑅,𝑃𝑃∗𝑉𝑉𝑃𝑃)
𝑉𝑉𝑇𝑇
  (4.6) 
In equation 4.6, all concentration values have units of micrograms per milliliter, 
and all volumes have units of milliliters of volume per species.  
Constants a and b are defined as unitless volume ratios of solution and PNAs in 
equations 4.7 and 4.8. These values are substituted into equation 4.6 to yield equation 4.9. 
𝑎𝑎 = 𝑉𝑉𝑊𝑊
𝑉𝑉𝑇𝑇
    (4.7) 
𝑏𝑏 = 𝑉𝑉𝑃𝑃
𝑉𝑉𝑇𝑇
    (4.8) 
𝐶𝐶𝑇𝑇 = 𝑎𝑎𝐶𝐶𝑅𝑅,𝑊𝑊 + 𝑏𝑏𝐶𝐶𝐸𝐸 + 𝑏𝑏𝐶𝐶𝑅𝑅,𝑃𝑃   (4.9) 
Using an estimated 2PN density (1.1 g/ml) and measured dialysis cassette 
volume, the calculated values of a for 2PN at 5 and 10 mg/ml were 0.996 and 0.992, 
respectively. In addition, the calculated values of b for 5 and 10 mg/ml PNA 
concentrations are 0.004 and 0.008, respectively. 
Mass balances were written for encapsulated drug, total released drug and drug in 
the dialysis sink (MS) in equations 4.10, 4.11 and 4.12. 
𝑑𝑑𝑀𝑀𝐸𝐸
𝑑𝑑𝑑𝑑
= −𝑘𝑘𝐶𝐶𝑀𝑀𝐸𝐸 + 𝑘𝑘𝑅𝑅𝑀𝑀𝑅𝑅,𝑃𝑃   (4.10) 
𝑑𝑑𝑀𝑀𝑅𝑅
𝑑𝑑𝑑𝑑
= 𝑘𝑘𝐶𝐶𝑀𝑀𝐸𝐸 − 𝑘𝑘𝑅𝑅𝑀𝑀𝑅𝑅,𝑃𝑃 − 𝑘𝑘𝐷𝐷𝑀𝑀𝑅𝑅,𝑊𝑊 + 𝑘𝑘𝐷𝐷𝑀𝑀𝑆𝑆  (4.11) 
𝑑𝑑𝑀𝑀𝑆𝑆
𝑑𝑑𝑑𝑑
= 𝑘𝑘𝐷𝐷𝑀𝑀𝑅𝑅,𝑊𝑊 − 𝑘𝑘𝐷𝐷𝑀𝑀𝑆𝑆   (4.12) 
Mass balances were converted to concentration in equations 4.13, 4.14 and 4.15 
by assuming that species volumes remain constant over time, and by substituting mass for 
volume times the concentration. 
𝑉𝑉𝑃𝑃
𝑑𝑑𝐶𝐶𝐸𝐸
𝑑𝑑𝑑𝑑
= −𝑘𝑘𝐶𝐶𝑉𝑉𝑃𝑃𝐶𝐶𝐸𝐸 + 𝑘𝑘𝑅𝑅𝑉𝑉𝑃𝑃𝐶𝐶𝑅𝑅,𝑃𝑃  (4.13) 
𝑉𝑉𝑇𝑇
𝑑𝑑𝐶𝐶𝑅𝑅
𝑑𝑑𝑑𝑑
= 𝑘𝑘𝐶𝐶𝑉𝑉𝑃𝑃𝐶𝐶𝐸𝐸−𝑘𝑘𝑅𝑅𝑉𝑉𝑃𝑃𝐶𝐶𝑅𝑅,𝑃𝑃−𝑘𝑘𝐷𝐷𝑉𝑉𝑊𝑊𝐶𝐶𝑅𝑅,𝑆𝑆 + 𝑘𝑘𝐷𝐷𝑉𝑉𝑆𝑆𝐶𝐶𝑆𝑆 (4.14) 
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𝑉𝑉𝑆𝑆
𝑑𝑑𝐶𝐶𝑆𝑆
𝑑𝑑𝑑𝑑
= 𝑘𝑘𝐷𝐷𝑉𝑉𝑊𝑊𝐶𝐶𝑅𝑅,𝑊𝑊 − 𝑘𝑘𝐷𝐷𝑉𝑉𝑆𝑆𝐶𝐶𝑆𝑆  (4.15) 
In equations 4.14 and 4.15, VS is the volume of the dialysis sink (1000 ml). 
Differential rate equations 4.13, 4.14 and 4.15 were rearranged into equations 
4.16, 4.17 and 4.18, respectively. In equation 4.18, 0.001 is calculated volume ratio of the 
dialysis cassette (1 ml) to the dialysis sink (1 L). 
𝑑𝑑𝐶𝐶𝐸𝐸
𝑑𝑑𝑑𝑑
= −𝑘𝑘𝐶𝐶𝐶𝐶𝐸𝐸+𝑘𝑘𝑅𝑅𝐶𝐶𝑅𝑅,𝑃𝑃   (4.16) 
𝑑𝑑𝐶𝐶𝑅𝑅
𝑑𝑑𝑑𝑑
= 𝑏𝑏(𝑘𝑘𝐶𝐶𝐶𝐶𝐸𝐸 − 𝑘𝑘𝑅𝑅𝐶𝐶𝑅𝑅,𝑃𝑃) − 𝑘𝑘𝐷𝐷(𝑎𝑎𝐶𝐶𝑅𝑅,𝑊𝑊 − 𝐶𝐶𝑆𝑆) (4.17) 
𝑑𝑑𝐶𝐶𝑆𝑆
𝑑𝑑𝑑𝑑
= 0.001 ∗ 𝑘𝑘𝐷𝐷�𝑎𝑎 ∗ 𝐶𝐶𝑅𝑅,𝑊𝑊 − 𝐶𝐶𝑆𝑆�  (4.18) 
The unitless ratio of weakly bound drug to released drug in solution is defined as 
the PNA-water partition coefficient (KP) in equation 4.19. Mass balances can be written 
for released drug in equation 4.20 and converted to concentration in equation 4.21.  
𝐾𝐾𝑃𝑃 =
𝐶𝐶𝑅𝑅,𝑃𝑃
𝐶𝐶𝑅𝑅,𝑊𝑊
    (4.19) 
𝑀𝑀𝑅𝑅 = 𝑀𝑀𝑅𝑅,𝑃𝑃 + 𝑀𝑀𝑅𝑅,𝑊𝑊   (4.20) 
𝑉𝑉𝑇𝑇𝐶𝐶𝑅𝑅 = 𝑉𝑉𝑃𝑃𝐶𝐶𝑅𝑅,𝑃𝑃 + 𝑉𝑉𝑊𝑊𝐶𝐶𝑅𝑅,𝑊𝑊   (4.21) 
By solving equation 4.21 for CR,P or CR,W and substituting in Kp for CR,W or CR,P, 
respectively, the concentration of each species of released drug can be described in terms 
of total released drug as in equations 4.22 and 4.23. 
𝐶𝐶𝑅𝑅,𝑊𝑊 =
𝐶𝐶𝑅𝑅
𝑑𝑑+𝑏𝑏𝐾𝐾𝑃𝑃
   (4.22) 
𝐶𝐶𝑅𝑅,𝑃𝑃 =
𝐾𝐾𝑃𝑃∗𝐶𝐶𝑅𝑅
𝑑𝑑+𝑏𝑏𝐾𝐾𝑃𝑃
   (4.23) 
Equations 4.22 and 4.23 are substituted into equations 4.16, 4.17 and 4.18 to yield 
equations 4.24, 4.25 and 4.26, respectively. In addition, equations 4.22 and 4.23 were 
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substituted into equation 4.9, and the equation was rewritten as 4.27. Drug release 
profiles were simultaneously fitted to equations 4.24, 4.25, 4.26 and 4.27 using a 
weighting factor of 2 to determine kC, kR, KP and kD using Scientist 3.0 (Micromath, St. 
Louis, MO). 
𝑑𝑑𝐶𝐶𝐸𝐸
𝑑𝑑𝑑𝑑
= −𝑘𝑘𝐶𝐶𝐶𝐶𝐸𝐸+𝑘𝑘𝑅𝑅
𝐾𝐾𝑃𝑃∗𝐶𝐶𝑅𝑅
𝑑𝑑+𝑏𝑏𝐾𝐾𝑃𝑃
   (4.24) 
𝑑𝑑𝐶𝐶𝑅𝑅
𝑑𝑑𝑑𝑑
= 𝑏𝑏(𝑘𝑘𝐶𝐶𝐶𝐶𝐸𝐸 −
𝑘𝑘𝑅𝑅∗𝐾𝐾𝑃𝑃∗𝐶𝐶𝑅𝑅
𝑑𝑑+𝑏𝑏𝐾𝐾𝑃𝑃
) − 𝑘𝑘𝐷𝐷(
𝑑𝑑∗𝐶𝐶𝑅𝑅
𝑑𝑑+𝑏𝑏𝐾𝐾𝑃𝑃
− 𝐶𝐶𝑆𝑆) (4.25) 
𝑑𝑑𝐶𝐶𝑆𝑆
𝑑𝑑𝑑𝑑
= 0.001 ∗ 𝑘𝑘𝐷𝐷 �
𝑑𝑑∗𝐶𝐶𝑅𝑅
𝑑𝑑+𝑏𝑏𝐾𝐾𝑃𝑃
− 𝐶𝐶𝑆𝑆�  (4.26) 
𝐶𝐶𝑇𝑇 = 𝐶𝐶𝑅𝑅 + 𝑏𝑏𝐶𝐶𝐸𝐸   (4.27) 
For spiked drug release experiments, all drug in the dialysis cassette is initially 
assumed to be released. In contrast, all drug in the dialysis cassette is initially assumed to 
be encapsulated in drug-loaded PNA introduced in release experiments. 
4.2.6 Chemical Stability and Photostability of Nile Blue 
 NB was dissolved at 50 μg/ml in McCoy’s 5A cell media and added into a quartz 
cuvette. The NB-containing cuvette was stored in the dark at 37 °C while gently mixing.  
The absorbance spectrum of NB in the cuvette was measured from 450 nm to 750 nm at 
0, 1, 2 and 5 days post-storage. In addition, NB was dissolved at 100 μg/ml in deionized 
water and added into a 96 well plate. The fluorescence of NB (Ex 632 nm/Em 680 nm) in 
the plate was measured 10 times over a period of 10 minutes. 
4.2.7 Statistics 
 All values in figures are reported as mean±standard deviation of three 
measurements. Groups of measurements are compared by one-way ANOVA with 
Bonferroni’s post-test correction, and pairs of measurements are compared by a Student’s 
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t test unless otherwise noted. Statistical significance in tables and figures is indicated by * 
(p<0.05), ** (p<0.01) or *** (p<0.001). 
4.3 Results 
4.3.1  Hydrophobicity of the PNA Core Environment Controls Drug Loading 
 Drug loading and encapsulation efficiencies of PNAs are described in Table 4.1. 
Both 2PN and 3PN successfully entrapped CFZ and DOC. 3PN had a higher drug loading 
efficiency than 2PN for both drugs, possibly due to favorable interactions between the 
model drugs and PAL in the PNA core. The drug loading and encapsulation efficiency of 
both DOC-loaded 2PN and 3PN increased in order of no excipient, PAL, and DOCA. 
Because CFZ-loaded 3PN already had high drug loading and encapsulation efficiencies, 
hydrophobic excipients were not added to PNAs.  
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Table 4.1. Drug loading of 2PN and 3PN with and without stabilizing excipients. 
PNA Excipient Drug 
Drug 
Loading 
Efficiency 
(w/w %) 
Molar Drug  
Loading Efficiency 
(mol Drug/ 
mol PNA) 
Encapsulation 
Efficiency 
(w/w %) 
2PN None CFZ 3.0±0.1*** 11.5±0.4 30.5±0.9 
3PN None CFZ 8.7±0.4*** 21.3±1.0 94.7±3.8 
PNA*** Excipient*** Drug 
Drug 
Loading 
Efficiency 
(w/w %) 
Molar Drug  
Loading Efficiency 
(mol Drug/ 
mol PNA) 
Encapsulation 
Efficiency  
(w/w %) 
2PN None DOC 1.5±0.1 3.1±0.2 15.1±0.1 
2PN PAL DOC 2.3±0.1 5.0±0.2 23.0±0.2 
2PN DOCA DOC 4.6±0.1 10.0±0.2 47.9±0.5 
3PN None DOC 3.4±0.1 7.4±0.2 34.7±0.4 
3PN PAL DOC 4.1±0.1 8.9±0.2 42.9±0.1 
3PN DOCA DOC 6.6±0.1 14.3±0.2 71.0±0.8 
Drug loading efficiency, molar drug loading efficiency and encapsulation efficiency are 
reported as mean±SD (n=3). Statistical significance is determined by either a Student’s t-
test (CFZ-loaded PNAs) or a two-way ANOVA with Bonferroni’s post-test correction 
(DOC-loaded PNAs) for each group as described in the methods section. For the two-
way ANOVA, statistical significance is indicated on each parameter. 
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4.3.2  HPLC-Based Methods Indicate a Longer Drug Release Half-Life Than Solvato-
Fluorochromic Methods 
Drug release profiles of DOC and CFZ from 2PN and 3PN were measured using 
both HPLC-based and SFC methods (Figures 4.2 and 4.3). Because CFZ and DOC were 
non-fluorescent up to 10 mg/ml, fluorescence of the model drugs did not interfere with 
the observed SFC spectra of PNAs. Figure 4.2 shows drug release profiles for DOC-
loaded 2PN and 3PN, in which HPLC signals from the dialysis method and SFC signals 
decreased as DOC escaped the dialysis cassettes. CFZ-loaded PNAs showed similar drug 
release trends (Figure 4.3). Table 4.2 summarizes the kinetic parameters of 2PN and 3PN 
determined by both HPLC-based and SFC methods. For each drug-loaded PNA, the 
HPLC-based method indicated a longer drug release half-life than the SFC method. It 
should be noted that the specific excitation and emission wavelengths used for SFC 
measurements did not affect the mean values of SFC kinetic parameters, but the weak 
fluorescence signals from sub-optimal measurement conditions significantly increased 
measurement variability.   
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Figure 4.2. Docetaxel release measurements from 2PN (A/B) and 3PN (C/D) using 
HPLC- and SFC-based methods (A/C). SFC spectra of 2PN (B) and 3PN (D). 
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Figure 4.3. Carfilzomib release measurements from 2PN (A/B) and 3PN (C/D) using 
HPLC- and SFC-based methods (A/C). SFC spectra of 2PN (B) and 3PN (D). 
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Table 4.2. Parameters from a first order kinetic model of drug release for 2PN and 3PN 
from HPLC- and SFC-based methods. 
PNA Drug Method t1/2 (h) k (h-1) kSFC/kHPLC 
2PN CFZ HPLC 4.89 (4.22-5.82) 0.14 (0.12-0.16) 2.64 (1.79-3.49) SFC 1.89 (1.74-2.07) 0.37 (0.34-0.40) 
3PN CFZ HPLC 4.66 (3.91-5.76) 0.15 (0.12-0.18) 1.73 (0.88-2.59) SFC 2.68 (2.32-3.18) 0.26 (0.22-0.30) 
2PN DOC HPLC 2.25 (2.05-2.49) 0.31 (0.28-0.34) 1.39 (1.02-1.75) SFC 1.62 (1.54-1.72) 0.43 (0.40-0.45) 
3PN DOC HPLC 5.14 (4.64-5.76) 0.13 (0.12-0.15) 1.92 (1.27-2.58) SFC 2.75 (2.49-3.08) 0.25 (0.23-0.28) 
Kinetic parameters are reported as mean with 95% CI in parenthesis. The error for 
kSFC/kHPLC is propagated from individual rate measurements. The 95% CI of the drug 
release rate ratio is compared to 1 to evaluate if drug release rates are statistically 
similar.  
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4.3.3  Drug Binding to PNAs Reduces the Accuracy of HPLC-Based Measurements but 
Minimally Affects Solvato-Fluorochromic Measurements 
Figure 4.4 shows free CFZ, spiked CFZ, and CFZ-loaded 2PN release profiles. 
Drug release rates increased in order of drug-loaded 2PN, spiked drug, and free drug for 
high and low PNA concentrations. The free CFZ release half-life was greater than 10 
minutes, suggesting that the diffusion rate of free drug through dialysis membrane could 
affect the measured drug release rate. Spiked drug release measurements showed a longer 
drug release half-life than free drug release measurements at high and low concentrations, 
indicating that the PEG shell of PNAs can bind drug and slow drug release. In addition, 
drug-loaded 2PN displayed a longer half-life than either spiked or free drug. Figure 4.5 
shows SFC measurements of spiked drug and spiked blank DMSO release. Because 
PNAs are not present in the dialysis cassette for free CFZ release experiments, solvato-
fluorochromism could not be used to measure free CFZ release profiles. In contrast to 
HPLC-based measurements which directly detected spiked drug by HPLC without 
interference from DMSO, the spiked DMSO interfered with the SFC measurements of 
drug release. Spiked drug slightly increased the initial PNA fluorescence from DMSO-
corrected spiked drug SFC measurements, but the SFC signal was unaffected after 1 
hour. Based on these observations, a mathematical model was developed to account for 
drug binding to PNAs and diffusion through the dialysis membrane during drug release 
measurements.  
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Figure 4.4. HPLC-based measurements for the mechanistic modeling of drug release 
from PNAs. Measurements were performed at 10 mg/ml (A) and 5 mg/ml (B) 2PN 
concentration using carfilzomib as a model drug. 
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Figure 4.5. SFC-based measurements for the mechanistic modeling of drug release from 
PNAs. Measurements were performed at high (10 mg/ml) 2PN concentration (A-C) and 
low (5 mg/ml) 2PN concentration (D-F).Released drug could not be easily detected at 
high or low PNA concentrations (C,F). 
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4.3.4  Mechanistic Modeling Indicates that Solvato-Fluorochromic Drug Release Rates 
Are Insensitive to Free Drug  
 Figure 4.6 illustrates a mechanistic model of drug release kinetics from PNAs. 
The released drug diffusion rate through the dialysis membrane (kD), the rate of 
encapsulated drug leaving PNA core (kC), the rate of drug re-entering the PNA core (kR) 
and the released drug water-PNA partition coefficient (KP) are determined by non-linear 
regression as described in the methods section. It should be noted that a weighting value 
of 2 reduced the standard error of modeling parameters compared to other weighting 
values, but the weighting value did not significantly affect the mean values of each 
parameter. Table 4.3 shows CFZ release kinetic parameters at high and low 2PN 
concentrations from HPLC-based and SFC methods. The kinetic parameters from HPLC-
based measurements were independent of PNA concentration, but it is possible that the 
selection of a larger PNA concentration range for future experiments could increase the 
differences between parameters. Since the 95% confidence interval of kR overlapped 
zero, the re-entry of drugs into the PNA core was negligible under these experimental 
conditions. Because the 95% confidence intervals of KP and kD were non-zero, weak drug 
binding and slow diffusion affected HPLC-based drug release measurements. In contrast 
to HPLC-based methods, kD and KP were not detectable by the SFC method. As a result, 
these observations revealed that released drug would not directly affect SFC 
measurements in comparison to HPLC-based methods using the experimental conditions 
described for these drug release measurements.  
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Figure 4.6. Graphical description of the mechanistic model for CFZ release from 2PN 
during dialysis-based measurements. The model accounts for drug rebinding to PNAs 
and diffusion through dialysis membrane. 
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Table 4.3. Kinetic parameters from the mechanistic model of drug release from CFZ-
loaded 2PN. 
Method PNA Concentration (mg/ml) kC (h
-1) kR*105 (h-1) 
HPLC 10 0.170 (0.090-0.249) 0.3 (-4.3-5.0) 
HPLC 5 0.116 (0.049-0.182) 8.1 (-32.2-39.6) 
SFC 10 0.37 (0.31-0.43) --- 
SFC 5 0.39 (0.35-0.43) --- 
Method PNA Concentration (mg/ml) KP (unitless) kD (h
-1) 
HPLC 10 121.5 (60.5-182.5) 0.429 (0.361-0.497) 
HPLC 5 95.7 (45.4-146.0) 0.421 (0.365-0.478) 
SFC 10 --- --- 
SFC 5 --- --- 
Kinetic parameters are reported as mean with 95% CI in parentheses. Parameters were 
compared by a Student’s T test. Statistical significance is indicated as described in the 
methods section. 
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4.3.5 Hydrophobic Excipients Alter Both the HPLC- and Solvato-Fluorochromic-Based 
Drug Release Rates of PNAs  
Figures 4.7 and 4.8 show HPLC-based and SFC drug release measurements from 
DOC-loaded 2PN and 3PN that are stabilized by DOCA or PAL. Because the 
mechanistic model could not be used for SFC measurements as described in the previous 
section, HPLC- and SFC-based release rates were compared using a first order kinetic 
model (equation 4.1). DOCA and PAL increased the initial fluorescence of PNAs during 
SFC measurements, presumably due to increased dye-drug interactions within the core of 
PNAs. Kinetic parameters of drug release from excipient-stabilized PNAs are 
summarized in Table 4.4. The addition of hydrophobic excipients to PNAs decreased the 
difference between drug release rates that were measured by HPLC-based and SFC 
methods. In addition, both DOCA and PAL slightly decreased the drug release half-life 
of PNAs that were determined by HPLC-based methods, possibly due to increased drug 
loading in 2PN and 3PN.   
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Figure 4.7. Docetaxel release measurements from excipient-stabilized 2PN containing 
either DOCA (A/B) or PAL (C/D) using HPLC- and SFC-based methods (A/C). SFC 
spectra of DOCA-stabilized 2PN (B) and PAL-stabilized 2PN (D). 
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Figure 4.8. Docetaxel release measurements from excipient-stabilized 3PN containing 
either DOCA (A/B) or PAL (C/D) using HPLC- and SFC-based methods (A/C). SFC 
spectra of DOCA-stabilized 3PN (B) and PAL-stabilized 3PN (D). 
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Table 4.4. Parameters from a first order kinetic model for drug release for excipient-
stabilized PNAs from HPLC- and SFC-based methods.  
PNA Excipient Method t1/2 (h) k (h-1) kSFC/kHPLC 
2PN None HPLC 2.25 (2.05-2.49) 0.31 (0.28-0.34) 1.39 (1.02-1.75) SFC 1.62 (1.54-1.72) 0.43 (0.40-0.45) 
3PN None HPLC 5.14 (4.64-5.76) 0.13 (0.12-0.15) 1.92 (1.27-2.58) SFC 2.75 (2.49-3.08) 0.25 (0.23-0.28) 
2PN DOCA HPLC 2.12 (1.89-2.40) 0.33 (0.29-0.37) 0.91 (0.47-1.34) SFC 2.30 (2.07-2.59) 0.30 (0.27-0.34) 
3PN DOCA HPLC 2.27 (2.09-2.50) 0.30 (0.28-0.33) 2.20 (1.62-2.78) SFC 1.05 (0.96-1.15) 0.66 (0.60-0.72) 
2PN PAL HPLC 2.24 (2.16-2.32) 0.31 (0.30-0.32) 0.77 (0.69-0.85) SFC 2.93 (2.83-3.03) 0.24 (0.23-0.25) 
3PN PAL HPLC 3.07 (2.73-3.51) 0.23 (0.20-0.25) 1.04 (0.61-1.48) SFC 2.95 (2.56-3.32) 0.24 (0.20-0.28) 
Data for PNAs without excipients is reproduced from Table 4.2. Kinetic parameters are 
reported as mean with 95% CI in parenthesis. The error for kSFC/kHPLC is propagated 
from individual rate measurements. The 95% CI of the drug release rate ratio is 
compared to 1 to evaluate if drug release rates are statistically similar.  
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4.3.6 Nile Blue Remains Chemically Stable during Solvato-Fluorochromic Drug 
Release Measurements 
 Figure 4.9 shows the chemical stability and photostability of NB under the 
experimental conditions of the SFC measurements. The absorbance spectra of NB 
remained consistent up to 5 days post-storage. In addition, changes in the maximum 
absorbance of NB (632 nm) over time were not statistically significant. In addition, 
changes in the fluorescence intensity of NB were not statistically significant after 10 
measurements of the same sample over 10 minutes. 
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Figure 4.9. Chemical stability (A) and photostability (B) of NB in cell media or deionized 
water, respectively.  
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4.4 Discussion 
4.4.1 Solvato-Fluorochromism Measures a Step of Drug Release 
The measurement of drug release profiles is an important step for developing safe 
and effective nanoparticle drug carriers for cancer chemotherapy (202, 203). Drug release 
profiles indicate time-dependent changes in the amount of drugs that nanoparticles 
release into the blood or the tumor. Nanoparticles are typically designed to minimize drug 
release in the blood that can increase normal tissue exposure to drugs and cause organ 
damage or other adverse effects (204). In contrast, drug release into the interstitial space 
of tumors can facilitate the accumulation of active drugs in cancer cells (205). 
Nanoparticles that accumulate selectively in tumors and release drugs at slow rates have 
improved the therapeutic efficacy of anticancer drugs by maximizing drug delivery into 
tumor cells (204). 
Despite their significance to cancer treatment efficacy, in vivo drug release 
profiles for nanoparticle drug carriers are often only estimated from in vitro 
measurements of drug concentrations in nanoparticles, which are often completed using 
HPLC-based methods that measure remaining drug during dialysis-based experiments. 
As a result, the real-time determination of drug release in the blood and in tumors is 
currently unavailable (167, 168, 174). Previous studies reported that HPLC-based 
methods could inaccurately estimate in vivo drug release profiles for PNAs when drugs 
bind to nanoparticles (206). Drug release profiles from HPLC-based methods may also be 
inaccurate if drugs are chemically unstable or diffuse slowly through the dialysis 
membrane (207). As an alternative method to determine drug release from the core of 
PNAs and potentially other types of nanoparticles, the SFC method was investigated for 
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the real-time, direct measurement of drug release from PNAs compared to HPLC-based 
methods for measuring drug remaining in dialysis cassettes.  
Differences between in vivo and in vitro drug release rates from nanoparticles are 
often attributed to decreased in vivo nanoparticle concentrations following treatment 
compared to in vitro measurement conditions. For example, some drug-loaded polymer 
micelles sustain drug release in vitro, but they can release drug rapidly following dilution 
after intravenous injection (208). Polymer nanoassemblies are made from covalently 
tethered polymer chains that form unimolecular particles. These unimolecular particles 
remain intact upon dilution in the blood following intravenous injection as opposed to 
other multimolecular nanoparticles (209). Therefore, the in vivo dilution of PNAs is not 
expected to alter drug release rates due to dissociation of the hydrophobic core.  
Two poorly soluble model drugs, CFZ and DOC (5 μg/ml and 10 μg/ml 
maximum solubility in water, respectively), were successfully entrapped in PNAs under 
various conditions. Both CFZ and DOC showed first-order drug release kinetics, 
although CFZ exhibited weak drug binding to 3PN based on tailing in drug release 
profiles. However, other drug-loaded PNAs showed complete drug release. Interestingly, 
2PN with an ionic core entrapped hydrophobic CFZ, possibly due to favorable 
interactions between the tetrapeptide backbone of CFZ and cationic PEI backbone or 
charged amines on NB. In comparison to the HPLC-based method which only provided 
information about the time-dependent changes of drug concentrations in the dialysis 
cassette, the SFC method indicated dynamic changes in the PNA core environment 
during drug release by showing unique SFC spectra and intensities for each PNA 
formulation. 
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4.4.2 Mechanistic Modeling Compares HPLC- and Solvato-Fluorochromic-Based 
Methods for Dialysis-Based Drug Release Measurements 
 To further investigate the effects of drug binding on HPLC-based and SFC 
methods, spiked drug release experiments were performed. Drug release rates from the 
HPLC-based method increased in order of drug-loaded 2PN, spiked drug, and free drug 
for both high and low concentrations of 2PN. These data indicate that the diffusion of 
free drug through the dialysis membrane slows apparent drug release rates, which is often 
overlooked in HPLC-based methods. Unexpectedly, the SFC signals of PNAs increased 
in the presence of DMSO used to dissolve CFZ during the spiked drug release 
experiments. Spiked drug release data corrected for DMSO interference revealed that 
weakly bound drugs and drugs in solution could not be detected. As a result, CFZ that is 
weakly bound to 2PN or in solution would not affect SFC-based methods compared to 
HPLC-based methods. These results indicate that the SFC method is less sensitive to drug 
binding than HPLC-based methods under these experimental conditions, and that the SFC 
method would provide more accurate information about drugs leaving the core of the 
nanoparticle drug carriers than HPLC-based methods. However, additional work is 
needed to verify if this conclusion is valid for PNAs with higher drug loadings or 
increased substitution of fluorochromic dyes. 
 The unexpected increase in SFC signals from DMSO raised concerns about 
potential interactions between PNAs and other hydrophobic molecules in solution. To 
address these concerns, SFC drug release profiles for 3PN were compared to a physical 
mixture of 2PN and hydrophobic excipients such as PAL. DOC was selected as a model 
drug because it showed no tailing in drug release profiles. Drug release profiles revealed 
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that DOCA and PAL increased drug entrapment in PNAs but also accelerated drug 
release rates. In addition, hydrophobic excipients were confirmed to induce no change in 
the SFC spectra of PNAs. PNAs with PAL, either covalently conjugated to the core or 
physically mixed in the core, should have the same molecular components (i.e., 3PN 
compared to 2PN and PAL), but they showed distinct SFC spectra. 2PN retained its SFC 
spectra in the presence of PAL, although a physical mixture of 2PN and PAL exhibited 
greater SFC intensity than 2PN. Hydrophobic excipients also increased the SFC intensity 
for 3PN without affecting the shape of its SFC spectra.  
It was initially hypothesized that SFC-based drug release rates would by equal to 
HPLC-based drug release rates that were corrected for drug rebinding and diffusion. 
However, kSFC values were significantly greater than kC, indicating that factors other than 
drug rebinding and diffusion contribute to these differences. Factors other than drug 
rebinding and diffusion could be decreasing apparent drug release rates measured by 
HPLC compared to SFC, but the possible nature of these factors is unclear. In contrast, 
SFC-based methods could be overestimating drug release compared to HPLC-based 
methods. The fluorescence of NB-conjugated PNAs increased linearly in response to 
drug loading, suggesting that increased apparent drug release rates from SFC-based 
methods are not due to detection method limitations. PNAs could contain a 
heterogeneous core environment, in which only the region of the core environment near 
the scaffold is sensitive to drug loading. In this region, NB can interact with hydrophobic 
drug molecules. The core environment closer to the PNA-water interface may not contain 
NB, because the NB molecule is small and covalently conjugated to the polymer scaffold. 
In this region, hydrophobic drugs do not interact with NB. In addition, water may enter 
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the outside of the core, but fail to diffuse evenly throughout the core. If these statements 
are valid, SFC-based drug release measurements would measure the diffusion of drugs 
out of the NB-enriched region of the PNA core. Because drug molecules diffuse towards 
the PNA-water interface, drug in the NB-enriched region of the PNA core could decrease 
before the concentrations near the interface decrease. In this manner, SFC drug release 
rates would measure a step of drug release, but not the rate-limiting step indicating 
overall drug release rates. Unfortunately, experimental measurements of PNA core 
heterogeneity remain challenging. Future studies may elucidate the relationship between 
SFC drug release rates, HPLC-based drug release rates and physical processes occurring 
during drug release.  
4.4.3 Mechanistic Modeling Assesses the Thermodynamic Conditions of Dialysis-Based 
Drug Release Measurements 
Dialysis-based drug release measurements depend on a sink condition in the 
dialysis solution in order to assure that in vitro drug release rates are accurate. 
Researchers often assume that sink conditions are maintained if nanoparticle solutions are 
dialyzed into a solution with a much greater volume than the nanoparticle solution (210). 
The dialysis sink is expected to maintain an activity gradient between nanoparticles and 
the solution that facilitates drug diffusion out of the nanoparticle core. However, a large 
dialysis sink does not guarantee sink conditions for drug release, because the chemical 
potential of the drug at the nanoparticle interface relative to the solution is often non-zero 
(211). It is hypothesized that in vivo conditions such as reduced PNA concentrations and 
blood flow promote the removal of released drugs from PNAs, allowing PNAs to 
maintain sink conditions in vivo. By comparing HPLC-based drug release rates from the 
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first order kinetic model to HPLC-based drug release rates from the mechanistic model, 
the presence or absence of a sink condition can be assessed. Differences between these 
release rates were not statistically significant, suggesting that HPLC-based drug release 
measurements are occurring under sink conditions. However, due to the size of the 95% 
confidence intervals, more precise methods of assessing sink conditions during dialysis-
based drug release measurements may be needed. 
The PNA-water partition coefficient (Kp) of carfilzomib allowed investigators to 
measure the re-binding of hydrophobic drugs in solution to PNAs. For sink conditions to 
be maintained during drug release, the dilution of hydrophobic drugs after they were 
released into the dialysis solution would either prevent drugs from re-binding to the 
surface of PNAs or make the process difficult to observe and quantify experimentally. 
The mechanistic modeling of CFZ release from 2PN indicated that the PNA-water 
partition coefficient of CFZ was non-zero. As a result, sink conditions cannot be assumed 
for these drug release measurements. In order to allow for sink conditions during future 
drug release studies, the rebinding of drugs to PNAs could be reduced by sequestering 
released drug in the dialysis solution. For example, carfilzomib has been shown to form 
cyclodextrin complexes (212). Determining the appropriate experimental conditions for 
using cyclodextrins to sequester released CFZ is a future area of work.  
The mechanistic model of drug release also allowed researchers to account for the 
potential re-entry of drugs into the PNA core. The re-entry parameter (kR) allowed the 
model to account for two potential experimental conditions: 1) a high released drug 
concentration that causes the chemical potential of released drug and drug at the PNA-
water interface to be equal, and 2) a high chemical potential of drug at the PNA-water 
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interface relative to solution that slows drugs entry into solution but does not necessarily 
affect drug leaving the core. The 95% confidence interval of the modeled kinetic 
parameter for drug re-entry (kR) was not statistically different from zero. This observation 
suggests that either the released drug is unlikely to interact with the PNA core due to a 
small surface area of the core compared to the released drug binding area, or that PNAs 
did not have a high enough initial drug concentration to detect the re-entry of drug into 
the core of PNAs. Future experiments using a variety of model drugs at several drug 
loading values may elucidate the necessary properties of both nanoparticles and drugs to 
observe the re-entry of released drugs into the PNA core. 
The addition of hydrophobic excipients to 3PN was expected to alter SFC signals 
by controlling drug distribution in the core, but it also decreased the DOC release rate 
measured by HPLC. Carboxylate anions at the interface of excipient-stabilized PNAs 
could increase the apparent drug release rate by decreasing Kp. This phenomenon would 
be difficult to measure experimentally, because excipients are not conjugated to the core 
of PNAs and can diffuse into solution over time. As a result, the Kp value of excipient-
stabilized PNAs may change during the release measurement. In order to investigate the 
effects of excipients on the PNA-water partition coefficient of drugs, investigators could 
identify excipients that can be conjugated to the core of PNAs while introducing a 
carboxylate anion to the surface of the PNA core, or they could chemically modify 
DOCA or PAL so that they can be conjugated to PNAs without affecting the carboxylate 
anion. Additionally, interactions between released drugs and excipients could decrease 
kD. The effects of excipient-drug interactions on drug diffusivity should be investigated in 
future work. 
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4.4.4 Excipients Increase Drug Concentrations in the Nanoassembly Core 
Hydrophobic excipients were expected to increase DOC encapsulation in order of 
no excipient, DOCA, and PAL, because PAL (logP=7.2) is more lipophilic than DOCA 
(logP=3.5) (213, 214). However, DOCA increased DOC loading by 2% more than PAL 
in both 2PN and 3PN. Although PAL and DOCA increased the DOC release half-life for 
2PN from SFC methods, the excipients unexpectedly accelerated DOC release from 3PN 
from HPLC methods. Based on these results, it is speculated that the excipients mix with 
PNAs during drug loading and increase core hydrophobicity and drug entrapment, while 
NB detects the core environment changes and emits a stronger SFC intensity. However, 
carboxyl groups on PAL and DOCA keep the excipients near the core-shell interface and 
prevent direct contact between the excipients and NB, allowing PNAs to maintain their 
distinct fluorescence spectra. Excipients may leave the core of excipient-stabilized PNAs 
quickly along with drugs and accelerate drug release rates. Figure 4.10 illustrates this 
potential mechanism.  
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Figure 4.10. Graphical description of the theoretical mechanism for the effects of 
excipients on solvato-fluorochromism.  
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4.4.5 Advantages of Solvato-Fluorochromic Drug Release Measurements 
 This study suggests that the SFC method has the potential to monitor drug release 
from PNAs with a hydrophobic core. Although 2PN has a higher NB molar substitution 
than 3PN, drug-loaded 3PN showed greater fluorescence intensity than drug-loaded 2PN, 
suggesting that PAL kept drugs in the PNA core and forced water out of the core. As a 
result, hydrophobic drugs could interact with NB more efficiently in the hydrophobic 
3PN core than in the hydrophilic 2PN core. Importantly, drug loading did not alter the 
maximum absorbance wavelengths for both PNAs. When DOCA was added to DOC-
loaded 2PN and PAL was added to DOC-loaded 3PN, the HPLC-based and SFC methods 
showed statistically similar drug release rates. These observations suggest that the 
excipients could help hydrophobic drug molecules stay in the PNA core and interact with 
NB during drug release.  
 It should be noted that the HPLC-based method could not detect changes in the 
PNA core environment. The HPLC-based method failed to distinguish between DOC 
release profiles of 3PN and 2PN physically mixed with PAL, but the SFC method 
detected distinct SFC spectra for each formulation. The SFC method also indicated that 
hydrophobic excipients increased the initial dye-drug interactions in the core of PNAs, 
but the drug-dye interactions decreased quicker than in PNAs without excipients. This 
observation suggests that excipients may diffuse into solution over time, and the diffusion 
of excipients accelerates drug diffusion out of the nanoassembly core. Therefore, in 
comparison to HPLC-based methods, the SFC method provides more information 
regarding changes in the physicochemical properties within the nanoassembly core 
during drug delivery.  
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In regard to future clinical applications, SFC-based drug release determination 
may have two primary advantages over HPLC-based methods. First, SFC methods may 
enable researchers to perform in situ drug release measurements. In this study, SFC 
measurement timepoints and PNA concentrations were matched to HPLC timepoints and 
PNA concentrations in order to directly compare the methods, but fluorescence signals 
could be measured directly from tissues as well as dialysis cassettes without having to 
sample the solutions for fluorescence measurements (215, 216). Second, the SFC method 
may provide investigators with real-time drug release profiles that describe drug release 
more accurately than mathematical models of drug release kinetics using HPLC-based 
methods. Mathematical models of drug release from HPLC-based methods can 
oversimplify drug release kinetics by assuming that drug release rates remain constant 
over time. In addition, many HPLC-based methods sample high initial drug 
concentrations more than low terminal drug concentrations, which can increase fitting 
error by overweighting initial or terminal drug concentrations. However, SFC methods 
can provide real-time information about drugs leaving the nanoparticle core, which may 
overcome some of the limitations of mathematical modeling associated with HPLC-based 
method analysis. Therefore, NB-conjugated PNAs are expected to allow clinicians to 
address some of the limitations of HPLC-based methods and eventually perform in situ 
real-time measurements of drug concentrations in nanoparticles circulating in the 
bloodstream or accumulating in targeted tissues including tumors. 
4.4.6 Limitations of Solvato-Fluorochromic Drug Release Measurements 
Despite their previous applications described in chapter 2 and in the literature 
(217), SFC dyes have several limitations for measuring drug release from various 
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nanoparticle drug carriers. First, SFC dyes must remain in the nanoparticle core to detect 
accurate chemical properties within the nanoparticle core environment. Physically 
entrapped dyes in nanoparticles could diffuse into solution and reduce the SFC signal, 
which would cause the SFC method to overestimate drug release rates. For this reason, 
NB was covalently conjugated to PNAs with stable amide and imine bonds that prevent 
NB from leaving the PNA core during SFC measurements. In addition, SFC dyes must 
detect the entire nanoassembly core environment in order to accurately measure 
nanoassembly core properties. Therefore, nanoparticles should be designed to allow 
chemically conjugated SFC dyes to disperse throughout the entire nanoassembly core. 
Future experiments should determine if the spatial distribution of SFC dyes in the core of 
PNAs is homogeneous or heterogeneous.  
SFC dyes in the nanoparticle core must remain intact during drug release 
experiments in order to measure accurate drug release. Chemical degradation of SFC 
dyes could decrease the fluorescence intensity of dye-loaded nanoparticles and increase 
SFC drug release rates. Based on the optical characterization of NB, the dye is chemically 
stable for up to 5 days in cell culture media at 37 °C. Therefore, NB in 2PN and 3PN 
should be chemically stable under the described experimental conditions. The 
photostability of NB was also confirmed for up to 10 fluorescence measurements under 
the described experimental conditions. In addition, solvato-fluorochromism of dyes in the 
nanoparticle core should be selective for encapsulated drugs in order to avoid interactions 
with hydrophobic small molecules such as free lipids that could diffuse into the 
hydrophobic core of nanoparticles and interfere with SFC signals (80, 218, 219). Based 
on the negligible value of the measured rate of drug re-entry into the PNA core, 
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hydrophobic small molecules are not expected to enter the PNA core and interact with 
fluorochromic dyes.  
The sensitivity of the SFC method to detect drug in the PNA core indicates the 
potential of this method to measure accurate drug release rates. By measuring the 
fluorescence of PNAs, 1.5% and 3% drug loading by weight could be detected in DOC-
loaded and CFZ-loaded 2PN. During SFC drug release measurements, 20% of the initial 
drug loading could be detected in PNAs before reaching minimal fluorescence values. 
Based on these values, minimum drug loading values of 0.3% DOC and 0.6% CFZ by 
weight could be detected by measuring the fluorescence of NB-conjugated PNAs. 
Estimations of the minimum detectable drug loading by solvato-fluorochromism are 
higher than the minimum detection limit of the HPLC-based method used in study. 
However, it should be noted that the minimum detectable drug loading was estimated 
from drug release data, and that a direct measurement of the SFC detection limit could 
indicate a higher sensitivity of the SFC method to detect drugs entrapped in the 
nanoassembly core.  
It should be noted that 1) the SFC method is intended to only detect drugs leaving 
the nanoparticle core, 2) the SFC method cannot distinguish free drug in solution from 
drug that is weakly bound to the surface of the carriers, and 3) the relationship between 
SFC drug release measurements and the amount of biologically active drug in solution 
needs to be further elucidated. As a result, SFC measurements may overestimate free 
drug concentrations in tumor tissue. Mechanistic modeling showed that some released 
drug binds to the surface of PNAs and slows drug release during HPLC-based 
measurements, but previous research suggests that drug binding may not significantly 
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affect drug release rates in vivo because of low PNA concentrations in the blood or 
interstitial space compared to dialysis cassettes (220, 221). Determining the relationship 
between SFC drug release rates and drug concentrations in tissues is a significant area of 
future work. 
4.5 Conclusions 
A novel, SFC-based drug release measurement method was developed to 
overcome the limitations of HPLC-based methods for dialysis-based drug release 
measurements, such as unanticipated molecular interactions and complicated mass 
transfer effects between drugs, PNAs, and dialysis membranes. The SFC method 
demonstrated a facile and accurate determination of drug release rates compared to 
HPLC-based methods. A comparisons of both methods revealed that HPLC-based 
methods may be inaccurate at determining drug release involving interactions among 
drug, drug carriers, and hydrophobic excipients. Mechanistic modeling confirmed that 
drug rebinding and slow drug diffusion would influence HPLC-based but not the SFC-
based method. These results indicate that the SFC method holds great promise to measure 
drug release rates for PNAs and potentially other nanoparticle drug carriers with 
improved convenience and accuracy compared to HPLC-based methods. 
 
**Portions of Chapter 4 were previously published in (222). Reproduced with permission 
from Springer: Pharmaceutical Research, Volume 34, Issue 2, 2017, Pages 394-407, 
Figures 1, 4-10, and Text. Copyright 2016 is given to the publication in which the 
material was originally published. 
Copyright (C) Derek Reichel 2017  
162 
 
 
 
 
 
 
 
 
CHAPTER FIVE 
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5  CHEMICAL MODIFICATIONS TO PNAs BASED ON A SOLVATO-
FLUOROCHROMIC CHARACTERIZATION OF THE NANOASSEMBLY CORE 
ENVIRONMENT TO CONTROL DRUG RELEASE AND IMPROVE TEMPORAL 
DRUG DISTRIBUTION 
5.1  Introduction 
 Drug release rates from nanoparticles are often used to predict the spatial and 
temporal distribution of drugs in tumors, but modulating drug release rates in order to 
improve cancer treatment efficacy remains challenging (223). Nanoparticles with small 
diameters (10-100 nm) often accumulate in the leaky vasculature surrounding tumors at 
3-12 hours post-injection and deliver anticancer drugs into the tumor interstitium (224, 
225). Optimal drug release rates from nanoparticles can increase the accumulation of 
anticancer drugs in tumors by maximizing drug release from nanoparticles accumulated 
in the tumor vasculature (226). Rapid drug release rates can force nanoparticles to release 
drugs in blood vessels before the nanoparticles can accumulate in tumors (227). Drugs 
that are released in blood vessels may not reach tumors due to rapid renal clearance or 
off-target accumulation in healthy organs causing dose-limiting toxicity. In addition, slow 
drug release rates may decrease treatment efficacy by reducing peak anticancer drug 
concentrations in cancer cells. Therefore, methods of modulating drug release rates from 
nanoparticles are needed to increase anticancer drug accumulation in tumors and improve 
treatment efficacy.  
 The core environment of drug-loaded nanoparticles controls drug release into 
tumor tissue, but drug release rates remain difficult to modulate due to complicated 
thermodynamic and mass transport effects between drugs and polymers in the 
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nanoparticle core. For polymeric nanoparticles such as PNAs, diffusion out of the PNA 
core and binding to hydrophobic polymers are two main factors governing drug release 
(228, 229). Drugs must diffuse through the hydrophobic mesh-like core environment to 
reach the interface between the core and the hydrophilic shell. Diffusion rates of drugs in 
the hydrophobic core are influenced by both the chemical properties of the hydrophobic 
groups in the core and the pore size of the hydrophobic mesh. The hydrophobic core 
often contains water molecules that can interact with drugs or weakly hydrophobic 
portions of the core and influence diffusion rates. After drugs diffuse to the core-shell 
interface, they must cross the shell and partition into the surrounding solution. 
Environmental factors such as the solution pH and the chemical potential of drug at the 
interface in relation to the surrounding media can reduce drug release rates by decreasing 
the amount of drug that can partition into the surrounding solution (230). Researchers 
often control drug release rates from nanoparticles by altering the core environment 
hydrophobicity, which can slow diffusion by increasing the affinity of the drug for the 
core (231). Unfortunately, this approach is often ineffective at controlling drug release 
rates, because the specific effects of hydrophobic interactions on drug release are difficult 
to elucidate from drug release profiles. Experimental methods for determining the 
thermodynamic and mass transport effects contributing to poor drug release rates may 
identify rational approaches to modify the PNA core environment in order to control drug 
release rates. 
 Solvato-fluorochromism was previously identified as a useful method to probe the 
nanoparticle core environment and monitor its chemical properties during drug delivery. 
Although PAL was attached to the core of PNAs to create a hydrophobic core 
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environment capable of entrapping drugs, the quenched fluorescence of NB in the PNA 
core indicated that some water remained in the core and decreased the nanoassembly core 
hydrophobicity. The presence of water in the nanoassembly core was attributed to amines 
on the polymer scaffold that can interact with water molecules entering the PNA core. In 
addition, charged amine groups in the core can also repel cationic drugs or draw 
counterions into the PNA core. Chemical modifications to the polymer scaffold in the 
core of PNAs may remove these ionizable functional groups from the nanoassembly core. 
For example, primary amines can be end-capped by chemical reactions that form stable, 
unionizable amide bonds. In addition, secondary and tertiary amines can be removed 
from the core by synthesizing PNAs with polymer scaffolds that lack ionizable secondary 
or tertiary amines. Therefore, chemical modifications to PNAs to reduce the water 
concentration in the hydrophobic core promise to sustain drug release and improve 
temporal and spatial drug distribution in tumors. 
This study addresses the drug delivery limitations of fluorochromic PNAs by 
rationally modifying the chemical environment of the nanoassembly core based on 
solvato-fluorochromism. These improved PNAs are synthesized similarly to 
fluorochromic PNAs (Figure 5.1). However, the remaining ionizable groups on polymer 
scaffolds were removed by replacing the PEI scaffold with a PLL scaffold, and by end-
capping the remaining primary amines with either a chloroacetyl chloride (CAC) or 
acetic anhydride (AA) reaction. The core environments of these PNAs are fine-tuned to 
increase drug entrapment, avoid burst drug release and fine-tune drug release half-lives. 
In order to determine the effects of drug properties such as pKa or functional groups on 
drug loading and release, the entrapment and release of model drugs carfilzomib (CFZ) 
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and docetaxel (DOC) were determined. CFZ and DOC were selected as model anticancer 
drugs with distinct chemical structures (peptide vs. taxane), ionization potential (pKa of 
5.1 for the morpholine group of CFZ vs. 11.0 for the carbamate group of DOC) and 
lipophilicity (logP of 4.2 vs. 2.4), respectively. Drug release kinetics of end-capped PNAs 
were evaluated using three models: a first order kinetic model, the Korsmeyer-Peppas 
model and the unsteady state spherical diffusion model. A first order kinetic model 
allowed the comparison of half-lives to determine the effects of polymer scaffold and 
end-capping groups on drug release. The Korsmeyer-Peppas model was selected as a 
semi-empirical model that indicates the mechanism of drug release from PNAs and 
justifies the selection of mechanistic drug release models. The unsteady state spherical 
diffusion model was selected as a mechanistic model that can measure the diffusivity of 
drug molecules in the core of PNAs. By removing ionizable functional groups from the 
nanoassembly core, this study evaluates the effects of ionizable groups on drug release 
from PNAs and validates solvato-fluorochromism as a beneficial method for 
characterizing the core environment of PNAs and potentially other nanoparticle drug 
carriers. 
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Figure 5.1. Graphical description of the end-capping approach to remove amines from 
the core of PNAs (A). Six PNAs were synthesized by varying the polymer scaffold and 
amine end-capping modification (B) to fine-tune drug release properties of PNAs (C). 
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5.2  Materials and Methods 
5.2.1  Materials 
 α-Succinimidyloxysuccinyl-ω-methoxy-poly(ethylene glycol) (NHS-activated 
PEG, 5 kDa) was purchased from NOF America (White Plains, NY). Branched 
poly(ethylene imine) (PEI, 25 kDa), poly(L-lysine) (PLL, 15-30 kDa), acetic anhydride 
(AA), chloroacetyl chloride (CAC), HEPES sodium salt, palmitoyl chloride (PAL-Cl) 
and fluorescamine were purchased from Sigma Aldrich (St. Louis, MO). Acetonitrile 
(ACN), diethyl ether, dimethyl sulfoxide (DMSO), ethanol, pyridine, tetrahydrofuran 
(THF), water, phosphate buffered saline (PBS), dialysis membranes with molecular 
weight cut-off (MWCO) of 6-8 or 100 kDa, centrifugal filters (100 kDa MWCO) and 
dialysis cups (20 kDa MWCO) were purchased from Fisher Scientific (Waltham, MA). 
Carfilzomib (CFZ) and docetaxel (DOC) were purchased from LC Laboratories 
(Woburn, MA). To remove low molecular weight impurities from PEI before reactions, 
PEI was dialyzed in water overnight using a 100 kDa MWCO membrane. All other 
chemicals were used without further purification.  
5.2.2 Synthesis of Unmodified and End-Capped PNAs with Various Polymer Scaffolds  
 As shown in Figure 5.2, PNAs containing various scaffolds and end-capping 
groups were synthesized by tethering NHS-activated PEG and PAL-Cl to PEI or PLL to 
yield 3P (PEG-PEI-PAL) and 3P’ (PEG-PLL-PAL). 3P and 3P’ were further reacted with 
either AA or CAC to yield 3PAA (PEG-PEI-PAL-AA), 3P’AA (PEG-PLL-PAL-AA), 
3PCAC (PEG-PEI-PAL-CAC) and 3P’CAC (PEG-PLL-PAL-CAC). The synthesis of 3P 
was described in chapter 2. NHS-activated PEG (1951.8 mg) was reacted with PLL 
(100.0 mg) in a 4:1 mixed solution of HEPES buffer and DMSO for 3 days. The reaction 
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yielded PEG-PLL, which was purified by dialysis and collected after freeze drying. A 
portion of the PEG-PLL (1000.0 mg) was reacted with PAL-Cl (299 μl) at 40 °C for 2 
hours in THF. To neutralize hydrochloric acid by-products formed during reactions, 
pyridine was added to the reaction mixtures in equal volume ratios to the acyl chloride 
reagents of all acyl chloride reactions 15 minutes after adding the reagent. The product 
3P’ was purified by ether precipitation and dialysis, and then collected after freeze 
drying. 3P and 3P’ (100.0 mg each) were separately reacted with either AA (19.3 μl for 
each) at room temperature overnight in DMSO or with CAC (16.7 μl for each) at 40 °C 
for 2 hours in THF. Each AA or CAC reaction products was purified by dialysis and 
collected after freeze drying, yielding AA- and CAC-modified 3P and 3P’.   
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Figure 5.2. Synthesis protocol for unmodified and end-capped PNAs. All PNAs are 
shown to contain potentially unreacted primary amines. 
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5.2.3  Physical Characterization of Unmodified and End-Capped PNAs  
 Primary amines remaining in the core of PNAs were directly quantified using the 
amine-reactive fluorogenic dye fluorescamine. Because of potential fluorescence 
interactions between amine-conjugated fluorescamine and NB in the core of PNAs, 
primary amines in NB-conjugated PNAs were not quantified by fluorescamine in chapter 
2. The PNAs 3P, 3PAA, 3PCAC, 3P’, 3P’AA and 3P’CAC were separately dispersed in 
1:1 DMSO/water solutions at 1 mg/ml, and fluorescamine was dissolved in DMSO at 10 
mg/ml. Ten microliters of fluorescamine solution was added to 100 μl of blank solution 
and each PNA solution. The fluorescence of amine-conjugated fluorescamine (Ex 390 
nm/Em 460 nm) in each solution was measured using a plate reader (Spectramax M5, 
Sunnyvale, CA). The baseline signal was removed from each sample by subtracting the 
fluorescence of the blank solution from the fluorescence of each sample. The baseline-
corrected sample fluorescence was then normalized to the fluorescence of 3P (3PAA and 
3PCAC) or 3P’ (3P’AA and 3P’CAC). The relative size and dispersity of PNAs was 
determined by GPC as described in chapter 2 (Asahipak GF-7M, PBS, 0.5 ml/min, 40 °C, 
calibrated using PEG standards). The chemical compositions of each PNA were 
determined by proton NMR spectroscopy (Varian 400 MHz, DMSO-d6). The diameter 
and surface charge of each PNA was also determined by DLS (Zetasizer Nano ZS, 
Malvern, UK). 
5.2.4  Hydrophobic Drug Loading of End-Capped PNAs  
 Stock solutions of PNAs (3P, 3PCAC, 3PAA, 3P’, 3P’CAC and 3P’AA; 100 
mg/ml) and drugs (CFZ and DOC; 1 mg/ml) were prepared in ethanol. Each PNA 
solution was mixed with either CFZ or DOC solution in a round-bottom flask, aiming for 
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10% drug loading. The mixed solutions were evaporated under reduced pressure to 
prepare thin films, which were rehydrated with deionized water and sonicated for 5 
minutes. PNA solutions were then centrifuged for 1 minute at 1000 RPM to remove free 
drug and other insoluble impurities. The supernatants were then collected and lyophilized 
for storage. The drug loading efficiency, molar drug loading efficiency and encapsulation 
efficiency of PNAs was determined from reconstituted samples using HPLC as described 
in chapter 4.  
5.2.5  Drug Release Measurements from Unmodified and End-Capped PNAs  
 Drug-loaded PNAs were dispersed in PBS (10 mg/ml). Each drug-loaded PNA 
solution (500 μl) was added to dialysis cups and dialyzed at 37 °C in 1 l of PBS. Aliquots 
of each sample (50 μl) from within the dialysis cups were collected at 0, 1, 3, 6, 24 and 
48 hours. Drug remaining in these aliquots was quantified by HPLC, and the drug release 
profiles for each drug-PNA combination were fitted to multiple kinetic models of drug 
release using Prism (GraphPad, La Jolla, CA). Initially, drug release models were fit to 
first order kinetic models (equation 4.1) as described in chapter 4.  
 In order to further elucidate the mechanism of drug release from PNAs, drug 
release profiles were fit to the Korsmeyer-Peppas model of drug release in equation 5.1. 
𝑀𝑀𝐼𝐼
𝑀𝑀∞
= 𝐾𝐾𝑡𝑡𝑑𝑑    (5.1) 
 In equation 5.1, Mt is the mass of released drug at time t, M∞ is the mass of 
released drug after an infinite amount of time, K is a kinetic constant with units of inverse 
hours and N is a unitless constant determined experimentally. Equation 5.1 was 
simplified to equation 5.2. 
𝐶𝐶𝐼𝐼
𝐶𝐶0
= 𝐾𝐾𝑡𝑡𝑑𝑑    (5.2) 
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 In equation 5.2, Ct/C0 is the concentration ratio of drug in the dialysis cup at time 
t to the initial concentration as a percent. For drug release modeling, an N value with 
standard error of mean equal to or below 0.45 was defined as Fickian diffusion-controlled 
drug release, while N values between 0.45 and 0.85 were defined as non-Fickian 
transport-based drug release.  
 An unsteady state spherical diffusion model of mass transfer was developed to 
determine the diffusivity of drugs in the PNA core. The model was based on detailed 
derivations by Arifin et al. (232). Initially, PNAs were assumed to be spherical and have 
a constant diameter during drug release. The core-shell interface was also assumed to 
have zero chemical potential for the drug (sink condition). Equation 5.3 below describes 
diffusion-controlled drug release from a sphere obeying these assumptions. 
𝑀𝑀𝐼𝐼
𝑀𝑀∞
= 1 − 6
𝜋𝜋2
∗ ∑ 1
𝑚𝑚2
∗ 𝑒𝑒
−𝐷𝐷∗𝐼𝐼2∗𝜋𝜋2∗𝐼𝐼
𝐼𝐼2∞𝑚𝑚=1   (5.3) 
 In equation 5.3, Mt is the mass of released drug at time t, M∞ is the mass of 
released drug after an infinite time, D is the drug diffusivity with units of m2/s, and a is 
the radius of the hydrophobic core with units of m (core radius measurement described 
below). In order to simplify comparison, D is reported in units of cm2/s and a is reported 
in units of nm. Equation 5.3 can be rearranged in terms of concentration in the form of 
equation 5.4. 
𝐶𝐶 = 𝐶𝐶0 ∗
6
𝜋𝜋2
∗ ∑ 1
𝑚𝑚2
∗ 𝑒𝑒
−𝐷𝐷∗𝐼𝐼2∗𝜋𝜋2∗𝐼𝐼
𝐼𝐼2∞𝑚𝑚=1   (5.4) 
 In equation 5.4, C is the concentration of drug in the dialysis cup in micrograms 
per milliliter. At the initial timepoint, the concentration of drug is equal to the total initial 
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drug concentration C0 with units of micrograms per milliliter and the infinite sum is equal 
to π2/6. Therefore, equation 5.4 can be further simplified into equation 5.5. 
𝐶𝐶𝐼𝐼
𝐶𝐶0
= 6
𝜋𝜋2
∗ ∑ 1
𝑚𝑚2
∗ 𝑒𝑒
−𝐷𝐷∗𝐼𝐼2∗𝜋𝜋2∗𝐼𝐼
𝐼𝐼2∞𝑚𝑚=1   (5.5) 
 Drug release profiles were fit to equation 5.5. In order to assure the accurate 
fitting of drug release profiles, weighting values were adjusted between 0 and 2. Because 
the higher order terms in the infinite series converged to zero quickly, equation 5.5 was 
approximated to ten terms in order to prevent overfitting of the data. 
 The radius of the hydrophobic core (a) of PNAs in equation 5.5 was estimated 
using equation 5.6, which assumes the hydrodynamic diameter of a PNA is equal to two 
times the sum of the radii of the hydrophobic core and PEG shell (233).  
𝐷𝐷𝐻𝐻𝐻𝐻𝐷𝐷 = 2 ∗ 𝑅𝑅𝑆𝑆𝐻𝐻𝐸𝐸𝑆𝑆𝑆𝑆 + 2 ∗ 𝑎𝑎   (5.6) 
 In equation 5.6, DHYD is the hydrodynamic diameter of nanoparticles measured by 
DLS, a is the radius of the hydrophobic core and RSHELL is the radius of the PEG shell. 
All diameters and radii have units of nm. RSHELL is determined using equation 5.7.  
𝑅𝑅𝑣𝑣ℎ𝑒𝑒𝑣𝑣𝑣𝑣 = 2𝑅𝑅𝐺𝐺,𝑃𝑃𝐸𝐸𝐺𝐺 − 2 ∗ 0.215𝑀𝑀𝑊𝑊0.583  (5.7) 
 In equation 5.7, RG,PEG and MW are the radius of gyration (nm) and molecular 
weight of PEG (g/mol), respectively. For the methoxy-terminated 5 kDa PEG in the shell 
of PNAs, RSHELL was determined to be 6.16 nm. 
5.2.6 Statistics 
 All values are reported as mean±standard deviation of triplicate measurements, 
while model parameters are described as mean±SEM unless indicated otherwise. Groups 
of measurements were compared using one-way ANOVA with Bonferroni’s post hoc 
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test, while pairs were compared with a Student’s t test. Statistical significance is indicated 
by * (p<0.05), ** (p<0.01) or *** (p<0.001). 
5.3  Results 
5.3.1  End-Capping Groups Do Not Affect the Size or Surface Charge of PNAs 
 Proton NMR confirmed the successful synthesis of 3P [PEG (3.54 ppm, s, relative 
area 1.000), PEI (2.32 ppm, s, relative area 0.017; 2.44 ppm, s; 2.55 ppm, s; 2.60 ppm, s; 
2.66 ppm, s, relative area 0.019), and PAL (0.83 ppm, d, relative area 0.022; 1.20 ppm, s, 
relative area 0.082)] and 3P’ [PEG (3.51 ppm, s, relative area 1.000), PLL (1.24 ppm, s, 
relative area 0.043; 2.23 ppm, m, relative area 0.102; 2.60 ppm, s, relative area 0.007; 
2.68 ppm, s, relative area 0.009; 2.97 ppm, s, relative area 0.009; 3.24 ppm, s, relative 
area 0.118; 3.42 ppm, s, relative area 0.117; 3.68 ppm, s, relative area 0.012; 4.09 ppm, s, 
relative area 0.007; 7.78 ppm, s, relative area 0.008), and PAL (0.83 ppm, d, relative area 
0.006; 1.23 ppm, s, relative area 0.043; 1.46 ppm, s, relative area 0.021)]. Acetyl peaks 
on 3PAA (1.90 ppm, s, relative area 0.017) and 3P’AA (1.78 ppm, s, relative area 0.011) 
confirmed AA end-capping, while acetyl chloride peaks on 3PCAC (4.15 ppm, s, relative 
area 0.018) and 3P’CAC (4.27 ppm, s, relative area 0.006) confirmed CAC end-capping. 
The calculated molar substitutions (defined in chapter 2) of PEG, PAL, CAC, and AA on 
the polymer scaffolds of PNAs are described in Table 5.1. Based on the molar 
substitution of each component, 52 to 100 percent of primary amines on these PNAs were 
end-capped. GPC confirmed that 3P, 3PCAC, 3PAA, 3P’, 3P’CAC and 3P’AA had 
uniform molecular weight distribution and were free of small molecule impurities as 
shown in Figure 5.3.  
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Table 5.1. Molar substitution of unmodified and end-capped PNAs. PEG, PAL and end-
capping group substitution were determined by NMR quantification. 
 Molar Substitution (mol/mol primary 
amine on scaffold) (%) 
Remaining Amines (mol/mol 
primary amine on scaffold) (%) 
PNA PEG PAL CAC AA NH2 
3P 10.0±0.3 55.0±1.4 --- --- 35.0±1.4 
3PCAC 10.0±0.3 55.0±1.4 20.0±0.5 --- 15.0±1.5 
3PAA 10.0±0.3 55.0±1.4 --- 23.0±0.6 12.0±1.6 
3P’ 5.0±0.1 47.0±1.2 --- --- 48.0±1.2 
3P’CAC 5.0±0.1 47.0±1.2 33.0±0.8 --- 15.0±1.4 
3P’AA 5.0±0.1 47.0±1.2 --- 48.0±1.2 0.0±1.7 
PEG, PAL, CAC and AA substitution are reported as measurement±measurement error 
for NMR (n=1). CAC and AA were not detectable on 3P or 3P’. CAC was not detectable 
on 3PAA or 3P’AA, while AA was not detectable on 3PCAC or 3P’CAC. Error from 
PEG, PAL, CAC and AA quantification were propagated into the remaining amine 
quantification. 
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Figure 5.3. Gel permeation chromatographs of unmodified and end-capped PNAs 3P (A), 
3PCAC (B), 3PAA (C), 3P’ (D), 3P’CAC (E) and 3P’AA (F). Chromatographs were 
measured by UV-visible absorbance detector at 220 nm. 
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 The diameter and surface charge of the PNAs were measured by DLS. As 
summarized in Table 5.2, all PNAs were between 15 and 40 nm in diameter. End-capping 
reactions slightly decreased the diameter of 3P, but the reactions increased the diameter 
of 3P’. However, the size changes of each PNA following end-capping reactions were not 
statistically significant. All PEI-based PNAs had zeta potentials between -10 and 10 mV 
indicating a neutral surface. The PEG in the shell of PEI-based PNAs shields any charged 
groups remaining in the core and allows the PNAs to have a neutral surface charge. 
3P’AA without core amines also had a neutral surface, but 3P’ and 3P’CAC with core 
amines had large positive zeta potentials (>10 mV) indicating a positively charged 
surface. These results suggest that the PEG in the shell of PLL-based PNAs may not 
shield charged groups in the core from the surface. The differences in surface charge 
between PEI-based PNAs are not statistically significant, but the differences in surface 
charge between 3P’AA and 3P’ or 3P’CAC are statistically significant. The diameter and 
zeta potential of drug-loaded PNAs could not be directly determined by DLS due to the 
turbidity of the samples which prevented the accurate detection of scattered light.  
Increased turbidity of PNA colloidal solutions after drug loading could be due to two 
factors: 1) increased diameter of drug-loaded PNAs increasing light scattering by the 
Tyndall effect (234), or 2) disruption of the palmitate in the  nanoassembly core leading 
to the formation of a cloudy emusion near the PNA core due to undesired interactions 
between water and palmitate groups. Further studies are needed to elucidate the causes 
for cloudiness of drug-loaded PNAs.   
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Table 5.2. Physicochemical properties of unmodified and end-capped PNAs.  
Nanoparticle Diameter (nm) Zeta Potential (mV) PDI (unitless)  
3P 35.2±5.5 -5.2±0.8 0.38±0.04  
3PCAC 32.6±7.8 -1.3±0.6 0.37±0.01  
3PAA 29.5±4.6 -4.1±0.7 0.42±0.08  
3P’ 16.3±3.0 29.5±1.6 0.56±0.02  
3P’CAC 22.4±3.4 26.0±3.5 0.54±0.01  
3P’AA 22.4±2.8 -6.0±0.6*** 0.62±0.09  
Diameter, zeta potential and PDI are reported as mean±SD (n=3). Statistical 
significance is determined by a one-way ANOVA with Bonferroni’s post-test correction 
for each group as described in the methods section. 
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5.3.2  End-Capping Group Bulkiness and Scaffold Amine Steric Hindrance Control 
End-Capping Reaction Yields 
 A fluorescamine assay was used to quantify the remaining primary amines in 
PNAs after end-capping reactions with AA or CAC. Figure 5.4 shows the normalized 
fluorescence of fluorescamine-modified PEI- and PLL-based PNAs. All PNAs were in 
the linear range of a fluorescamine calibration curve. The AA reaction decreased the 
fluorescence of 3PAA by 65% compared to 3P, and the reaction decreased the 
fluorescence of 3P’AA by greater than 99% compared to 3P’. The decreases in 
fluorescence correspond to a 65% and greater than 99% molar substitution yield for AA 
on 3PAA and 3P’AA, respectively. By comparing the changes in fluorescence to the 
remaining primary amines on 3P or 3P’ before the reaction, the molar substitution of AA 
on PNAs could be determined. These decreases in fluorescence correspond to 23% and 
48% AA molar substitution of 3PAA and 3P’AA, respectively, which is in agreement 
with NMR quantification. In contrast, the CAC modification showed false positive 
signals during the fluorescamine assay which were not in agreement with NMR 
quantification. The CAC reaction increased the fluorescence of 3PCAC by 54% 
compared to 3P, and it increased the fluorescence of 3P’CAC by 68% compared to 3P’. 
The decreases in fluorescence correspond to a 54% and 68% increase in primary amines 
on 3PCAC and 3PCAC following the reaction with CAC. These increases correspond to 
a 19% and 33% increase in primary amines on 3P and 3P’, respectively. False positives 
from the fluorescamine assay may be due to three causes: 1) physical interactions 
between amine-conjugated fluorescamine and CAC groups in the core of PNAs that alter 
the electronic environment of the dye, 2) an unexpected reaction between fluorescamine 
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and CAC that produces a highly fluorescent side product, or 3) fluorescence of CAC 
groups in the same wavelength range as amine-conjugated fluorescamine. It should be 
noted that fluorescamine reacts with primary amines by nucleophilic addition of the 
amine (235), and that chloride groups are unlikely to undergo the same addition. In 
addition, both 3PCAC and 3P’CAC were non-fluorescent under fluorescamine 
measurement conditions. Although physical reactions between CAC groups and reacted 
fluorescamine in the core of PNAs are hypothesized to increase fluorescence signals, 
further studies are needed to elucidate a detailed mechanism of the increased fluorescence 
signals. Other amine-reactive fluorogenic dyes such as ninhydrin were considered as an 
alternative method of directly quantifying the remaining primary amines in the core of 
CAC-reacted PNAs, but the elevated temperature often required for these reactions may 
degrade the peptide scaffold of 3P’ PNAs and generate primary amines that increase the 
fluorescence signal following the assay (236, 237). Because NMR quantification was 
verified as an accurate method to determine the AA end-capping yield of PNAs, the 
NMR quantification was used exclusively to determine the end-capping reaction yield of 
CAC-modified PNAs.  
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Figure 5.4. Fluorescamine quantification of primary amines in unmodified and end-
capped PNAs. Primary amines were quantified in PEI-based (A) and PLL-based (B) 
PNAs and normalized to unmodified PNAs for each group.   
183 
5.3.3  Removal of Amines from the PNA Core Increases Drug Loading and 
Encapsulation Efficiency 
 The drug loading and encapsulation efficiencies of PNAs are summarized in 
Table 5.3. End-capped PNAs increased CFZ loading compared to unmodified PNAs, and 
end-capping reactions allowed PNAs to stably entrap DOC. In addition, PLL-based 
PNAs had higher CFZ and DOC loading efficiencies than PEI-based PNAs. These 
differences in drug loading efficiencies between PNAs are statistically significant. Both 
3P and 3P’were unable to stably entrap DOC, and thus DOC-loaded 3P and 3P’ were not 
tested further. For both PEI- and PLL-based PNAs, drug loading and encapsulation 
efficiency were highest with the AA modification. Statistical trends of the drug loading 
and encapsulation efficiencies of PNAs are summarized in Figure 5.5.  
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Table 5.3. Drug loading of unmodified and end-capped PNAs. 
Drug PNAs 
Drug Loading 
Efficiency (w/w 
%) 
Molar Drug 
Loading Efficiency 
(mol Drug/mol 
PNA) 
Encapsulation 
Efficiency (w/w 
%) 
 3P 4.3±0.2 9.7±0.5 44.5±1.8 
CFZ 3PCAC 6.7±0.5 15.4±1.1 71.8±5.7 
 3PAA 6.8±0.2 15.5±0.5 73.5±2.1 
 3P’ 5.3±0.5 4.4±0.4 55.8±5.2 
CFZ 3P’CAC 8.3±1.0 7.2±0.9 90.1±10.4 
 3P’AA 8.8±0.7 7.5±0.6 96.2±7.2 
 3P --- --- --- 
DOC 3PCAC 3.3±0.1 6.8±0.2 34.2±2.0 
 3PAA 4.7±0.1 9.6±0.2 49.3±1.1 
 3P’ --- --- --- 
DOC 3P’CAC 6.2±1.0 4.8±0.8 66.4±10.8 
 3P’AA 7.6±0.7 5.8±0.5 81.9±7.9 
Drug loading efficiency, molar drug loading efficiency and encapsulation efficiency are 
reported as mean±SD (n=3). Statistical significance is indicated in Figure 5.5. 
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Figure 5.5. Drug loading efficiency of unmodified and end-capped PNAs. Drug loading 
was determined using the model drugs carfilzomib (A,C) and docetaxel (B,D).  
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5.3.4  Amine End-Capping Groups Sustain Drug Release from PNAs  
 Figures 5.6 and 5.7 show drug release profiles from CFZ- and DOC-loaded 
PNAs, respectively. The first order kinetic model was a good approximation for the 
release of CFZ and DOC from drug-loaded PNAs. Drug release rates were consistent 
over 48 hours, and burst release was not observed for the PNAs used in this study. This 
model failed to provide any mechanistic information about drug release mechanisms 
from PNAs, but it did provide a facile method of comparing drug release between 
formulations. End-capping modifications increased the half-life of CFZ release from 
PNAs in order of no, CAC, and AA modifications for both PEI- and PLL-based PNAs, 
with the exception of CFZ-loaded 3P’CAC which decreased its drug release half-life 
(Table 5.4 and Figure 5.8). In addition, the AA modification increased the half-life of 
DOC release compared to CAC modification for both PEI- and PLL-based PNAs. PLL-
based PNAs increased drug release half-life compared to PEI-based PNAs with the 
exception of CFZ-loaded 3P’CAC. These results suggest that the chemical modification 
of PNAs to remove charged groups from the core can increase drug release half-life and 
sustain drug release over time. 
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Figure 5.6. Carfilzomib release profiles from unmodified and end-capped PNAs 3P (A), 
3PCAC (B), 3PAA (C), 3P’ (D), 3P’CAC (E) and 3P’AA (F). 
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Figure 5.7. Docetaxel release profiles from unmodified and end-capped PNAs 3P (A), 
3PCAC (B), 3PAA (C), 3P’ (D), 3P’CAC (E) and 3P’AA (F). Due to poor drug loading of 
3P (A) and 3P’ (D), drug release was not measured from these PNAs. 
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Table 5.4. Parameters from a first order kinetic model for drug release from unmodified 
and end-capped PNAs.  
Drug PNAs t1/2 (h) k (h-1) 
 3P 4.1 (3.0-6.6) 0.169 (0.106-0.233) 
CFZ 3PCAC 17.5 (14.9-21.1) 0.040 (0.033-0.046) 
 3PAA 23.1 (17.8-33.2) 0.030 (0.020-0.039) 
 3P’ 6.5 (4.9-9.6) 0.107 (0.072-0.142) 
CFZ 3P’CAC 3.6 (2.7-5.5) 0.190 (0.127-0.253) 
 3P’AA 28.2 (24.5-33.1) 0.024 (0.020-0.028) 
 3P --- --- 
DOC 3PCAC 4.8 (3.6-7.1) 0.146 (0.097-0.194) 
 3PAA 5.3 (3.7-9.5) 0.130 (0.072-0.187) 
 3P’ --- --- 
DOC 3P’CAC 22.3 (18.8-27.5) 0.031 (0.025-0.037) 
 3P’AA 26.6 (22.3-33.1) 0.026 (0.021-0.031) 
Kinetic parameters are reported as mean with 95% CI in parentheses. Differences in 
kinetic parameters between each model were compared by an extra sum of squares F 
test. Statistical significance is reported in figure 5.8. 
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Figure 5.8. Drug release half-lives from unmodified and end-capped PNAs. Drug release 
half-lives were determined using the model drugs carfilzomib (A,C) and docetaxel (B,D).  
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5.3.5 Drug Diffusion through the Hydrophobic Core of PNAs Controls Drug Release  
 Figure 5.9 shows drug release profiles of PNAs that were modeled with the 
Korsmeyer-Peppas model. The Korsmeyer-Peppas model fit the drug release profiles 
well for all PNAs except for DOC-loaded 3P’CAC, which underestimated terminal drug 
release for weighting values of 0, 1 and 2. Table 5.5 shows kinetic parameters from the 
Korsmeyer-Peppas model. End-capping reactions decreased the kinetic constant K 
compared to unmodified PNAs, which confirms the results from the first-order kinetic 
models. In all cases, AA-modified PNAs had lower K than CAC-modified PNAs. PLL-
based PNAs decreased K for DOC compared to PEI-based PNAs, but the scaffold had a 
minimal effect on K for CFZ-loaded PNAs. Figure 5.10 compares N values of drug 
release from end-capped PNAs. The 95% confidence intervals of the N values for most 
PNAs contained 0.45, indicating that drug release was diffusion-controlled. The 95% 
confidence intervals of the N values for CFZ-loaded 3PCAC and 3PAA were between 
0.45 and 0.65, indicating that other transport processes in addition to diffusion may 
control drug release. The 95% confidence intervals of the N values for PNAs was not 
greater than 0.85, suggesting that a receding boundary of the hydrophobic core did not 
contribute to drug release. Based on these findings, drug release profiles were further 
modeled using a diffusion-based drug release model.  
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Figure 5.9. Drug release profiles of unmodified and end-capped PNAs using the 
Korsmeyer-Peppas drug release model. Drug release profiles were measured using 
model drugs CFZ (A-F) and DOC (G-L). Due to poor DOC loading of 3P (G) and 3P’ 
(J), drug release was not measured from these PNAs.  
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Table 5.5. Kinetic parameters for drug release from unmodified and end-capped PNAs 
using the Korsmeyer-Peppas model. N values indicate a Fickian diffusion-controlled 
(N=0.45), a non-Fickian transport-controlled (0.45<N<0.85), or an anomalous 
transport-controlled drug release mechanism (N>0.85). 
Drug PNA K (h-1) N (unitless) Release Mechanism 
 3P 24.0 (16.5-31.5) 0.46 (0.34-0.57) Fickian Diffusion 
CFZ 3PCAC 8.5 (5.9-11.1) 0.61 (0.53-0.70) Non-Fickian Transport 
 3PAA 7.3 (4.3-10.2) 0.55 (0.46-0.65) Non-Fickian Transport 
 3P’ 18.3 (11.5-25.1) 0.50 (0.36-0.63) Fickian Diffusion 
CFZ 3P’CAC 25.1 (15.2-35.0) 0.44 (0.30-0.58) Fickian Diffusion 
 3P’AA 8.7 (6.3-11.1) 0.52 (0.45-0.60) Fickian Diffusion 
 3P - - - 
DOC 3PCAC 24.1 (17.7-30.5) 0.38 (0.30-0.46) Fickian Diffusion 
 3PAA 21.1 (15.2-27.1) 0.41 (0.32-0.49) Fickian Diffusion 
 3P’ - - - 
DOC 3P’CAC 10.2 (5.6-14.9) 0.49 (0.40-0.60) Fickian Diffusion 
 3P’AA 11.2 (7.0-15.4) 0.46 (0.37-0.55) Fickian Diffusion 
Kinetic parameters are reported as mean with 95% CI in parentheses. The 95% 
confidence intervals of N values were compared to 0.45 to determine the drug release 
mechanism.  
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Figure 5.10. N values from the Korsmeyer-Peppas drug release model for unmodified 
and end-capped PNAs.  
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5.3.6 Amine End-Capping Groups Decrease Drug Diffusivity in the Core of PNAs 
 Figure 5.11 shows drug release profiles for CFZ and DOC using an unsteady state 
spherical diffusion model. Semi-log plots of concentration vs. time were slightly curved, 
but the model fit the data well up to 90% of drug released. Table 5.6 summarizes the drug 
diffusivities and hydrophobic core diameters of various PNAs. In comparison to the 
estimated diffusivity of free CFZ or DOC at 37 °C in water from the Stokes-Einstein 
equation, PNAs reduced drug diffusivity by 4- to 5-fold, perhaps due to increased density 
and interactions with the PNA core. Amine end-capping reactions decreased the radius of 
the hydrophobic core for PEI-based PNAs, but they increased the hydrophobic core 
radius of PLL-based PNAs. PLL-based PNAs had smaller core radii than PEI-based 
PNAs for each end-capping modification, possibly due to the compact secondary 
structure of unmodified PLL compared to PEI. Figure 5.12 compares drug diffusivities in 
the core of end-capped PNAs. AA modifications decreased the diffusivity of both CFZ 
and DOC in PNAs, but CAC modifications increased the diffusivity of CFZ in 3P’CAC. 
These results suggest that end-capping modifications to PNAs can sustain drug release 
from the core of PEI-based PNAs by decreasing the diffusivity of drugs in the PNA core, 
but that end-capping modifications of PLL-based PNAs sustain drug release by 
increasing the diameter of the hydrophobic core.  
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Figure 5.11. Drug release profiles of unmodified and end-capped PNAs using the 
unsteady state spherical diffusion model. Drug release profiles were measured using the 
model drugs CFZ (A-F) and DOC (G-L). Due to poor DOC loading of 3P (G) and 3P’ 
(J), drug release was not measured from these PNAs.  
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Table 5.6. Diffusion parameters for PNA-encapsulated drugs from the unsteady state 
spherical diffusion model (equation 5.5). Diffusion parameters for free drugs were 
estimated using the Stokes-Einstein equation and are included for comparison. 
Drug PNA a (nm) D (cm2/s) *1018 
CFZ None --- 53,400 
 3P 11.4±2.8 3.90 (2.70-5.10) 
CFZ 3PCAC 10.1±3.9 0.89 (0.73-1.05) 
 3PAA 8.6±2.3 0.27 (0.22-0.33) 
 3P’ 2.0±1.5 0.07 (0.06-0.08) 
CFZ 3P’CAC 5.0±1.7 0.93 (0.81-1.05) 
 3P’AA 5.0±1.4 0.10 (0.08-0.11) 
DOC None --- 53,000 
 3P 11.4±2.8 --- 
DOC 3PCAC 10.1±3.9 1.50 (1.08-1.93) 
 3PAA 8.6±2.3 0.95 (0.63-1.22) 
 3P’ 2.0±1.5 --- 
DOC 3P’CAC 5.0±1.7 0.13 (0.11-0.15) 
 3P’AA 5.0±1.4 0.11 (0.08-0.13) 
Hydrophobic radius is reported as mean±SD. The error is propagated from equation 5.7 
into equation 5.6. The diffusivity is reported as the mean with 95% CI in parentheses.  
Statistical significance is determined in Figure 5.12.  
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Figure 5.12. Drug diffusivities in the core of unmodified and end-capped PNAs from the 
unsteady state spherical diffusion model.  
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5.4  Discussion 
5.4.1 PNAs with an Uncharged Core are Effective Carriers for Hydrophobic Drugs 
 PNAs forming globular, micellar and vesicular structures have drawn attention as 
multifunctional drug carriers over the past several decades (238-240). Unfortunately, the 
therapeutic efficacy of PNAs is often disappointing due to particle instability, low drug 
entrapment, and rapid drug release in the blood (241-243). Polymer micelles are used as 
FDA-approved drug delivery vehicles (244, 245), but micelles often demonstrate initial 
burst drug release followed by sustained long-term drug release. This two-step drug 
release pattern reduces drug accumulation in tumors, which can limit the efficacy of 
cancer chemotherapy (246). Drugs that are released from drug carriers that are away from 
the tumor may accumulate in healthy tissues and cause undesired side effects (247). Two-
step drug release profiles are often attributed to drugs that remain weakly bound to the 
polymer shell of nanoassemblies, even after extensive purification (248, 249). Unlike free 
drugs that often co-exist as impurities along with drug-loaded carriers, weakly bound 
drugs cannot be easily separated from drug-loaded nanoassemblies without removing 
entrapped drugs. Therefore, despite the critical need to fine-tune drug release from 
nanoparticles, preventing burst drug release from PNAs remains difficult. 
A simplified form of PNA with a charged scaffold (PEI or PLL), hydrophobic 
groups (PAL), and amine end-capping pendant groups (CAC and AA) was synthesized. 
By following this process, a family of polymer nanoassemblies was synthesized for 
entrapping CFZ and DOC. The data demonstrated that all six PNAs were small enough to 
maintain sufficient PEG shell density in order to minimize weak binding of drugs or other 
molecules to the surface of PNAs (250). Amine end-capping modifications to the core of 
200 
PNAs did not significantly affect their particle size, suggesting that chemical 
modifications to the nanoparticle core do not prevent PNAs from permeating throughout 
small blood vessels in the body. PNAs were also uniform in molecular weight 
distribution, which maintains the intermolecular consistency of nanoassemblies and 
minimizes changes in dispersity among the formulations after core modifications.  
 The fluorescamine characterization and NMR quantification of PNAs showed that 
NHS-activated PEG and palmitoyl chloride reactions could not remove all remaining 
primary amines from the core of PNAs, but amine end-capping reagents further removed 
some of the remaining primary amines. This suggests that the steric hindrance of the 
remaining primary amines on PNAs increases following PEG and PAL reactions, which 
limits the molar substitution of larger hydrophilic polymers or hydrophobic groups on 
polymer scaffolds (251). Both AA and CAC modifications removed more remaining 
primary amines from 3P’ than from 3P, indicating that the primary amines on PLL are 
less hindered than the primary amines on PEI (252). AA modification of 3P’ removed all 
remaining primary amines in the PNA core, verifying that the use of small pendant 
groups and less sterically hindered scaffolds allows for the complete removal of 
remaining primary amines from PNAs. These results also indicate that the selection of 
polymer scaffolds with less sterically hindered amines or lower amine density may allow 
for higher substitution yields of PEG and PAL on PNAs.  
5.4.2 End-Capping Modifications Modulate Drug Encapsulation and Release 
 Experimental results show that amine end-capping groups increased the drug 
loading and encapsulation efficiency of PNAs. Charged amines in the PNA core may 
prevent drugs from entering nanoassemblies during loading. In addition, these results 
201 
demonstrated that PLL, a polymer scaffold with minimal ionic effects resulting in a 
distinct pKa value, could increase drug loading compared to PEI, a polymer scaffold with 
significant ionic effects and a broad pKa value (253, 254). Therefore, removing ionic 
groups to increase the hydrophobicity of the PNA core is an effective approach to 
increase drug loading and ultimately improve the delivery of anticancer drugs to tumors. 
Drug release profiles of CFZ-loaded PNAs demonstrated that this experimental 
approach helped to prevent the burst release of CFZ from PNAs compared to previously 
developed CFZ-loaded polymer micelles (255). Drug release studies also indicated that 
PNAs could fine-tune drug release as a function of scaffold and pendant group 
modifications to the core. The drug release half-lives of PNAs ranged from 4 to 28 hours 
as amines were removed from the core by changing scaffold from PEI to PLL and by 
increasing the end-capping group substitution from no modification to AA modification. 
Although some primary amines of 3P were reacted during the conjugation of PEG and 
PAL to the scaffold, the remaining primary, secondary and tertiary amines make the core 
of 3P charged (256). Because of this core charge, drugs could be weakly bound in the 3P 
core and release quickly compared to 3P’ with only primary amines. 
5.4.3 Mechanistic Modeling Elucidates a Mechanism for Controlling Drug Release 
from PNAs 
 In order to determine the mechanism for the changes in drug release profiles of 
PNAs following end-capping reactions, drug release profiles were fit to several 
mathematical models. Initially, a first order kinetic model was used to determine the 
effects of end-capping modifications on overall drug release rates. Although this model 
indicated that end-capping modifications increase the drug release half-lives of PNAs, it 
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fails to provide detailed information about drug release mechanisms from PNAs (257). It 
was hypothesized that the rate-determining step of drug release from PNAs was the 
diffusion of drug out of the PNA core, and that end-capping modifications decreased drug 
diffusivity in the PNA core. In order to elucidate the rate-determining step for drug 
release from PNAs, the drug release profiles were then fit to the Korsmeyer-Peppas 
model of drug release. By comparing the N values from fitted drug release profiles to 
literature, a rate-determining step could be determined (258). For N values equal to 0.45, 
the drug release is controlled by the Fickian diffusion of drug molecules out of the 
hydrophobic core. Fickian diffusion indicates that the diffusivity value of drug in the 
nanoparticle core is independent of both time and drug concentration. The 95% 
confidence intervals for the N values of most drug-PNA combinations overlapped 0.45, 
indicating that drug release from these PNAs occurred because of Fickian diffusion 
(259). N values between 0.45 and 0.85 indicate that non-Fickian transport processes 
control drug release. Non-Fickian transport processes refer to a combination of Fickian 
diffusion and a time- or drug concentration-dependent change in nanoparticle core 
environment during drug release such as a glass transition for polymers (260). The 95% 
confidence intervals for the N values of CFZ-loaded 3PCAC and 3PAA were between 
0.45 and 0.85, indicating that CFZ loading may alter the rigidity of the PNA core or alter 
diffusion rates in the core of these PNAs (261). N values above 0.85 indicate that 
processes other than diffusion control the release of drug from the nanoparticle core. 
None of the 95% confidence intervals of the N values for PNAs were greater than 0.85.  
 Because the Korsmeyer-Peppas model indicated that the rate-determining step for 
drug release was diffusion, an unsteady state spherical diffusion model was used to 
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measure drug diffusivity in the PNA core. End-capping modifications to 3P decreased 
CFZ diffusivity, suggesting that end-capping modifications reduce the pore sizes for drug 
diffusion in the PNA core. In contrast, end-capping modifications increased the 
hydrophobic core diameter of PLL-based PNAs but had a minimal effect on drug 
diffusivity, suggesting that end-capping modifications of PLL-based PNAs do not affect 
the pore sizes in the core of these PNAs. 
5.4.4 PNAs with a Positive Core Charge Release Carfilzomib Quickly Compared to 
Similar PNAs with a Neutral Core 
 The CFZ release half-life of 3P’CAC was shorter than initially expected. 
Although drug release rate trends suggest that the CFZ release half-life of 3P’CAC would 
be 22 hours, the observed CFZ release half-life of 3P’CAC was 4 hours. One explanation 
for the relatively short CFZ release half-life of 3P’CAC is that the positive core charge of 
3P’CAC drew charged molecules into the PNA core. In this highly charged core 
environment, CFZ may become positively charged and repel from the cationic core 
environment. In contrast, DOC is not easily ionizable and hydroxyl groups on DOC may 
favorably interact with charged molecules in the PNA core. Therefore, pendant groups 
that do not increase core charge of PNAs would achieve stable entrapment and sustained 
release of hydrophobic anticancer drugs. 
5.5  Conclusions 
 In this study, a novel delivery system was developed for CFZ and DOC by using 
polymer nanoassemblies (PNAs). Six PNAs were synthesized with various polymer 
scaffolds and end-capping modifications to determine the effects of ionizable groups in 
the PNA core on drug delivery. Removing charged groups from the core of PNAs 
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increased their drug loading and encapsulation efficiency, while also sustaining drug 
release and increasing their drug release half-life. In addition, mechanistic modeling 
showed that drug release from PNAs was controlled by decreasing drug diffusivity in the 
nanoassembly core. In summary, this study has demonstrated a mechanism-based, facile 
engineering method for the development of PNA drug carriers that can entrap drugs at 
high yields and enhance their therapeutic efficacy by suppressing initial burst drug 
release. 
 
 
 
 
 
 
 
 
 
 
 
**Portions of Chapter 5 were previously published in (262). Reproduced with permission 
from Future Science Group: Therapeutic Delivery, Volume 7, Issue 10, Pages 665-681, 
Figures 1-7 and Text. Copyright 2016 is given to the publication in which the material 
was originally published. 
Copyright (C) Derek Reichel 2017 
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CHAPTER SIX 
PNAs WITH CONTROLLED DRUG RELEASE PROFILES IMPROVE 
CARFILZOMIB EFFICACY BY PREVENTING RAPID DRUG METABOLISM AND 
SUSTAINING PROTEASOME INHIBITION IN CELLS 
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6 PNAs WITH CONTROLLED DRUG RELEASE PROFILES IMPROVE 
CARFILZOMIB EFFICACY BY PREVENTING RAPID DRUG METABOLISM AND 
SUSTAINING PROTEASOME INHIBITION IN CELLS 
6.1  Introduction 
 The inhibition of novel biological targets such as the proteasome has emerged as a 
promising approach to improve cancer treatment. The proteasome is a multi-protease 
enzyme complex that plays an essential role in the regulation of cellular processes by 
degrading the proteins involved in cell proliferation and signaling (263). Small molecule 
inhibitors of proteasomes can increase the accumulation of misfolded proteins in cells. 
The accumulation of misfolded proteins in cancer cells following sustained proteasome 
inhibition causes cell stress leading to apoptosis. Because of the essential role that the 
proteasome plays in the survival of all living cells, the selectivity of proteasome 
inhibitors towards cancer cells was initially questioned (264). However, several studies 
have validated proteasome inhibition as a selective method for killing rapidly 
proliferating cancer cells compared to normal cells (265). In particular, cancer cells that 
are resistant to other conventional and targeted chemotherapies have shown sensitivity to 
proteasome inhibitors (266, 267). Three proteasome inhibitors (bortezomib, carfilzomib 
and ixazomib) have received FDA approval for cancer treatment (268-270).  
Carfilzomib (CFZ) is a second-generation proteasome inhibitor with the potential 
to treat solid tumors, but its clinical applications have been limited to blood cancers such 
as multiple myeloma (271). CFZ showed efficacy at treating a variety of solid cancers in 
animal models (272, 273). While many clinical studies have proposed the use of CFZ in 
solid tumors, clinical trials in breast, lung, and colon cancers were unsuccessful (274). 
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The limited clinical applications of CFZ are often attributed to its poor biopharmaceutical 
properties such as its rapid clearance that limits the accumulation of active drug in tumors 
and prevents the sustained inhibition of proteasomes in cancer cells (275). Therefore, 
there is a need to improve the biopharmaceutical properties of CFZ in order to increase 
drug accumulation in solid tumors and improve treatment efficacy. 
CFZ is clinically available as an intravenous cyclodextrin formulation 
(Kyprolis®), but this formulation fails to increase the metabolic stability of CFZ (276). 
Although cyclodextrin complexation increased the solubility of CFZ, the half-life of CFZ 
in blood after intravenous injection of Kyprolis is less than 30 minutes (277, 278). The 
poor half-life of CFZ in blood is typically attributed to the rapid extrahepatic metabolism 
of free drug. As free CFZ is degraded in the blood, the cyclodextrin complex rapidly 
dissociates to maintain thermodynamic equilibrium between the free CFZ, the unbound 
cyclodextrin and the CFZ-cyclodextrin complex. As a result, cyclodextrin formulations of 
CFZ fail to increase the accumulation of CFZ in solid tumors. Therefore, there is a 
growing need to develop novel formulations of CFZ to expand the therapeutic benefits of 
proteasome inhibition therapy to a variety of human cancers. 
 Previously, polymer micelle (PM) carriers for CFZ were developed using FDA-
approved materials, but these formulations had poor pharmacokinetic properties that 
limited their in vivo efficacy (160). Several drug-loaded PMs are either used clinically 
(e.g., Genexol, Nanoxel) or are undergoing clinical trials (e.g., NK012, NK105, 
SP1049C, NC-6004) for the controlled delivery of anticancer drugs to solid tumors (279-
281). These formulations reduced the systemic, cardiac, hepatic, and renal toxicities of 
anticancer drugs (282). In a previous study, CFZ-loaded PMs protected the drug from 
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enzymatic degradation in the presence of mouse liver homogenate (255). However, the 
antitumor efficacy of CFZ-loaded PMs was similar to cyclodextrin-complexed CFZ. This 
unexpected result was attributed to the poor drug release properties of CFZ-loaded PMs 
such as burst release and rapid drug release rates (160). In addition, the dilution of PMs 
after intravenous injection can destabilize the micelles and increase drug release into the 
blood. Stable PNA formulations of CFZ with improved drug release properties may 
increase the in vivo treatment efficacy of CFZ by protecting the drug from extrahepatic 
metabolism and sustaining drug release into solid tumors. 
 In this study, the treatment efficacy of CFZ-loaded PNAs was compared to free 
CFZ using cell-based assays mimicking in vivo drug delivery conditions. 3P’AA was 
selected as a model PNA with the highest CFZ loading and release half-life of the 
previously tested formulations in chapter 5. The metabolic stability, cytotoxicity and 
proteasome inhibition profile of CFZ formulations were identified as three key factors 
controlling the in vivo treatment efficacy of CFZ. HT29 colon cancer cells were used as a 
model cell line for CRC tumors, while H23 lung cancer cells were selected as a model 
cell line with well-characterized proteasome activity profiles following treatment with 
proteasome inhibitors. The results from this study will indicate the potential of 
nanoparticle drug carriers with sustained CFZ release to improve the treatment of solid 
tumors and justify further in vivo experiments. 
6.2 Materials and Methods 
6.2.1 Materials and Cells 
 3P’AA was synthesized and loaded with CFZ as described in chapter 5. 
Epoxomicin, ethylenediaminetetraacetic acid (EDTA), resazurin sodium salt, sodium 
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dodecyl sulfate (SDS), and Tris-HCl were purchased from Sigma Aldrich (St. Louis, 
MO). A fluorogenic peptide substrate Succinate-Leu-Leu-Val-Tyr-(7-amino-4-
methylcoumarin) (Suc-LLMY-AMC) was purchased from Biovision (Milpitas, CA). 
Acetonitrile (ACN), dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), water 
and Hanks’ balanced salt solution (HBSS) were purchased from Fisher Scientific 
(Waltham, MA). Passive lysis buffer solution was purchased from Promega (Madison, 
WI). 20S proteasome assay buffer (20 mM Tris-HCl, 0.5 mM EDTA, 0.035% SDS, pH 
8.0) was prepared by dissolving components in water and adjusting the pH with sodium 
hydroxide. Carfilzomib (CFZ) was purchased from LC Laboratories (Woburn, MA). 
McCoy’s 5A media (M5A), RPMI-1640 media and 0.05% trypsin/EDTA were purchased 
from GE Healthcare (Logan, UT). Fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals (Flowery Branch, GA). The human lung cancer cell line H23 and human 
colon cancer cell line HT29 were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). H23 cells were cultured in RPMI-1640 media with 10% FBS, 
while HT29 cells were cultured in M5A with 10% FBS. All ATCC recommendations 
were followed for both cell lines. Cells were cultured in a humidified environment with 
5% CO2 at 37 °C. 
6.2.2  Screening of Carfilzomib Degradation Conditions 
 A stock solution of CFZ was prepared (DMSO, 10 mg/ml). Ten microliters of 
CFZ stock solution was added to 990 microliters of acetonitrile, M5A containing 25% 
inactivated FBS (iFBS), M5A containing 25% active FBS (aFBS) and M5A without 
FBS. The CFZ-spiked solutions were stored at 37 °C while gently mixing. Aliquots (50 
μl) of each solution were removed after 0, 30 and 60 minutes. Each aliquot was diluted in 
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50 μl of acetonitrile to quench the degradation reactions. The quenched aliquots were 
then centrifuged at 14,500 RPM for 20 minutes to remove serum proteins and other 
insoluble impurities. Drug concentrations in each sample were quantified using HPLC as 
described in chapter 2. Drug concentration measurements were normalized to the initial 
sample concentration for each condition. To determine if any drug concentration changes 
in the samples were due to drug precipitation during centrifugation, 10 μl of CFZ stock 
solution was added to 990 μl of deionized water and the solution was immediately 
centrifuged at 1000 RPM for 1 minute. Sample aliquots before and after centrifugation 
were diluted in acetonitrile (1:1 v/v) to prevent any potential further drug precipitation. 
Changes in drug concentration following centrifugation were measured by HPLC and 
normalized to the initial sample concentration.  
6.2.3  Cytotoxicity of Carfilzomib-Loaded PNAs and Free Carfilzomib With and Without 
Pre-Incubation in Cell Media 
 HT29 cells were seeded in 96 well plates at 3,000 cells per well. Cells were 
treated with either fresh or pre-incubated CFZ. Pre-incubation of CFZ in FBS for 1 hour 
at 37 °C was selected as an experimental condition to mimic the expected extrahepatic 
metabolism of CFZ in the blood following intravenous administration. Briefly, serial 
dilutions of free CFZ and CFZ-loaded PNAs were prepared in DMSO and PBS, 
respectively, and added to M5A to create 2X stock solutions of free CFZ and CFZ-loaded 
PNAs. Half of each solution was immediately diluted with M5A containing 20% FBS to 
yield 1X solutions in M5A containing 10% FBS (fresh), while the other half was stored at 
37 °C for 1 hour with mixing before dilution (pre-incubated). Cells were treated with 
fresh or pre-incubated CFZ (free or PNAs) for 72 hours. Cell viability was measured by 
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adding 10 μl of 1 mM resazurin solution to each well and measuring the fluorescence of 
the oxidized product resorufin (Ex 560 nm/Em 590 nm) after 3 hours of incubation. Cell 
viability was calculated from equation 6.1. 
𝐶𝐶𝑉𝑉 = (𝐹𝐹𝑆𝑆𝐹𝐹𝑆𝑆−𝐹𝐹𝑆𝑆𝐹𝐹𝑀𝑀)
(𝐹𝐹𝑆𝑆𝐹𝐹𝑉𝑉−𝐹𝐹𝑆𝑆𝐹𝐹𝑀𝑀)
∗ 100%   (6.1) 
 In equation 6.1, CV is the percent cell viability, FLUS is the fluorescence of CFZ-
treated samples, FLUM is the average fluorescence of media-only samples, and FLUV is 
the fluorescence of vehicle-treated cells. All fluorescence measurements have units of 
relative fluorescence units. The half maximal inhibitory concentration (IC50) of each 
formulation was calculated from a sigmoidal fit of the cell viability vs. the logarithm of 
drug concentration using Prism 5.0 (Graphpad, La Jolla, Ca). The IC50 value has units of 
nM. 
6.2.4  Carfilzomib Treatment of Cells and Proteasome Collection 
 H23 cells were seeded in 12 well plates at 150,000 cells per well. Cells were 
treated with 7 nM of either free CFZ or CFZ-loaded PNAs for 0, 6, 24, 48 or 72 hours. 
The media was removed after treatment and the cells were washed twice with HBSS. 
Cells were lysed in passive lysis buffer for 15 minutes, and soluble proteins were 
collected after centrifuging the cell lysate at 14,000 RPM for 20 minutes and collecting 
the supernatant. 
6.2.5  Proteasome Activity Measurement in the Cell Lysates of Carfilzomib-Treated 
Cells 
 Total protein concentrations in the supernatants of cell lysates were quantified 
using a Bradford assay, which was calibrated using protein standards. The supernatants of 
the cell lysates were diluted in 20S proteasome assay buffer to create a 55.6 μg total 
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protein/ml stock solution. Ninety microliters of cell lysate stock solution for each sample 
was added to a 96 well plate and incubated at room temperature for 60 minutes. Ten 
microliters of 1 mM Suc-LLMY-AMC substrate solution was added to each well. The 
fluorescence of the wells was measured (Ex 360 nm/Em 460 nm) every minute for 1 hour 
at 37 °C using a plate reader. To account for non-proteasomal proteolytic activity in cell 
lysate solutions, cell lysate solutions were treated with the 20S proteasome-inhibitor  
epoxomicin (10 μM) and the proteasome activity of these solutions was subtracted from 
the activity of CFZ-treated sample measurements. The proteasome activities of H23 cells 
treated with either free CFZ or CFZ-loaded PNAs were reported as a percentage of the 
proteasome activity of untreated H23 cells.  
6.2.6 Statistics 
 All values are reported as mean±standard deviation of three measurements unless 
described otherwise. Groups of measurements were compared to each other using a one-
way analysis of variance (ANOVA) with Bonferroni’s post hoc test. Pairs of 
measurements are compared with Student’s t test. Statistical significance is indicated by * 
(p<0.05), ** (p<0.01) or *** (p<0.001). 
6.3 Results 
6.3.1  Serum Minimizes Carfilzomib Degradation in Cell Media 
 Stability profiles of CFZ are shown in Figure 6.1. CFZ concentrations remain 
consistent in acetonitrile or M5A containing FBS. However, the CFZ concentration 
decreases by 62% after 1 hour in M5A without FBS. As CFZ peaks on the HPLC 
decreased, a peak with a shorter retention time (1.6 min vs. 2.0 min) appeared. It should 
be noted that CFZ degrades rapidly in human blood containing serum proteins, and that 
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differences between FBS-containing media and whole blood may contribute to this 
discrepancy. A full discussion of these differences is postponed until the discussion 
section. Centrifugation did not decrease the measured CFZ concentration in control 
samples, indicating that any decreases in CFZ concentrations during experiments are not 
attributed to drug precipitation.   
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Figure 6.1. Stability of free CFZ at 37 °C in various solvent conditions. CFZ was stored 
in acetonitrile (ACN), McCoy’s 5A with 25% inactive FBS (M5A+iFBS), McCoy’s 5A 
with 25% active FBS (M5A+aFBS) or pure McCoy’s 5A (M5A) following 0, 30 or 60 
minutes of incubation.  
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6.3.2  Carfilzomib-Loaded PNAs Maintain Drug Cytotoxicity after Pre-Incubation 
 The cytotoxicity of fresh and pre-incubated CFZ in HT29 colon cancer cells are 
shown in Figure 6.2 and Table 6.1. The differences in IC50 values between fresh and pre-
incubated free CFZ are statistically significant, but the differences between fresh and pre-
incubated CFZ-loaded PNAs are not statistically significant. Differences between the 
IC50 ratios of free CFZ and CFZ-loaded PNAs are statistically significant. Figure 6.3 
compares the predicted changes in CFZ cytotoxicity based on drug concentrations to the 
measured cytotoxicity changes in cancer cells. For CFZ-loaded PNAs, released drug was 
assumed to degrade, while encapsulated drug was assumed to remain stable. Based on 
changes in drug concentrations from the HPLC quantification of free CFZ following pre-
incubation, the free CFZ and CFZ-loaded PNA IC50 ratio are predicted to be 2.61 and 
1.02, respectively. The differences between predicted and measured treatment efficacy 
were not statistically significant, but the differences between each formulation were 
significant. These results suggest that PNAs with sustained drug release can prevent drug 
degradation and deliver active drug to cancer cells. 
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Figure 6.2. Cytotoxicity of fresh and pre-incubated free CFZ (A) and carfilzomib-loaded 
PNAs (B). Zoomed-in graphs of free CFZ (C) and PNAs (D).   
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Table 6.1. Cytotoxicity parameters of fresh and pre-incubated free CFZ and CFZ-loaded 
PNAs. 
Formulation Treatment Condition IC50 (nM) IC50 Ratio 
Free CFZ  Fresh 28.6 (23.1-35.3)* --- 
Free CFZ  Pre-Incubated 85.5 (76.2-96.1)* 2.99 (2.08-3.89)* 
CFZ-Loaded PNAs Fresh 42.1 (37.4-47.3) --- 
CFZ-Loaded PNAs Pre-Incubated 44.7 (41.6-48.0) 1.06 (0.83-1.29)* 
Pharmacological parameters are presented as mean with 95% CI in parentheses. Error 
in the IC50 ratio is propagated from each IC50 value. IC50 values for each formulation and 
IC50 ratios were compared by a Student’s t-test. Statistical significance is indicated as 
described in the methods section.   
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Figure 6.3. Predicted and measured changes in the cytotoxicity of free CFZ and CFZ-
loaded PNAs.  
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6.3.3  Carfilzomib-Loaded PNAs Sustain Long-Term Proteasome Inhibition in Cancer 
Cells  
 Proteasome inhibition profiles of H23 lung cancer cells treated with either free 
CFZ or CFZ-loaded PNAs are shown in Figure 6.4. The proteasome activity of H23 cells 
decreased at 6 hours compared to untreated samples. Some proteasome activity was 
recovered up to 48 hours post-treatment for both formulations compared to 6 hours post-
treatment. Free CFZ-treated cells continued to recover proteasome activity at 72 hours 
post-treatment compared to 48 hours, but PNA-treated cells decreased proteasome 
activity. Free CFZ-treated cells had reduced proteasome activity compared to PNA- 
treated cells at initial times post-treatment, but PNA-treated cells had reduced proteasome 
activity compared to free CFZ-treated cells at 72 hours post-treatment.   
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Figure 6.4. Proteasome activity of H23 cancer cells treated with free CFZ or CFZ-loaded 
PNAs. Proteasome activity was measured at 6, 24, 48 and 72 hours post-treatment and 
normalized to the activity of proteasomes from untreated cells (A). The AUC of 
proteasome activity from each sample was also compared (B).   
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6.4 Discussion 
6.4.1 PNAs Reduce the Degradation of Carfilzomib 
 CFZ is promising for the effective treatment of a variety of human cancers, but it 
has been ineffective in clinical trials for solid tumors (267). These discouraging results 
are often attributed to extrahepatic metabolism that prevents the necessary accumulation 
of active drug in solid tumors. As a result, misfolded proteins fail to accumulate in cancer 
cells and cause cell stress leading to apoptosis (283). PMs were previously reported as a 
promising formulation to solubilize hydrophobic anticancer drugs and prevent drug 
metabolism, but PMs had similar treatment efficacy to clinically available cyclodextrin 
formulations (160). In contrast to PMs that can dissociate after injection and release CFZ 
into the blood, unimolecular PNAs may remain stable and sustain drug release. 
Therefore, this study compares free CFZ to CFZ-loaded PNAs using in vitro models to 
determine the effects of sustained release on proteasome inhibition and cytotoxicity. 
 Physiologically relevant models of in vivo drug metabolism are difficult to 
develop, because the factors contributing to metabolic stability profiles such as in vitro 
exposure time, enzyme concentrations and buffer conditions must be carefully optimized 
for each drug (284, 285). One common in vitro metabolism model is the liver 
homogenate model, in which drugs are exposed to proteins collected from liver tissue 
(286). Changes in drug concentrations over time are correlated to in vivo metabolic drug 
stability, but previous studies suggest that the accuracy of these models at predicting in 
vivo metabolism are limited for drugs undergoing extrahepatic metabolism (287). As an 
alternative to liver homogenate experiments, a facile method was developed to mimic the 
extrahepatic metabolism of CFZ and predict the metabolic stability of CFZ. Although 
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M5A does not contain all of the enzymes present in whole blood, 60% of the free CFZ in 
M5A was found to degrade within one hour. In contrast, over 95% of CFZ degraded 
within 5 minutes following exposure to liver homogenate, which significantly 
overestimates CFZ degradation rates in vivo (60). These results suggest that the storage of 
free CFZ in cell media without FBS may be advantageous compared to compared to liver 
homogenate studies at predicting extrahepatic metabolism due to drug hydrolysis (288). 
 Although CFZ can rapidly metabolize in whole blood and other tissue 
homogenates (60), CFZ remained stable in active FBS-containing media mimicking 
whole blood. This surprising result suggests that FBS-containing cell media fails to 
mimic the enzymatic properties of whole human blood, and that the chemical 
components of M5A contribute to observed CFZ degradation profiles. Two potential 
factors could contribute to these differences: 1) the manufacturing steps for FBS 
preparation such as coagulation and centrifugation may not collect the specific proteases 
from whole blood that cause CFZ degradation, and 2) the peptide bonds in carfilzomib 
may not be substrates for bovine serum proteases. Further work is needed to determine 
enzymatic activity of proteases in FBS compared to human serum. CFZ remains 
relatively stable under neutral and slightly acidic conditions in water, but recent 
publications suggest that the formation of chloride adducts increases the in vitro 
hydrolysis of the epoxyketone group on CFZ (289, 290). This observation suggests that 
the high chloride concentrations in M5A (>110 mM) may contribute to epoxyketone ring 
opening, but that interactions between CFZ and serum proteins protect CFZ from 
degradation in serum-containing samples. However, significant experimental work is 
needed to test this hypothesis.  
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6.4.2 Controlled Release of Carfilzomib from PNAs Sustains Proteasome Inhibition 
 CFZ-loaded PNAs can increase proteasome inhibition in cancer cells compared to 
free CFZ at 72 h post-treatment. Sustained proteasome inhibition in cancer cells may 
increase the efficacy of CFZ in MM or solid tumors by increasing the accumulation of 
misfolded proteins in cancer cells (291). However, it should be noted that IC50 values are 
lower for free CFZ than for CFZ-loaded PNAs, and that initial proteasome inhibition is 
greater with free CFZ than with CFZ-loaded 3P’AA. In addition, the area under the curve 
(AUC) up to 72 hours post-treatment indicating overall proteasome activity is slightly 
greater for CFZ-loaded PNAs than for free CFZ (1888 vs 1551 normalized activity/h, 
respectively, p>0.05). Taken together, these results suggest that short-term proteasome 
inhibition controls in vitro CFZ cytotoxicity, and that in vitro cytotoxicity measurements 
of proteasome inhibitors may not mimic the long-term proteasome inhibition necessary 
for solid tumor treatment. Determining the relationship between in vitro proteasome 
inhibition profiles and the in vivo effects of sustained proteasome inhibition in solid 
tumors is an important area of future work.  
6.4.3 PNAs May Increase the Accumulation of Active Carfilzomib in Solid Tumors 
 By extending the drug release half-life of CFZ, PNAs can increase the 
accumulation of active drug in solid tumors compared to free drugs. Nanoassemblies 
such as PNAs can passively accumulate in the porous vasculature of solid tumors and  
increase the concentration of nanoparticles in tumor tissue compared to healthy tissue 
(282). The maximum accumulation of nanoassemblies in the vasculature surrounding 
solid tumors typically occurs between 3 to 6 hours after intravenous injection (292, 293). 
Based on drug release measurements in chapter 5, 3P’AA will release less than 15% of 
224 
drug before accumulating in solid tumors, which decreases the amount of free drug 
released into the blood before PNAs can reach solid tumors. Therefore, PNAs are 
expected to increase the amount of active anticancer drugs delivered to tumors and 
potentially enhance anticancer efficacy (294, 295). Future studies will focus on 
elucidating the benefits of PNA drug delivery in animal models of solid tumors. 
6.5 Conclusions 
In this study, the treatment efficacies of free CFZ and CFZ-loaded PNAs were 
compared using in vitro drug metabolism, cytotoxicity and proteasome activity models. 
The sustained release of CFZ from PNAs maintained drug efficacy after pre-incubation 
compared to free CFZ. Changes in the efficacy of free CFZ following pre-incubation 
corresponded to predictions based on HPLC quantification of active drug, suggesting that 
drug activity controls cytotoxicity. In addition, PNAs with a longer drug release half-life 
sustained proteasome inhibition in model cancer cell lines compared to free drug, 
suggesting that CFZ delivery using PNAs can modulate proteasome activity in various 
types of cancer cells. Overall, this study has demonstrated the advantages of PNAs to 
protect CFZ from metabolic degradation, maintain cytotoxicity and extend proteasome 
inhibition in cancer cells to potentially improve the efficacy of CFZ in solid tumors. 
 
**Portions of Chapter 6 were previously published in (262). Reproduced with permission 
from Future Science Group: Therapeutic Delivery, Volume 7, Issue 10, Pages 665-681, 
Figures 8-10 and Text. Copyright 2016 is given to the publication in which the material 
was originally published. 
Copyright (C) Derek Reichel 2017  
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7 CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Conclusions 
7.1.1 Dye Entrapment in Polymer Nanoassemblies Enable Fluorochromism for 
Theranostics 
 In this work, dyes were entrapped in the core of polymer nanoassemblies in order 
to create PNAs for cancer theranostics. The conjugation of non-fluorochromic dyes such 
as IR820 and Alexa Fluor® 546 to the polymer scaffold created PNAs without 
fluorochromism. Non-fluorochromic PNAs such as 3P’IR820 and 3P’A546 had 
consistent fluorescence properties in various solvent and core environments. The 
consistent fluorescence properties of non-fluorochromic PNAs allowed for the accurate 
quantification of PNAs in agarose gels, organs and sectioned tissue samples. In contrast, 
the conjugation of the model fluorochromic dye NB to the nanoassembly core yielded 
PNAs with fluorochromism. While the fluorescence of free NB was quenched in water, 
NB in the core of the PEI-based PNAs fluoresced strongly. Fluorochromic PNAs 
detected environmental properties such as acidity and nanoparticle core environment 
properties such as drug loading. Therefore, the entrapment of fluorochromic dyes in 
PNAs enabled fluorochromism in comparison to PNAs entrapping traditional fluorescent 
dyes.  
 In order to investigate the effects of the PNA core environment on 
fluorochromism, NB was attached to the polymer scaffold of PNAs with either an ionic 
or a hydrophobic core environment. PNAs with a hydrophobic core environment (3PN) 
fluoresced strongly in comparison to PNAs with an ionic core environment (2PN), 
suggesting that increasing the PNA core hydrophobicity prevents fluorescence quenching 
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of NB by forcing water out of the PNA core. 3PN fluoresced at lower excitation and 
emission wavelengths than 2PN, indicating that interactions between hydrophobic groups 
and dyes increase the energy of their fluorescence emission spectra. 2PN had decreased 
fluorescence in acidic solution while 3PN had increased fluorescence, suggesting that 
shifts in fluorescence spectra contribute to the halo-fluorochromic properties of PNAs. 
Taken together, these results suggest that the core environment of PNAs must be 
carefully considered to maximize the fluorochromism of entrapped dyes. 
 The effects of polymer scaffold composition on dye fluorochromism were also 
evaluated using PNAs with fewer (3P’N) or no amines in core (3P’NAA). Amines were 
removed from the PNA core by replacing the PEI scaffold with a PLL scaffold (3P’N) 
lacking secondary and tertiary amines, and by further end-capping and remaining primary 
amines on the scaffold (3P’NAA). The fluorescence of 3P’N could not be detected, 
suggesting that the PLL scaffold draws water into the PNA core compared to the PEI 
scaffold and quenches NB fluorescence. The further removal of remaining primary 
amines restored the fluorescence of PNAs but interfered with their fluorochromism. 
Therefore, interactions between amines on the polymer scaffold and fluorochromic dyes 
in the core of PNAs contribute to the fluorochromism of PNAs entrapping fluorochromic 
dyes. 
7.1.2 Halo- and Solvato-Fluorochromism are Useful Theranostic Properties 
 The halo-fluorochromism of PNAs allowed for the sensitive and accurate 
detection of metastatic tumors compared to PNAs without fluorochromism. 3PN diffused 
into agarose gels and fluoresced strongly in tumor microenvironment conditions 
(pH<7.0) compared to healthy tissue (pH=7.4). In addition, PNAs failed to interact with 
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ions or proteins that could cause false positive fluorescence signals in healthy tissue by 
altering the acidity of nanoassembly core. Although PNAs without fluorochromism 
fluoresced throughout healthy organs, healthy liver and metastatic tumors in the liver, 
3PN minimized background fluorescence signals in healthy tissues and identified the 
acidic perimeter of liver metastatic tumors. As a result, halo-fluorochromic PNAs are 
promising tools for the early and accurate detection of tumor metastasis, which can allow 
for effective cancer treatment and potentially reduce cancer mortality. 
 The solvato-fluorochromism of PNAs allowed for the detection of drug release 
from the PNA core. A fluorescence-based method of measuring drug release from PNAs 
was developed and compared to HPLC-based methods for measuring drug release during 
dialysis-based drug release measurements. Although HPLC-based methods measure 
encapsulated and released drug, solvato-fluorochromism only detected drug release from 
the PNA core. Solvato-fluorochromism indicated that PNAs released drug very quickly in 
comparison to HPLC-based methods, but molecular modeling of HPLC-based 
measurements indicated that drug rebinding and slow diffusion did not cause these 
differences. Based on this observation, it was hypothesized that PNAs contain a NB-
enhanced region by the polymer scaffold in the PNA core, and that solvato-
fluorochromism is only sensitive to drug diffusion out of this region and towards the 
interface. As a result, solvato-fluorochromism may detect one step of drug release, but 
drug release rates determined by solvato-fluorochromism may not represent the rate-
limiting step of in vivo drug release. Hydrophobic excipients forced drug into the PNA 
core and increased the solvato-fluorochromism of PNAs, suggesting that interactions 
between drugs and dyes control the SFC intensity and spectra of dyes. Based on this 
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information, solvato-fluorochromism may be a beneficial method for investigating drug 
release processes in the core of PNAs without interference from drug rebinding or 
diffusion.  
7.1.3 Theranostics Overcomes Some Limitations of Cancer Nanotechnology 
 PNAs with controlled drug release profiles can increase drug accumulation in 
tumors and improve treatment efficacy, but many nanoparticles have rapid drug release 
rates that limit their treatment efficacy. The solvato-fluorochromism of PNAs indicated 
that the polymer scaffolds draw water into the nanoassembly core and decreases the core 
hydrophobicity, which weakens the interactions between hydrophobic drugs and PNAs. 
Based on this observation, ionizable amines were removed from the polymer scaffolds of 
PNAs in order to increase core hydrophobicity and sustain drug release. The removal of 
amines increased both the drug encapsulation and drug release half-life of model drugs 
CFZ and DOC. This result suggests that chemical modifications based on solvato-
fluorochromism can improve the drug delivery properties of PNAs for cancer 
chemotherapy. 
 Controlled drug release from PNAs can increase the metabolic stability of drugs 
and increase drug accumulation in solid tumors in comparison to free drugs. Free CFZ 
remained stable in organic solvents and in cell media containing FBS, but CFZ degraded 
in cell media without serum. CFZ lost therapeutic efficacy following pre-incubation in 
cell media, but CFZ-loaded PNAs maintained their efficacy for up to one hour. CFZ-
loaded PNAs decreased proteasome activity in H23 lung cancer cells compared to free 
carfilzomib after 72 hours, suggesting that the sustained release of carfilzomib from 
PNAs can modulate proteasome activity and sustain treatment efficacy. Based on these 
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observations, PNAs may improve CFZ treatment efficacy by delivering active drug to 
solid tumors and increasing drug accumulation in cancer cells. 
7.2 Future Directions 
7.2.1 Increase the Tumor Penetration and Halo-Fluorochromism of PNAs for the 
Improved Detection of Metastatic Tumors 
 Halo-fluorochromic PNAs accumulated at the perimeter of liver metastatic tumors 
and detected the acidic interstitium of tumors. Although PNAs identified metastatic CRC 
tumors on the livers of mice, the GFP signals from metastatic tumors were not in perfect 
agreement with the fluorescence signals from halo-fluorochromic PNAs. Increasing the 
penetration of halo-fluorochromic PNAs into metastatic tumors would increase the 
accumulation of PNAs in the hypoxic and acidic regions of tumor tissue, which would 
increase the accuracy of liver MCRC detection. One method to achieve this goal is to 
decrease their diameter of nanoparticles entrapping halo-fluorochromic dyes, so that 
nanoparticles diffuse further into tumors (296). A second method is to increase the 
porosity of metastatic tumors such as by co-administration of tissue-penetrating peptides 
with PNAs (297, 298). In addition, increasing the halo-fluorochromism of dyes in PNAs 
can maximize the fluorescence signal of PNAs that are accumulating in the hypoxic 
region of metastatic tumors.  
7.2.2 Predict the Treatment Efficacy of Drug-Loaded PNAs in Tumors from Solvato-
Fluorochromic Drug Release Profiles 
 Solvato-fluorochromic PNAs indicated real-time drug release profiles in a non-
invasive manner. Because fluorescence imaging can measure the fluorescence of organs, 
solvato-fluorochromic drug release profiles hold promise to predict treatment efficacy 
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based on measured drug delivery into tumors. In order to accomplish this, several 
characteristics of PNAs must be determined. First, the relationship between active drug 
concentrations in organs and drug release from PNAs must be evaluated. Next, the effects 
of tissue penetration on solvato-fluorochromic measurements of drug release in organs 
should be determined. Then, by treating animals with drug-loaded solvato-fluorochromic 
PNAs and measuring both fluorescence changes and drug concentrations in tumors over 
time, the relationship between solvato-fluorochromic drug release profiles, drug 
concentrations in tumors and treatment efficacy can be determined.  
232 
REFERENCES 
1. Svenson S. Theranostics: are we there yet? Mol Pharm. 2013;10(3):848-856. 
2. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatforms for simultaneous 
cancer imaging and therapy: current approaches and future perspectives. 
Nanoscale. 2012;4(2):330-342. 
3. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of 
nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional 
platforms. Appl Biochem Biotechnol. 2011;165(7-8):1628-1651. 
4. Van Cutsem E, Verheul HM, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R, 
Seufferlein T. Imaging in Colorectal Cancer: Progress and Challenges for the 
Clinicians. Cancers (Basel). 2016;8(9). 
5. Jo SD, Ku SH, Won YY, Kim SH, Kwon IC. Targeted Nanotheranostics for 
Future Personalized Medicine: Recent Progress in Cancer Therapy. Theranostics. 
2016;6(9):1362-1377. 
6. Liu Y, Feng L, Liu T, Zhang L, Yao Y, Yu D, Wang L, Zhang N. Multifunctional 
pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in 
cancer. Nanoscale. 2014;6(6):3231-3242. 
7. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug 
Deliv Rev. 2012;64(13):1394-1416. 
8. Kwok M, Wu SP, Mo C, Summers T, Roschewski M. Circulating Tumor DNA to 
Monitor Therapy for Aggressive B-Cell Lymphomas. Curr Treat Options Oncol. 
2016;17(9):47. 
9. Lin J, Chuang CC, Zuo L. Potential roles of microRNAs and ROS in colorectal 
cancer: diagnostic biomarkers and therapeutic targets. Oncotarget. 2017. 
10. Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in colorectal cancer: 
A systematic review of recent advances and challenges. Biomed Pharmacother. 
2016;87:8-19. 
233 
11. Turner SA, Peterson JD, Pettus JR, de Abreu FB, Amos CI, Dragnev KH, 
Tsongalis GJ. The Pitfalls of Companion Diagnostics: Evaluation of Discordant 
EGFR Mutation Results from a Clinical Laboratory and a Central Laboratory. J 
Mol Diagn. 2016;18(3):331-335. 
12. Zheng M, Zhao P, Luo Z, Gong P, Zheng C, Zhang P, Yue C, Gao D, Ma Y, Cai 
L. Robust ICG theranostic nanoparticles for folate targeted cancer imaging and 
highly effective photothermal therapy. ACS Appl Mater Inter. 2014;6(9):6709-
6716. 
13. Lanza GM, Moonen C, Baker JR, Chang E, Cheng Z, Grodzinski P, Ferrara K, 
Hynynen K, Kelloff G, Lee Y-EK, Patri AK, Sept D, Schnitzer JE, Wood BJ, 
Zhang M, Zheng G, Farahani K. Assessing the barriers to image-guided drug 
delivery. Wiley Interdisciplinary Reviews: Nanomedicine and 
Nanobiotechnology. 2014;6(1):1-14. 
14. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-
guided drug delivery: current concepts and future directions. Mol Pharm. 
2010;7(6):1899-1912. 
15. Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, Benz R, 
Leoncini-Franscini L, Baerlocher GM, Duchosal MA, Csajka C, Buclin T. 
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage 
individualization: results from a randomized controlled trial. Cancer Chemother 
Pharmacol. 2014;74(6):1307-1319. 
16. Ojha T, Rizzo L, Storm G, Kiessling F, Lammers T. Image-guided drug delivery: 
preclinical applications and clinical translation. Expert Opin Drug Deliv. 
2015;12(8):1203-1207. 
17. Blau R, Krivitsky A, Epshtein Y, Satchi-Fainaro R. Are nanotheranostics and 
nanodiagnostics-guided drug delivery stepping stones towards precision 
medicine? Drug Resist Updat. 2016;27:39-58. 
18. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving 
paradigms. Cell. 2011;147(2):275-292. 
19. Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration 
during metastasis. Curr Opin Cell Biol. 2012;24(2):277-283. 
234 
20. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment 
heterogeneity on therapeutic response. Nature. 2013;501(7467):346-354. 
21. Xing M, Kooby DA, El-Rayes BF, Kokabi N, Camacho JC, Kim HS. 
Locoregional therapies for metastatic colorectal carcinoma to the liver--an 
evidence-based review. J Surg Oncol. 2014;110(2):182-196. 
22. Li D, Kang J, Golas BJ, Yeung VW, Madoff DC. Minimally invasive local 
therapies for liver cancer. Cancer Biol Med. 2014;11(4):217-236. 
23. Haeno H, Gonen M, Davis Meghan B, Herman Joseph M, Iacobuzio-Donahue 
Christine A, Michor F. Computational Modeling of Pancreatic Cancer Reveals 
Kinetics of Metastasis Suggesting Optimum Treatment Strategies. Cell. 
2012;148(1–2):362-375. 
24. Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T, Baba Y. Acidic 
extracellular microenvironment and cancer. Cancer Cell Int. 2013;13(1):89. 
25. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvironment Checkmates 
Cancer Therapy. Bioimpacts. 2013;3(4):149-162. 
26. Mohammad AS, Adkins CE, Dolan EL, Terrell-Hall TB, Lockman PR. Abstract 
2080: Demonstration of casual relationship between blood-tumor barrier 
permeability changes and chemotherapeutic uptake and effect in brain 
micrometastases of breast cancer. Cancer Res. 2016;76(14 Supplement):2080-
2080. 
27. Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt 
L. Liver Resection for Colorectal Metastases after Chemotherapy: Impact of 
Chemotherapy-Related Liver Injuries, Pathological Tumor Response, and 
Micrometastases on Long-term Survival. Ann Surg. 2013;258(5):731-742. 
28. Key J, Leary JF. Nanoparticles for multimodal in vivo imaging in nanomedicine. 
Int J Nanomedicine. 2014;9:711-726. 
29. Hu H, Huang P, Weiss OJ, Yan X, Yue X, Zhang MG, Tang Y, Nie L, Ma Y, Niu 
G, Wu K, Chen X. PET and NIR optical imaging using self-illuminating (64)Cu-
doped chelator-free gold nanoclusters. Biomaterials. 2014;35(37):9868-9876. 
235 
30. Jose J, Burgess K. Benzophenoxazine-based fluorescent dyes for labeling 
biomolecules. Tetrahedron. 2006;62(48):11021-11037. 
31. Yao Z, Hu X, Huang B, Zhang L, Liu L, Zhao Y, Wu H-C. Halochromism of a 
Polythiophene Derivative Induced by Conformational Changes and Its Sensing 
Application of Carbon Dioxide. ACS Appl Mater Inter. 2013;5(12):5783-5787. 
32. Marini A, Muñoz-Losa A, Biancardi A, Mennucci B. What is Solvatochromism? 
J Phys Chem B. 2010;114(51):17128-17135. 
33. Nandi LG, Facin F, Marini VG, Zimmermann LM, Giusti LA, da Silva R, 
Caramori GF, Machado VG. Nitro-substituted 4-
[(phenylmethylene)imino]phenolates: solvatochromism and their use as 
solvatochromic switches and as probes for the investigation of preferential 
solvation in solvent mixtures. J Org Chem. 2012;77(23):10668-10679. 
34. Thipperudrappa J, Deepa HR, Raghavendra UP, Hanagodimath SM, Melavanki 
RM. Effect of solvents, solvent mixture and silver nanoparticles on photophysical 
properties of a ketocyanine dye. Luminescence. 2017;32(1):51-61. 
35. Al-Ansari IA. Effects of Structure and Environment on the Spectroscopic 
Properties of (3-Amino-Substituted-Thieno[2,3-b] Pyridine-2-
yl)Pyridine/Quinolin-2-yl)(Phenyl)Methanones: Experimental and Theoretical 
Study. J Fluoresc. 2016;26(3):821-834. 
36. Li H, Wang C, She M, Zhu Y, Zhang J, Yang Z, Liu P, Wang Y, Li J. Two 
rhodamine lactam modulated lysosome-targetable fluorescence probes for 
sensitively and selectively monitoring subcellular organelle pH change. Anal 
Chim Acta. 2015;900:97-102. 
37. Stockert JC, Abasolo MI, Blazquez-Castro A, Horobin RW, Revilla M, Lombardo 
DM. Selective labeling of lipid droplets in aldehyde fixed cell monolayers by 
lipophilic fluorochromes. Biotech Histochem. 2010;85(5):277-283. 
38. Okuthe GE. DNA and RNA pattern of staining during oogenesis in zebrafish 
(Danio rerio): a confocal microscopy study. Acta Histochem. 2013;115(2):178-
184. 
236 
39. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery 
to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and 
distinct tumor imaging in vivo. Adv Drug Del Rev. 2013;65(1):71-79. 
40. Ponta A, Bae Y. PEG-poly(amino acid) block copolymer micelles for tunable 
drug release. Pharm Res. 2010;27(11):2330-2342. 
41. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle 
and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 
2013;48(3):416-427. 
42. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based 
Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. 
Pharm Res. 2016;33(10):2373-2387. 
43. Lytton-Jean AKR, Kauffman KJ, Kaczmarek JC, Langer R. Cancer 
Nanotherapeutics in Clinical Trials. In: Mirkin CA, Meade TJ, Petrosko SH, 
Stegh AH, editors. Nanotechnology-Based Precision Tools for the Detection and 
Treatment of Cancer. Cham: Springer International Publishing; 2015. p. 293-322. 
44. Chen F, Nayak TR, Goel S, Valdovinos HF, Hong H, Theuer CP, Barnhart TE, 
Cai W. In Vivo Tumor Vasculature Targeted PET/NIRF Imaging with 
TRC105(Fab)-Conjugated, Dual-Labeled Mesoporous Silica Nanoparticles. Mol 
Pharm. 2014;11(11):4007-4014. 
45. Ferber S, Baabur-Cohen H, Blau R, Epshtein Y, Kisin-Finfer E, Redy O, Shabat 
D, Satchi-Fainaro R. Polymeric nanotheranostics for real-time non-invasive 
optical imaging of breast cancer progression and drug release. Cancer Lett. 
2014;352(1):81-89. 
46. Cao P, Ponta A, Kim JA, Bae Y. Block copolymer crosslinked nanoassemblies 
co-entrapping acridine yellow and doxorubicin for cancer theranostics. British J 
Pharm Res. 2013;3(536-547). 
47. Dan M, Scott DF, Hardy PA, Wydra RJ, Hilt JZ, Yokel RA, Bae Y. Block 
copolymer cross-linked nanoassemblies improve particle stability and 
biocompatibility of superparamagnetic iron oxide nanoparticles. Pharm Res. 
2013;30(2):552-561. 
237 
48. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo 
pharmacokinetics and cellular interaction. Nanomedicine. 2016;11(6):673-692. 
49. Merian J, Gravier J, Navarro F, Texier I. Fluorescent nanoprobes dedicated to in 
vivo imaging: from preclinical validations to clinical translation. Molecules. 
2012;17(5):5564-5591. 
50. Zeng C, Shang W, Wang K, Chi C, Jia X, Fang C, Yang D, Ye J, Fang C, Tian J. 
Intraoperative Identification of Liver Cancer Microfoci Using a Targeted Near-
Infrared Fluorescent Probe for Imaging-Guided Surgery. Sci Rep. 2016;6:21959. 
51. Hue JJ, Lee HJ, Jon S, Nam SY, Yun YW, Kim JS, Lee BJ. Distribution and 
accumulation of Cy5.5-labeled thermally cross-linked superparamagnetic iron 
oxide nanoparticles in the tissues of ICR mice. J Vet Sci. 2013;14(4):473-479. 
52. Sayag D, Cabon Q, Texier I, Navarro FP, Boisgard R, Virieux-Watrelot D, 
Carozzo C, Ponce F. Phase-0/phase-I study of dye-loaded lipid nanoparticles for 
near-infrared fluorescence imaging in healthy dogs. Eur J Pharm Biopharm. 
2016;100:85-93. 
53. Wong CH, Choi LS, Yim SL, Lau KN, Chow HF, Hui SK, Sze KH. The effects 
of microenvironment polarity and dendritic branching of aliphatic hydrocarbon 
dendrons on the self-assembly of 2-ureido-4-pyrimidinones. Chem Asian J. 
2010;5(10):2249-2257. 
54. Chakravarty R, Hong H, Cai W. Image-Guided Drug Delivery with Single-Photon 
Emission Computed Tomography: A Review of Literature. Curr Drug Targets. 
2015;16(6):592-609. 
55. Justus CR, Dong L, Yang LV. Acidic tumor microenvironment and pH-sensing G 
protein-coupled receptors. Front Physiol. 2013;4:354. 
56. Alfarouk KO, Muddathir AK, Shayoub MEA. Tumor Acidity as Evolutionary 
Spite. Cancers (Basel). 2011;3(1):408. 
57. McIntyre A, Harris AL. The Role of pH Regulation in Cancer Progression. 
Recent Results Cancer Res. 2016;207:93-134. 
238 
58. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping 
and chemotherapeutics: I. Acid pH affects the distribution of chemotherapeutic 
agents in vitro. Biochem Pharmacol. 2003;66(7):1207-1218. 
59. Raghunand N, Mahoney BP, Gillies RJ. Tumor acidity, ion trapping and 
chemotherapeutics: II. pH-dependent partition coefficients predict importance of 
ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. 
Biochem Pharmacol. 2003;66(7):1219-1229. 
60. Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong 
A, Woo T, Bomba D, Li J, Infante JR. Clinical pharmacokinetics, metabolism, 
and drug-drug interaction of carfilzomib. Drug Metab Dispos. 2013;41(1):230-
237. 
61. Wang J, Lu Z, Gao Y, Wientjes MG, Au JL. Improving delivery and efficacy of 
nanomedicines in solid tumors: role of tumor priming. Nanomedicine (Lond). 
2011;6(9):1605-1620. 
62. Lu D, Wientjes MG, Lu Z, Au JL. Tumor priming enhances delivery and efficacy 
of nanomedicines. J Pharmacol Exp Ther. 2007;322(1):80-88. 
63. Hu C-MJ, Zhang L. Nanoparticle-based combination therapy toward overcoming 
drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1104-1111. 
64. Lee HJ, Bae Y. Brushed block copolymer micelles with pH-sensitive pendant 
groups for controlled drug delivery. Pharm Res. 2013;30(8):2077-2086. 
65. Reichel D, Rychahou P, Bae Y. Polymer nanoassemblies with solvato- and halo-
fluorochromism for drug release monitoring and metastasis imaging. Ther Deliv. 
2015;6(10):1221-1237. 
66. O'Connell CL, Nooney R, McDonagh C. Cyanine5-doped silica nanoparticles as 
ultra-bright immunospecific labels for model circulating tumour cells in flow 
cytometry and microscopy. Biosens Bioelectron. 2016;91:190-198. 
67. Han J, Zhang C, Liu F, Liu B, Han M, Zou W, Yang L, Zhang Z. Upconversion 
nanoparticles for ratiometric fluorescence detection of nitrite. Analyst. 
2014;139(12):3032-3038. 
239 
68. Kim H, Babu CR, Burgess DJ. Quantification of protonation in organic solvents 
using solution NMR spectroscopy: implication in salt formation. Int J Pharm. 
2013;448(1):123-131. 
69. Jose J, Ueno Y, Burgess K. Water-soluble Nile Blue derivatives: syntheses and 
photophysical properties. Chem Eur J. 2009;15(2):418-423. 
70. Madsen J, Canton I, Warren NJ, Themistou E, Blanazs A, Ustbas B, Tian X, 
Pearson R, Battaglia G, Lewis AL, Armes SP. Nile Blue-Based Nanosized pH 
Sensors for Simultaneous Far-Red and Near-Infrared Live Bioimaging. J Am 
Chem Soc. 2013;135(39):14863-14870. 
71. Cincotta L, Foley JW, Cincotta AH. Phototoxicity, redox behavior, and 
pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma 
cells. Cancer Res. 1993;53(11):2571-2580. 
72. Rheiner S, Bae Y. Increased poly(ethylene glycol) density decreases transfection 
efficacy of siRNA/poly(ethylene imine) complexes. AIMS Bioengineering. 
2016;3(4):454-467. 
73. Izunobi JU, Higginbotham CL. Polymer Molecular Weight Analysis by 1H NMR 
Spectroscopy. J Chem Educ. 2011;88(8):1098-1104. 
74. Gavrilov M, Monteiro MJ. Derivation of the molecular weight distributions from 
size exclusion chromatography. Eur Polym J. 2015;65:191-196. 
75. Qiu X, Zhou Z, Gobbi G, Redwine OD. Error Analysis for NMR Polymer 
Microstructure Measurement without Calibration Standards. Anal Chem. 
2009;81(20):8585-8589. 
76. Rheiner S, Rychahou P, Bae Y. Effects of the Lipophilic Core of Polymer 
Nanoassemblies on Intracellular Delivery and Transfection of siRNA. AIMS 
Biophysics. 2015;2(3):284-302. 
77. Segets D, Marczak R, Schafer S, Paula C, Gnichwitz JF, Hirsch A, Peukert W. 
Experimental and theoretical studies of the colloidal stability of nanoparticles-a 
general interpretation based on stability maps. ACS Nano. 2011;5(6):4658-4669. 
240 
78. Kalia J, Raines RT. Advances in Bioconjugation. Curr Org Chem. 
2010;14(2):138-147. 
79. Boens N, Leen V, Dehaen W. Fluorescent indicators based on BODIPY. Chem 
Soc Rev. 2012;41(3):1130-1172. 
80. Uchida Y, Maezawa Y, Uchida Y, Hiruta N, Shimoyama E. Molecular imaging of 
low-density lipoprotein in human coronary plaques by color fluorescent 
angioscopy and microscopy. PLoS One. 2012;7(11):e50678. 
81. Thapa U, Ismail K. Urea effect on aggregation and adsorption of sodium 
dioctylsulfosuccinate in water. J Colloid Interface Sci. 2013;406:172-177. 
82. Lee H. Molecular Dynamics Studies of PEGylated Single-Walled Carbon 
Nanotubes: The Effect of PEG Size and Grafting Density. The Journal of Physical 
Chemistry C. 2013;117(49):26334-26341. 
83. Mariella R, Brown K. A novel SN1 displacement: The reaction of tertiary amines 
with acetic anhydride. Can J Chem. 1971;49(20):3348-3351. 
84. Zhou J, Fang C, Chang T, Liu X, Shangguan D. A pH sensitive ratiometric 
fluorophore and its application for monitoring the intracellular and extracellular 
pHs simultaneously. J Mater Chem B. 2013;1(5):661-667. 
85. Sanli S, Altun Y, Guven G. Solvent Effects on pKa Values of Some Anticancer 
Agents in Acetonitrile–Water Binary Mixtures. J Chem Eng Data. 
2014;59(12):4015-4020. 
86. Perrin DD, Dempsey B, Serjeant EP. pKa prediction for organic acids and bases: 
Springer; 1981. 
87. Agency EM. Assessment Report: Kyprolis. 2015. 
88. Cheng L, Yang K, Chen Q, Liu Z. Organic Stealth Nanoparticles for Highly 
Effective in Vivo Near-Infrared Photothermal Therapy of Cancer. ACS Nano. 
2012;6(6):5605-5613. 
241 
89. Maeda H. Vascular permeability in cancer and infection as related to 
macromolecular drug delivery, with emphasis on the EPR effect for tumor-
selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(3):53-71. 
90. Zou P, Chen H, Paholak HJ, Sun D. Noninvasive fluorescence resonance energy 
transfer imaging of in vivo premature drug release from polymeric nanoparticles. 
Mol Pharm. 2013;10(11):4185-4194. 
91. Wang J, Gao PP, Yang XX, Wang TT, Wang J, Huang CZ. Real-time imaging of 
intracellular drug release from mesoporous silica nanoparticles based on 
fluorescence resonance energy transfer. J Mater Chem B. 2014;2(27):4379-4386. 
92. Lai J, Shah BP, Garfunkel E, Lee K-B. Versatile Fluorescence Resonance Energy 
Transfer-Based Mesoporous Silica Nanoparticles for Real-Time Monitoring of 
Drug Release. ACS Nano. 2013;7(3):2741-2750. 
93. Sarnat HB. Immunocytochemical markers of neuronal maturation in human 
diagnostic neuropathology. Cell Tissue Res. 2015;359(1):279-294. 
94. Liu J, Zang L, Wang Y, Liu G. Preparation of acridine orange-doped silica 
nanoparticles for pH measurement. J Lumin. 2014;147(0):155-158. 
95. Goetz M, Hoetker MS, Diken M, Galle PR, Kiesslich R. In vivo molecular 
imaging with cetuximab, an anti-EGFR antibody, for prediction of response in 
xenograft models of human colorectal cancer. Endoscopy. 2013;45(6):469-477. 
96. Martinez V, Henary M. Nile Red and Nile Blue: Applications and Syntheses of 
Structural Analogues. Chemistry – A European Journal. 2016;22(39):13764-
13782. 
97. Hill TK, Abdulahad A, Kelkar SS, Marini FC, Long TE, Provenzale JM, Mohs 
AM. Indocyanine Green-Loaded Nanoparticles for Image-Guided Tumor Surgery. 
Bioconjugate Chem. 2015;26(2):294-303. 
98. Yue C, Liu P, Zheng M, Zhao P, Wang Y, Ma Y, Cai L. IR-780 dye loaded tumor 
targeting theranostic nanoparticles for NIR imaging and photothermal therapy. 
Biomaterials. 2013;34(28):6853-6861. 
242 
99. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery 
to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and 
distinct tumor imaging in vivo. Adv Drug Del Rev. 2013;65(1):71-79. 
100. Robinson PJ. The early detection of liver metastases. Cancer Imaging. 
2002;2(2):1-3. 
101. Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks 
that regulate cancer metastasis. Semin Cancer Biol. 2012;22(3):234-249. 
102. Patanaphan V, Salazar OM. Colorectal cancer: metastatic patterns and prognosis. 
South Med J. 1993;86(1):38-41. 
103. Dhar V, Thomas RM, Ahmad SA. Repeat Hepatectomy for Colorectal Liver 
Metastases. In: Bentrem D, Benson AB, editors. Gastrointestinal Malignancies. 
Cham: Springer International Publishing; 2016. p. 203-220. 
104. Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable 
Metastatic Colorectal Cancer. Biomed Res Int. 2016;2016:7590245. 
105. Butler EB, Zhao Y, Munoz-Pinedo C, Lu J, Tan M. Stalling the engine of 
resistance: targeting cancer metabolism to overcome therapeutic resistance. 
Cancer Res. 2013;73(9):2709-2717. 
106. Cercek A, Goodman KA, Hajj C, Weisberger E, Segal NH, Reidy-Lagunes DL, 
Stadler ZK, Wu AJ, Weiser MR, Paty PB, Guillem JG, Nash GM, Temple LK, 
Garcia-Aguilar J, Saltz LB. Neoadjuvant Chemotherapy First, Followed by 
Chemoradiation and Then Surgery, in the Management of Locally Advanced 
Rectal Cancer. J Natl Compr Canc Netw. 2014;12(4):513-519. 
107. Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, Yamasaki 
M, Makari Y, Matsuura N, Mano M, Monden M. The effect of neoadjuvant 
chemotherapy on lymph node micrometastases in squamous cell carcinomas of 
the thoracic esophagus. Surgery. 2007;141(5):570-580. 
108. Kamiya M, Urano Y. Rapid and sensitive fluorescent imaging of tiny tumors in 
vivo and in clinical specimens. Curr Opin Chem Biol. 2016;33:9-15. 
243 
109. Maffione AM, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D. 
Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT 
in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl 
Med Mol Imaging. 2015;42(1):152-163. 
110. Weissleder R, Nahrendorf M. Advancing biomedical imaging. Proceedings of the 
National Academy of Sciences. 2015;112(47):14424-14428. 
111. Barnes KD, Shafirstein G, Webber JS, Koonce NA, Harris Z, Griffin RJ. 
Hyperthermia-enhanced indocyanine green delivery for laser-induced thermal 
ablation of carcinomas. Int J Hyperthermia. 2013;29(5):474-479. 
112. Wu L, Fang S, Shi S, Deng J, Liu B, Cai L. Hybrid polypeptide micelles loading 
indocyanine green for tumor imaging and photothermal effect study. 
Biomacromolecules. 2013;14(9):3027-3033. 
113. Kraft JC, Ho RJ. Interactions of indocyanine green and lipid in enhancing near-
infrared fluorescence properties: the basis for near-infrared imaging in vivo. 
Biochemistry. 2014;53(8):1275-1283. 
114. Yang B, Han X, Ji B, Lu R. Competition Between Tumor and Mononuclear 
Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and 
Strategies to Improve Tumor Accumulation. Curr Drug Deliv. 2016;13(8):1261-
1274. 
115. Mikhail AS, Eetezadi S, Ekdawi SN, Stewart J, Allen C. Image-based analysis of 
the size- and time-dependent penetration of polymeric micelles in multicellular 
tumor spheroids and tumor xenografts. Int J Pharm. 2014;464(1–2):168-177. 
116. Yokoi K, Kojic M, Milosevic M, Tanei T, Ferrari M, Ziemys A. Capillary-Wall 
Collagen as a Biophysical Marker of Nanotherapeutic Permeability into the 
Tumor Microenvironment. Cancer Res. 2014;74(16):4239-4246. 
117. Verkman AS. Diffusion in the extracellular space in brain and tumors. Phys Biol. 
2013;10(4):045003. 
118. . !!! INVALID CITATION !!! {Brown, 2016 #1360;Hoffman, 2015 #1659}. 
244 
119. Golovko D, Kedrin D, Yilmaz OH, Roper J. Colorectal cancer models for novel 
drug discovery. Expert Opin Drug Discov. 2015;10(11):1217-1229. 
120. Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease: pre-clinical 
animal models of cancer and their applications and utility in drug discovery. 
Biochem Pharmacol. 2014;87(1):150-161. 
121. Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in 
colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 
2014;25(3):651-657. 
122. Curtis LT, Rychahou P, Bae Y, Frieboes HB. A Computational/Experimental 
Assessment of Antitumor Activity of Polymer Nanoassemblies for pH-Controlled 
Drug Delivery to Primary and Metastatic Tumors. Pharm Res. 2016;33(10):2552-
2564. 
123. Curtis LT, England CG, Wu M, Lowengrub J, Frieboes HB. An interdisciplinary 
computational/experimental approach to evaluate drug-loaded gold nanoparticle 
tumor cytotoxicity. Nanomedicine. 2016;11(3):197-216. 
124. Frieboes HB, Wu M, Lowengrub J, Decuzzi P, Cristini V. A computational model 
for predicting nanoparticle accumulation in tumor vasculature. PLoS One. 
2013;8(2):e56876. 
125. Xu X, Sabanayagam CR, Harrington DA, Farach-Carson MC, Jia X. A hydrogel-
based tumor model for the evaluation of nanoparticle-based cancer therapeutics. 
Biomaterials. 2014;35(10):3319-3330. 
126. Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. J Nucl Med. 
2010;51(8):1167-1170. 
127. Chaudhari KR, Ukawala M, Manjappa AS, Kumar A, Mundada PK, Mishra AK, 
Mathur R, Monkkonen J, Murthy RS. Opsonization, biodistribution, cellular 
uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug 
delivery carrier. Pharm Res. 2012;29(1):53-68. 
128. Zhang M, Liu Y-Q, Ye B-C. Colorimetric assay for sulfate using positively-
charged gold nanoparticles and its application for real-time monitoring of redox 
process. Analyst. 2011;136(21):4558-4562. 
245 
129. Rausch K, Reuter A, Fischer K, Schmidt M. Evaluation of Nanoparticle 
Aggregation in Human Blood Serum. Biomacromolecules. 2010;11(11):2836-
2839. 
130. Chaudhari KR, Ukawala M, Manjappa AS, Kumar A, Mundada PK, Mishra AK, 
Mathur R, Mönkkönen J, Murthy RSR. Opsonization, Biodistribution, Cellular 
Uptake and Apoptosis Study of PEGylated PBCA Nanoparticle as Potential Drug 
Delivery Carrier. Pharm Res. 2012;29(1):53-68. 
131. Opitz AW, Czymmek KJ, Wickstrom E, Wagner NJ. Uptake, efflux, and mass 
transfer coefficient of fluorescent PAMAM dendrimers into pancreatic cancer 
cells. Biochim Biophys Acta. 2013;1828(2):294-301. 
132. Curtis LT, Wu M, Lowengrub J, Decuzzi P, Frieboes HB. Computational 
Modeling of Tumor Response to Drug Release from Vasculature-Bound 
Nanoparticles. PLoS One. 2015;10(12):e0144888. 
133. van de Ven AL, Wu M, Lowengrub J, McDougall SR, Chaplain MA, Cristini V, 
Ferrari M, Frieboes HB. Integrated intravital microscopy and mathematical 
modeling to optimize nanotherapeutics delivery to tumors. AIP Adv. 
2012;2(1):11208. 
134. Curtis LT, Rychahou P, Bae Y, Frieboes HB. A computational/experimental 
assessment of antitumor activity of polymer nanoassemblies for ph-controlled 
drug delivery to primary and metastatic tumors. Pharm Res. 2016;33:2552–2564. 
135. Wu M, Frieboes HB, Chaplain MA, McDougall SR, Cristini V, Lowengrub JS. 
The effect of interstitial pressure on therapeutic agent transport: coupling with the 
tumor blood and lymphatic vascular systems. J Theor Biol. 2014;355:194-207. 
136. Wu M, Frieboes HB, McDougall SR, Chaplain MA, Cristini V, Lowengrub J. The 
effect of interstitial pressure on tumor growth: coupling with the blood and 
lymphatic vascular systems. J Theor Biol. 2013;320:131-151. 
137. Macklin P, McDougall S, Anderson ARA, Chaplain MAJ, Cristini V, Lowengrub 
J. Multiscale modelling and nonlinear simulation of vascular tumour growth. 
Journal of Mathematical Biology. 2009;58(4-5):765-798. 
138. McDougall SR, Anderson ARA, Chaplain MAJ. Mathematical modelling of 
dynamic adaptive tumour-induced angiogenesis: Clinical implications and 
246 
therapeutic targeting strategies. Journal of Theoretical Biology. 2006;241(3):564-
589. 
139. Macklin P, McDougall S, Anderson AR, Chaplain MA, Cristini V, Lowengrub J. 
Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math 
Biol. 2009;58(4-5):765-798. 
140. Curtis LT, England  CG, Wu M, Lowengrub J, Frieboes HB. An interdisciplinary 
computational/experimental approach to evaluate drug-loaded gold nanoparticle 
tumor cytotoxicity. Nanomedicine (Lond). 2016;11(3):197-216. 
141. Wu M, Frieboes HB, McDougall SR, Chaplain MA, Cristini V, Lowengrub J. The 
effect of interstitial pressure on tumor growth: coupling with the blood and 
lymphatic vascular systems. J Theor Biol. 2013;320:131-151. 
142. Ponta A, Bae Y. Tumor-preferential sustained drug release enhances antitumor 
activity of block copolymer micelles. J Drug Target. 2014;22(7):619-628. 
143. Nugent LJ, Jain RK. Extravascular diffusion in normal and neoplastic tissues. 
Cancer Res. 1984;44(1):238-244. 
144. Kekelidze M, D'Errico L, Pansini M, Tyndall A, Hohmann J. Colorectal cancer: 
current imaging methods and future perspectives for the diagnosis, staging and 
therapeutic response evaluation. World J Gastroenterol. 2013;19(46):8502-8514. 
145. Terranova N, Girard P, Klinkhardt U, Munafo A. Resistance Development: A 
Major Piece in the Jigsaw Puzzle of Tumor Size Modeling. CPT Pharmacometrics 
Syst Pharmacol. 2015;4(6):320-323. 
146. Etrych T, Lucas H, Janouskova O, Chytil P, Mueller T, Mader K. Fluorescence 
optical imaging in anticancer drug delivery. J Control Release. 2016;226:168-181. 
147. Shao D, Lu MM, Zhao YW, Zhang F, Tan YF, Zheng X, Pan Y, Xiao XA, Wang 
Z, Dong WF, Li J, Chen L. The shape effect of magnetic mesoporous silica 
nanoparticles on endocytosis, biocompatibility and biodistribution. Acta 
Biomater. 2017;49:531-540. 
247 
148. Kumar R, Roy I, Ohulchanskky TY, Vathy LA, Bergey EJ, Sajjad M, Prasad PN. 
In vivo biodistribution and clearance studies using multimodal organically 
modified silica nanoparticles. ACS Nano. 2010;4(2):699-708. 
149. Sindhwani S, Syed AM, Wilhelm S, Glancy DR, Chen YY, Dobosz M, Chan 
WCW. Three-Dimensional Optical Mapping of Nanoparticle Distribution in 
Intact Tissues. ACS Nano. 2016;10(5):5468-5478. 
150. Shrinivas P, Kasapis S, Tongdang T. Morphology and mechanical properties of 
bicontinuous gels of agarose and gelatin and the effect of added lipid phase. 
Langmuir. 2009;25(15):8763-8773. 
151. Tufto I, Lyng H, Rofstad EK. Interstitial fluid pressure, perfusion rate and oxygen 
tension in human melanoma xenografts. Br J Cancer Suppl. 1996;27. 
152. Watson KD, Lai CY, Qin S, Kruse DE, Lin YC, Seo JW, Cardiff RD, Mahakian 
LM, Beegle J, Ingham ES, Curry FR, Reed RK, Ferrara KW. Ultrasound 
increases nanoparticle delivery by reducing intratumoral pressure and increasing 
transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res. 
2012;72(6):1485-1493. 
153. Durymanov MO, Rosenkranz AA, Sobolev AS. Current Approaches for 
Improving Intratumoral Accumulation and Distribution of Nanomedicines. 
Theranostics. 2015;5(9):1007-1020. 
154. Podduturi VP, Magaña IB, O’Neal DP, Derosa PA. Simulation of transport and 
extravasation of nanoparticles in tumors which exhibit enhanced permeability and 
retention effect. Comput Methods Programs Biomed;112(1):58-68. 
155. Tan J, Shah S, Thomas A, Ou-Yang HD, Liu Y. The influence of size, shape and 
vessel geometry on nanoparticle distribution. Microfluid Nanofluid. 2013;14(1-
2):77-87. 
156. Schultz SG, Solomon AK. Determination of the Effective Hydrodynamic Radii of 
Small Molecules by Viscometry. The Journal of General Physiology. 
1961;44(6):1189-1199. 
157. Krishna R. Diffusion in porous crystalline materials. Chem Soc Rev. 
2012;41(8):3099-3118. 
248 
158. Beck-Broichsitter M, Nicolas J, Couvreur P. Design attributes of long-circulating 
polymeric drug delivery vehicles. Eur J Pharm Biopharm. 2015;97(Pt B):304-317. 
159. Gao H, He Q. The interaction of nanoparticles with plasma proteins and the 
consequent influence on nanoparticles behavior. Expert Opin Drug Deliv. 
2014;11(3):409-420. 
160. Park JE, Chun S-E, Reichel D, Min JS, Lee S-C, Han S, Ryoo G, Oh Y, Park S-H, 
Ryu H-M, Kim KB, Lee H-Y, Bae SK, Bae Y, Lee W. Polymer micelle 
formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy 
and pharmacokinetic studies in mice. PLoS One. 2017;12(3):e0173247. 
161. Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? 
Cell Cycle. 2009;8(3):505-506. 
162. Vestvik IK, Egeland TAM, Gaustad J-V, Mathiesen B, Rofstad EK. Assessment 
of microvascular density, extracellular volume fraction, and radiobiological 
hypoxia in human melanoma xenografts by dynamic contrast-enhanced MRI. J 
Magn Reson Imaging. 2007;26(4):1033-1042. 
163. Keij JF, Bell-Prince C, Steinkamp JA. Staining of mitochondrial membranes with 
10-nonyl acridine orange, MitoFluor Green, and MitoTracker Green is affected by 
mitochondrial membrane potential altering drugs. Cytometry. 2000;39(3):203-
210. 
164. Weigel A, Schild D, Zeug A. Resolution in the ApoTome and the confocal laser 
scanning microscope: comparison. J Biomed Opt. 2009;14(1):014022. 
165. Tangrea MA, Mukherjee S, Gao B, Markey SP, Du Q, Armani M, Kreitman MS, 
Rosenberg AM, Wallis BS, Eberle FC, Duncan FC, Hanson JC, Chuaqui RF, 
Rodriguez-Canales J, Emmert-Buck MR. Effect of Immunohistochemistry on 
Molecular Analysis of Tissue Samples: Implications for Microdissection 
Technologies. J Histochem Cytochem. 2011;59(6):591-600. 
166. Dickerson M, Howerton B, Bae Y, Glazer E. Light-sensitive ruthenium complex-
loaded cross-linked polymeric nanoassemblies for the treatment of cancer. J 
Mater Chem B Mater Biol Med. 2016;4:394-408. 
249 
167. Lee HJ, Bae Y. Pharmaceutical differences between block copolymer self-
assembled and cross-linked nanoassemblies as carriers for tunable drug release. 
Pharm Res. 2013;30(2):478-488. 
168. Cao P, Ponta A, Kim JA, Bae Y. Block copolymer crosslinked nanoassemblies 
co-entrapping acridine yellow and doxorubicin for cancer theranostics. British J 
Pharm Res. 2013;3:536-547. 
169. Lee HJ, Ponta A, Bae Y. Polymer nanoassemblies for cancer treatment and 
imaging. Ther Deliv. 2010;1(6):803-817. 
170. Scott D, Bae Y. Block copolymer crosslinked nanoassemblies co-entrapping 
hydrophobic drugs and lipophilic polymer additives. J Pharm Drug Deliv Res. 
2013;2(1000116):1-5. 
171. Ponta A, Bae Y. PEG-poly(amino acid) block copolymer micelles for tunable 
drug release. Pharm Res. 2010;27(11):2330-2342. 
172. Bae Y. Drug delivery systems using polymer nanoassemblies for cancer 
treatment. Ther Delivery. 2010;1:361-363. 
173. Howard MD, Ponta A, Eckman AM, Jay M, Bae Y. Polymer micelles with 
hydrazone-ester dual linkers for tunable release of dexamethasone. Pharm Res. 
2011;28:2435-2446. 
174. Eckman AM, Tsakalozou E, Kang NY, Ponta A, Bae Y. Drug release patterns and 
cytotoxicity of PEG-poly(aspartate) block copolymer micelles in cancer cells. 
Pharm Res. 2012;29(7):1755-1767. 
175. Dickerson M, Winquist N, Bae Y. Photo-inducible crosslinked nanoassemblies 
for pH-controlled drug release. Pharm Res. 2014;31(5):1254-1263. 
176. Ao L, Reichel D, Hu D, Jeong H-Y, Kim KB, Bae Y, Lee W. Polymer micelle 
formulations of proteasome inhibitor carfilzomib for improved metabolic stability 
and anti-cancer efficacy in human multiple myeloma and lung cancer cell lines. J 
Pharmacol Exp Ther. 2015;355:168-173. 
250 
177. Lee HJ, Bae Y. The effect of core crosslinking degree on drug release patterns of 
pH-sensitive block copolymer crosslinked nanoassemblies. Nano Bull. 
2013;2:1302101-1302109. 
178. Akter S, Clem BF, Lee HJ, Chesney J, Bae Y. Block copolymer micelles for 
controlled delivery of glycolytic enzyme inhibitors. Pharm Res. 2012;29(3):847-
855. 
179. Scott D, Rohr J, Bae Y. Nanoparticulate formulations of mithramycin analogs for 
enhanced cytotoxicity. Int J Nanomed. 2011;6:2757-2767. 
180. Ponta A, Akter S, Bae Y. Degradable cross-linked nanoassemblies as drug 
carriers for heat shock protein 90 inhibitor 17-N-allylamino-17-
demethoxygeldanamycin. Pharmaceuticals. 2011;4:1281-1292. 
181. Lee HJ, Bae Y. Cross-linked nanoassemblies from poly(ethylene glycol)-
poly(aspartate) block copolymers as stable supramolecular templates for 
particulate drug delivery. Biomacromolecules. 2011;12:2686-2696. 
182. Alani AWG, Bae Y, Rao DA, Kwon GS. Polymeric micelles for the pH-
dependent controlled, continuous low dose release of paclitaxel. Biomaterials. 
2010;31(7):1765-1772. 
183. Bae Y, Nishiyama N, Fukushima S, Koyama H, Matsumura Y, Kataoka K. 
Preparation and biological characterization of polymeric micelle drug carriers 
with intracellular pH-triggered drug release property: Tumor permeability, 
controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. 
Bioconjugate Chem. 2005;16(1):122-130. 
184. Ponta A, Fugit KD, Anderson BD, Bae Y. Release, partitioning, and conjugation 
stability of doxorubicin in polymer micelles determined by mechanistic modeling. 
Pharm Res. 2015;32(5):1752-1763. 
185. Fugit KD, Xiang TX, Choi du H, Kangarlou S, Csuhai E, Bummer PM, Anderson 
BD. Mechanistic model and analysis of doxorubicin release from liposomal 
formulations. J Control Release. 2015;217:82-91. 
186. Wu H, Zhu L, Torchilin VP. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-
polymer micelles for cytosolic drug delivery. Biomaterials. 2013;34(4):1213-
1222. 
251 
187. Yadav S, Gupta S. Development and in vitro characterization of docetaxel-loaded 
ligand appended solid fat nanoemulsions for potential use in breast cancer 
therapy. Artif Cells Nano Biotechnol. 2015;43(2):93-102. 
188. Li J, Guo X, Liu Z, Okeke CI, Li N, Zhao H, Aggrey MO, Pan W, Wu T. 
Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for 
ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake 
studies. Drug Dev Ind Pharm. 2014;40(7):980-987. 
189. Dickerson M, Winquist N, Bae Y. Photo-inducible cross-linked nanoassemblies 
for controlled drug delivery. Pharm Res. 2013;31:1254-1263. 
190. Dickerson M, Bae Y. Block copolymer nanoassemblies for photodynamic therapy 
and diagnosis. Ther Deliv. 2013;4(11):1431-1441. 
191. Jin G-W, Bae Y. Reductant-dependent none-partial-complete degradation of 
block copolymer disulfide crosslinked nanoassemblies. J App Pharm Sci. 
2013;3:1-6. 
192. Bera A, Chandel AKS, Kumar CU, Jewrajka SK. Degradable/cytocompatible and 
pH responsive amphiphilic conetwork gels based on agarose-graft copolymers 
and polycaprolactone. J Mat Chem B. 2015;3(43):8548-8557. 
193. de Andrade DF, Zuglianello C, Pohlmann AR, Guterres SS, Beck RCR. Assessing 
the in vitro drug release from lipid-core nanocapsules: a new strategy combining 
dialysis sac and a continuous-flow system. AAPS PharmSciTech. 
2015;16(6):1409-1417. 
194. Fuchs K, Bize PE, Denys A, Borchard G, Jordan O. Sunitinib-eluting beads for 
chemoembolization: Methods for in vitro evaluation of drug release. Int J Pharm. 
2015;482(1):68-74. 
195. Salmela L, Washington C. A continuous flow method for estimation of drug 
release rates from emulsion formulations. International journal of pharmaceutics. 
2014;472(1):276-281. 
196. Wasik S, Arabski M, Drulis-Kawa Z, Gubernator J. Laser interferometry analysis 
of ciprofloxacin and ampicillin diffusion from liposomal solutions to water phase. 
Eur Biophy J. 2013;42(7):549-558. 
252 
197. Li Z, Paulson AT, Gill TA. Encapsulation of bioactive salmon protein 
hydrolysates with chitosan-coated liposomes. J Func Foods. 2015;19:733-743. 
198. Gullotti E, Yeo Y. Beyond the imaging: limitations of cellular uptake study in the 
evaluation of nanoparticles. J Control Release. 2012;164(2):170-176. 
199. Zhou Y, He C, Chen K, Ni J, Cai Y, Guo X, Wu XY. A New Method for 
Evaluating Actual Drug Release Kinetics of Nanoparticles inside Dialysis 
Devices via Numerical Deconvolution. J Control Release. 2016;243:11-20. 
200. Xie L, Beyer S, Vogel V, Wacker MG, Mantele W. Assessing the drug release 
from nanoparticles: Overcoming the shortcomings of dialysis by using novel 
optical techniques and a mathematical model. Int J Pharm. 2015;488(1):108-119. 
201. Reichel D, Rychahou P, Bae Y. Polymer nanoassemblies with solvato- and halo-
fluorochromic properties for real-time monitoring of drug release and pH-
enhanced ex vivo imaging of metastatic tumors. Ther Delivery. 2015;6:1221-
1237. 
202. Cheng Y, Xu T. The effect of dendrimers on the pharmacodynamic and 
pharmacokinetic behaviors of non-covalently or covalently attached drugs. Eur J 
Med Chem. 2008;43(11):2291-2297. 
203. Jaimes-Aguirre L, Gibbens-Bandala BV, Morales-Avila E, Ocampo-Garcia BE, 
Seyedeh-Fatemeh M, Amirhosein A. Polymer-Based Drug Delivery Systems, 
Development and Pre-Clinical Status. Curr Pharm Des. 2016;22(19):2886-2903. 
204. Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM, Luft JC, Bridges AS, Kuijer 
JL, Napier ME, Zamboni WC, DeSimone JM. Plasma, tumor and tissue 
pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and 
shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. 
Nanomedicine. 2013;9(5):686-693. 
205. Stylianopoulos T, Jain RK. Design considerations for nanotherapeutics in 
oncology. Nanomedicine. 2015;11(8):1893-1907. 
206. Diou O, Greco S, Beltran T, Lairez D, Authelin JR, Bazile D. A method to 
Quantify the Affinity of Cabazitaxel for PLA-PEG Nanoparticles and Investigate 
the Influence of the Nano-Assembly Structure on the Drug/Particle Association. 
Pharm Res. 2015;32(10):3188-3200. 
253 
207. Modi S, Anderson BD. Determination of Drug Release Kinetics from 
Nanoparticles: Overcoming Pitfalls of the Dynamic Dialysis Method. Mol Pharm. 
2013;10(8):3076-3089. 
208. Han HS, Choi KY, Ko H, Jeon J, Saravanakumar G, Suh YD, Lee DS, Park JH. 
Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy. 
J Controlled Release. 2015;200:158-166. 
209. Talelli M, Barz M, Rijcken CJF, Kiessling F, Hennink WE, Lammers T. Core-
crosslinked polymeric micelles: Principles, preparation, biomedical applications 
and clinical translation. Nano Today. 2015;10(1):93-117. 
210. Souza S. A Review of In Vitro Drug Release Test Methods for Nano-Sized 
Dosage Forms. Advances in Pharmaceutics. 2014;2014:12. 
211. Modi S, Anderson BD. Determination of Drug Release Kinetics from 
Nanoparticles: Overcoming Pitfalls of the Dynamic Dialysis Method. Mol Pharm. 
2013;10(8):3076-3089. 
212. Puskás I, Varga E, Tuza K, Szemán J, Fenyvesi É, Sohajda T, Szente L. 
Sulfobutylether-cyclodextrins: structure, degree of substitution and functional 
performance. In. Cyclodextrins: Synthesis, Chemical Applications and Role in 
Drug Delivery: Nova Science Publishers, Hauppauge, NY; 2015. p. 293-320. 
213. Cao L, Bornscheuer UT, Schmid RD. Lipase-catalyzed solid-phase synthesis of 
sugar esters. Influence of immobilization on productivity and stability of the 
enzyme. J Mol Cat B Enzymatic. 1999;6(3):279-285. 
214. Roda A, Minutello A, Angellotti MA, Fini A. Bile acid structure-activity 
relationship: evaluation of bile acid lipophilicity using 1-octanol/water partition 
coefficient and reverse phase HPLC. J Lipid Res. 1990;31(8):1433-1443. 
215. Hopfner T, Bluma A, Rudolph G, Lindner P, Scheper T. A review of non-invasive 
optical-based image analysis systems for continuous bioprocess monitoring. 
Bioprocess Biosyst Eng. 2010;33(2):247-256. 
216. Beutel S, Henkel S. In situ sensor techniques in modern bioprocess monitoring. 
Appl Microbiol Biotechnol. 2011;91(6):1493-1505. 
254 
217. Cho EJ, Holback H, Liu KC, Abouelmagd SA, Park J, Yeo Y. Nanoparticle 
Characterization: State of the Art, Challenges, and Emerging Technologies. Mol 
Pharm. 2013;10(6):2093-2110. 
218. Duan R, Li C, Liu S, Liu Z, Li Y, Zhu J, Hu X. A selective fluorescence 
quenching method for the determination of trace hypochlorite in water samples 
with nile blue A. J Taiwan Inst Chem Eng. 2015;50:43-48. 
219. Frick AA, Busetti F, Cross A, Lewis SW. Aqueous Nile blue: a simple, versatile 
and safe reagent for the detection of latent fingermarks. Chem Comm. 
2014;50(25):3341-3343. 
220. Fugit KD, Anderson BD. Dynamic, nonsink method for the simultaneous 
determination of drug permeability and binding coefficients in liposomes. Mol 
Pharm. 2014;11(4):1314-1325. 
221. Zambito Y, Pedreschi E, Di Colo G. Pharmaceutical Nanotechnology. Int J 
Pharm. 2012;434(1-2):28-34. 
222. Reichel D, Bae Y. Comparison of Dialysis- and Solvatofluorochromism-Based 
Methods to Determine Drug Release Rates from Polymer Nanoassemblies. Pharm 
Res. 2016. 
223. Lee JH, Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem 
Eng Sci. 2015;125:75-84. 
224. Yin W, Kimbrough CW, Gomez-Gutierrez JG, Burns CT, Chuong P, Grizzle WE, 
McNally LR. Tumor specific liposomes improve detection of pancreatic 
adenocarcinoma in vivo using optoacoustic tomography. J Nanobiotechnology. 
2015;13:90. 
225. Tucker-Schwartz JM, Beavers KR, Sit WW, Shah AT, Duvall CL, Skala MC. In 
vivo imaging of nanoparticle delivery and tumor microvasculature with 
multimodal optical coherence tomography. Biomed Opt Express. 2014;5(6):1731-
1743. 
226. Amjadi I, Rabiee M, Hosseini MS. Anticancer Activity of Nanoparticles Based on 
PLGA and its Co-polymer: In-vitro Evaluation. Iran J Pharm Res. 
2013;12(4):623-634. 
255 
227. Cha C, Jeong JH, Kong H. Poly(ethylene glycol)-poly(lactic-co-glycolic acid) 
core-shell microspheres with enhanced controllability of drug encapsulation and 
release rate. J Biomater Sci Polym Ed. 2015;26(13):828-840. 
228. Duncan TV. Release of engineered nanomaterials from polymer nanocomposites: 
the effect of matrix degradation. ACS Appl Mater Interfaces. 2015;7(1):20-39. 
229. Duncan TV, Pillai K. Release of engineered nanomaterials from polymer 
nanocomposites: diffusion, dissolution, and desorption. ACS Appl Mater 
Interfaces. 2015;7(1):2-19. 
230. Dinerman AA, Cappello J, El-Sayed M, Hoag SW, Ghandehari H. Influence of 
solute charge and hydrophobicity on partitioning and diffusion in a genetically 
engineered silk-elastin-like protein polymer hydrogel. Macromol Biosci. 
2010;10(10):1235-1247. 
231. Suksiriworapong J, Phoca K, Ngamsom S, Sripha K, Moongkarndi P, 
Junyaprasert VB. Comparison of poly(epsilon-caprolactone) chain lengths of 
poly(epsilon-caprolactone)-co-d-alpha-tocopheryl-poly(ethylene glycol) 1000 
succinate nanoparticles for enhancement of quercetin delivery to SKBR3 breast 
cancer cells. Eur J Pharm Biopharm. 2016;101:15-24. 
232. Arifin DY, Lee LY, Wang C-H. Mathematical modeling and simulation of drug 
release from microspheres: Implications to drug delivery systems. Adv Drug Del 
Rev. 2006;58(12–13):1274-1325. 
233. Sutton D, Wang S, Nasongkla N, Gao J, Dormidontova EE. Doxorubicin and β-
Lapachone Release and Interaction with Micellar Core Materials: Experiment and 
Modeling. Exp Biol Med. 2007;232(8):1090-1099. 
234. Kim K-M, Kim H-M, Choi M-H, Lee JK, Jeong J, Lee M-H, Kim YS, Paek S-M, 
Oh J-M. Colloidal Properties of Surface Coated Colloidal Silica Nanoparticles in 
Aqueous and Physiological Solutions. Science of Advanced Materials. 
2014;6(7):1573-1581. 
235. Stockert JC, Blazquez A, Galaz S, Juarranz A. A mechanism for the fluorogenic 
reaction of amino groups with fluorescamine and MDPF. Acta Histochem. 
2008;110(4):333-340. 
256 
236. Brewer J, Roberts C, Stimson W, Alexander J. Accurate determination of 
adjuvant-associated protein or peptide by ninhydrin assay. Vaccine. 
1995;13(15):1441-1444. 
237. Starcher B. A Ninhydrin-Based Assay to Quantitate the Total Protein Content of 
Tissue Samples. Anal Biochem. 2001;292(1):125-129. 
238. Bae Y. Drug delivery systems using polymer nanoassemblies for cancer 
treatment. Ther Deliv. 2010;1(3):361-363. 
239. Dickerson M, Howerton B, Bae Y, Glazer E. Light-Sensitive Ruthenium 
Complex-Loaded Cross-linked Polymeric Nanoassemblies for the Treatment of 
Cancer. J Mater Chem B Mater Biol Med. 2016;4(3):394-408. 
240. Lee HJ, Bae Y. Cross-linked nanoassemblies from poly(ethylene glycol)-
poly(aspartate) block copolymers as stable supramolecular templates for 
particulate drug delivery. Biomacromolecules. 2011;12(7):2686-2696. 
241. Owen SC, Chan DPY, Shoichet MS. Polymeric micelle stability. Nano Today. 
2012;7(1):53-65. 
242. Attia AB, Yang C, Tan JP, Gao S, Williams DF, Hedrick JL, Yang YY. The 
effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded 
biodegradable polymeric micelles. Biomaterials. 2013;34(12):3132-3140. 
243. Yang C, Attia AB, Tan JP, Ke X, Gao S, Hedrick JL, Yang YY. The role of non-
covalent interactions in anticancer drug loading and kinetic stability of polymeric 
micelles. Biomaterials. 2012;33(10):2971-2979. 
244. Li Z, Tan BH. Towards the development of polycaprolactone based amphiphilic 
block copolymers: molecular design, self-assembly and biomedical applications. 
Materials Science and Engineering: C. 2014;45:620-634. 
245. Pitto-Barry A, Barry NP. Pluronic® block-copolymers in medicine: from 
chemical and biological versatility to rationalisation and clinical advances. 
Polymer Chemistry. 2014;5(10):3291-3297. 
257 
246. Yoon HY, Koo H, Choi KY, Chan Kwon I, Choi K, Park JH, Kim K. Photo-
crosslinked hyaluronic acid nanoparticles with improved stability for in vivo 
tumor-targeted drug delivery. Biomaterials. 2013;34(21):5273-5280. 
247. Duan X, He C, Kron SJ, Lin W. Nanoparticle formulations of cisplatin for cancer 
therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016. 
248. Woodman JL, Suh MS, Zhang J, Kondaveeti Y, Burgess DJ, White BA, 
Prestwich GD, Kuhn LT. Carboxymethyl Hyaluronan-Stabilized Nanoparticles 
for Anticancer Drug Delivery. Int J Cell Biol. 2015;2015:249573. 
249. Wang Y, Li P, Kong L. Chitosan-modified PLGA nanoparticles with versatile 
surface for improved drug delivery. AAPS PharmSciTech. 2013;14(2):585-592. 
250. Rabanel J-M, Hildgen P, Banquy X. Assessment of PEG on polymeric particles 
surface, a key step in drug carrier translation. J Controlled Release. 2014;185:71-
87. 
251. Nauka PC, Lee J, Maynard HD. Enhancing Conjugation Yield of Brush Polymer-
Protein Conjugates by Increasing Linker Length at the Polymer End-Group. 
Polymer Chemistry. 2016;7(13):2352-2357. 
252. Pinter B, Fievez T, Bickelhaupt FM, Geerlings P, De Proft F. On the origin of the 
steric effect. Phys Chem Chem Phys. 2012;14(28):9846-9854. 
253. Richard I, Thibault M, De Crescenzo G, Buschmann MD, Lavertu M. Ionization 
behavior of chitosan and chitosan-DNA polyplexes indicate that chitosan has a 
similar capability to induce a proton-sponge effect as PEI. Biomacromolecules. 
2013;14(6):1732-1740. 
254. Curtis KA, Miller D, Millard P, Basu S, Horkay F, Chandran PL. Unusual Salt 
and pH Induced Changes in Polyethylenimine Solutions. PLoS One. 
2016;11(9):e0158147. 
255. Ao L, Reichel DA, Hu D, Jeong H, Kim KB, Bae Y, Lee W. Polymer Micelle 
Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic 
Stability and Anti-Cancer Efficacy in Human Multiple Myeloma and Lung 
Cancer Cell Lines. J Pharmacol Exp Ther. 2015. 
258 
256. Jager M, Schubert S, Ochrimenko S, Fischer D, Schubert US. Branched and linear 
poly(ethylene imine)-based conjugates: synthetic modification, characterization, 
and application. Chem Soc Rev. 2012;41(13):4755-4767. 
257. England CG, Miller MC, Kuttan A, Trent JO, Frieboes HB. Release kinetics of 
paclitaxel and cisplatin from two and three layered gold nanoparticles. Eur J 
Pharm Biopharm. 2015;92:120-129. 
258. Ritger PL, Peppas NA. A simple equation for description of solute release II. 
Fickian and anomalous release from swellable devices. J Controlled Release. 
1987;5(1):37-42. 
259. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release 
from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-223. 
260. Rehage G, Ernst O, Fuhrmann J. Fickian and non-Fickian diffusion in high 
polymer systems. Discuss Faraday Soc. 1970;49(0):208-221. 
261. Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable 
and degradable polymeric delivery systems. Expert Opinion on Drug Delivery. 
2010;7(4):429-444. 
262. Reichel D, Lee MJ, Lee W, Kim KB, Bae Y. Tethered Polymer Nanoassemblies 
for Sustained Carfilzomib Release and Prolonged Suppression of Proteasome 
Activity. Ther Delivery. 2016;(Accepted). 
263. Ciechanover A. Intracellular protein degradation: from a vague idea through the 
lysosome and the ubiquitin-proteasome system and onto human diseases and drug 
targeting. Bioorg Med Chem. 2013;21(12):3400-3410. 
264. Orlowski RZ, Kuhn DJ. Proteasome Inhibitors in Cancer Therapy: Lessons from 
the First Decade. Clin Cancer Res. 2008;14(6):1649-1657. 
265. Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL. Carfilzomib 
demonstrates broad anti-tumor activity in pre-clinical non-small cell and small 
cell lung cancer models. J Exp Clin Cancer Res. 2014;33(1):1-12. 
266. Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, Czuczman NM, Mavis C, Skitzki 
JJ, Czuczman MS. The novel proteasome inhibitor carfilzomib induces cell cycle 
259 
arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in 
rituximab-resistant lymphoma. Br J Haematol. 2013;162(5):657-669. 
267. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, Neslund-Dudas C, 
Mitra B, Dou QP. From bortezomib to other inhibitors of the proteasome and 
beyond. Curr Pharm Des. 2013;19(22):4025-4038. 
268. Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC. 
Bortezomib in multiple myeloma: systematic review and clinical considerations. 
2014. 2014;21(4):31. 
269. Redic K. Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol. 
2013;65(8):1095-1106. 
270. Shirley M. Ixazomib: First Global Approval. Drugs. 2016;76(3):405-411. 
271. Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment options for 
relapsed and refractory multiple myeloma. Blood. 2015;125(20):3085-3099. 
272. Mansour MA, Aljoufi MA, Al-Hosaini K, Al-Rikabi AC, Nagi MN. Possible role 
of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat 
hepatocellular carcinoma. Chem Biol Interact. 2014;215:17-24. 
273. Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL. Carfilzomib 
demonstrates broad anti-tumor activity in pre-clinical non-small cell and small 
cell lung cancer models. J Exp Clin Cancer Res. 2014;33(1):111. 
274. Papadopoulos KP, Burris HA, 3rd, Gordon M, Lee P, Sausville EA, Rosen PJ, 
Patnaik A, Cutler RE, Jr., Wang Z, Lee S, Jones SF, Infante JR. A phase I/II study 
of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer 
Chemother Pharmacol. 2013;72(4):861-868. 
275. Papadopoulos KP, Burris HA, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik 
A, Cutler RE, Wang Z, Lee S, Jones SF, Infante JR. A phase I/II study of 
carfilzomib 2–10-min infusion in patients with advanced solid tumors. Cancer 
Chemother Pharmacol. 2013;72(4):861-868. 
276. Sebestyen Z, Szepesi K, Szabo B. [Pharmaceutical applications of 
sulfobuthylether-beta-cyclodextrin]. Acta Pharm Hung. 2013;83(2):57-67. 
260 
277. Chu KS, Schorzman AN, Finniss MC, Bowerman CJ, Peng L, Luft JC, Madden 
AJ, Wang AZ, Zamboni WC, DeSimone JM. Nanoparticle drug loading as a 
design parameter to improve docetaxel pharmacokinetics and efficacy. 
Biomaterials. 2013;34(33):8424-8429. 
278. Luke DR, Wood ND, Tomaszewski KE, Damle B. Pharmacokinetics of 
sulfobutylether-beta-cyclodextrin (SBECD) in subjects on hemodialysis. Nephrol 
Dial Transplant. 2012;27(3):1207-1212. 
279. Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ. 
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel 
(Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors. J Thorac 
Oncol. 2015;10(12):1800-1806. 
280. Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, 
Cho EK. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and 
gemcitabine in patients with advanced non-small cell lung cancer. Cancer 
Chemother Pharmacol. 2014;74(2):277-282. 
281. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based 
Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. 
Pharm Res. 2016. 
282. Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted 
treatment in oncology: current insights. Int J Nanomedicine. 2015;10:1001-1018. 
283. Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig 
MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N. 
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates 
carfilzomib-induced multiple myeloma cell death. Br J Haematol. 
2015;169(3):423-434. 
284. Nguyen HQ, Kimoto E, Callegari E, Obach RS. Mechanistic Modeling to Predict 
Midazolam Metabolite Exposure from In Vitro Data. Drug Metab Dispos. 
2016;44(5):781-791. 
285. Liu R, Schyman P, Wallqvist A. Critically Assessing the Predictive Power of 
QSAR Models for Human Liver Microsomal Stability. J Chem Inf Model. 
2015;55(8):1566-1575. 
261 
286. Perryman AL, Stratton TP, Ekins S, Freundlich JS. Predicting Mouse Liver 
Microsomal Stability with "Pruned" Machine Learning Models and Public Data. 
Pharm Res. 2016;33(2):433-449. 
287. Fonsi M. Extrahepatic metabolism may complicate the IVIVC in rats. Drug 
Metab Lett. 2014;8(1):51-66. 
288. Nishimuta H, Houston JB, Galetin A. Hepatic, intestinal, renal, and plasma 
hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications 
for in vitro-in vivo extrapolation of clearance of prodrugs. Drug Metab Dispos. 
2014;42(9):1522-1531. 
289. Sestak V, Roh J, Klepalova L, Kovarikova P. A UHPLC-UV-QTOF study on the 
stability of carfilzomib, a novel proteasome inhibitor. J Pharm Biomed Anal. 
2016;124:365-373. 
290. Phizackerley KM, Jumaa M, Lopalco A, Wolfe BH, Ablan CD, Stella VJ. 
Mechanism of Degradation of an &#x3b1;-Keto-Epoxide, a Model for the 
Warhead for Various Proteasome Inhibitor Anticancer Agents. J Pharm 
Sci;106(4):1051-1061. 
291. Sun C, Roboti P, Puumalainen MR, Fryknas M, Wang X, D'Arcy P, Hult M, High 
S, Linder S, Swanton E. Elevation of proteasomal substrate levels sensitizes cells 
to apoptosis induced by inhibition of proteasomal deubiquitinases. PLoS One. 
2014;9(10):e108839. 
292. Mukherjee B, Das S, Chakraborty S, Satapathy BS, Das PJ, Mondal L, Hossain 
CM, Dey NS, Chaudhury A. Potentials of polymeric nanoparticle as drug carrier 
for cancer therapy: with a special reference to pharmacokinetic parameters. Curr 
Drug Metab. 2014;15(6):565-580. 
293. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo 
pharmacokinetics and cellular interaction. Nanomedicine (Lond). 2016;11(6):673-
692. 
294. Li Y, Lin J, Huang Y, Li Y, Yang X, Wu H, Wu S, Xie L, Dai L, Hou Z. Self-
Targeted, Shape-Assisted, and Controlled-Release Self-Delivery Nanodrug for 
Synergistic Targeting/Anticancer Effect of Cytoplasm and Nucleus of Cancer 
Cells. ACS Appl Mater Interfaces. 2015;7(46):25553-25559. 
262 
295. Liu H, Xu H, Jiang Y, Hao S, Gong F, Mu H, Liu K. Preparation, 
characterization, in vivo pharmacokinetics, and biodistribution of polymeric 
micellar dimethoxycurcumin for tumor targeting. Int J Nanomedicine. 
2015;10:6395-6410. 
296. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popović Z, 
Jain RK, Bawendi MG, Fukumura D. Multistage nanoparticle delivery system for 
deep penetration into tumor tissue. Proceedings of the National Academy of 
Sciences. 2011;108(6):2426-2431. 
297. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev 
Clin Oncol. 2010;7(11):653-664. 
298. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, 
Hanahan D, Mattrey RF, Ruoslahti E. Tissue-Penetrating Delivery of Compounds 
and Nanoparticles into Tumors. Cancer Cell. 2009;16(6):510-520. 
  
263 
VITA 
 
Derek Alexander Reichel 
 
EDUCATION 
 
2007-2012 B.S. Chemical Engineering, College of Engineering, The Ohio State 
University (summa cum laude, honors in research, graduate with 
distinction) 
 
HONORS AND AWARDS 
 
2016-2017 Graduate School Allocated Year Fellowship; UK College of Pharmacy  
 
2016 Graduate School Travel Award; UK College of Pharmacy   
 
2015 Monthly Publication Highlight, UK College of Pharmacy   
 
2014 Graduate School Travel Award; UK College of Pharmacy   
 
2012-2015 Daniel R. Reedy Quality Achievement Fellowship; University of 
Kentucky  
 
2012 Outstanding Undergraduate Award for Research; OSU Chemical 
Engineering   
 
2011-2012 Undergraduate Research Scholarship; OSU College of Engineering  
 
PUBLICATIONS 
 
Peer-Reviewed Journals 
 
9. Submitted: Davis, S.; Reichel, D.; Bae, Y.; Pennypacker, K.; Enhanced Stability of 
Leukemia Inhibitory Factor loaded in Nanoparticles Targeted to Ischemic Stroke and 
Other Inflammatory Diseases, Pharm. Res. 
 
8. Submitted: Rychahou, P.; Bae, Y.; Reichel, D.; Zaytseva, Y.; Lee, E. Y.; Napier, D.; 
Weiss, H. L.; Evers, B. M.; Targeting Colorectal Cancer Lung Metastasis with Lung-
Selective Drug Delivery, Proc. Natl. Acad. Sci. U.S.A. 
 
7. Submitted: Reichel, D.; Curtis, L.T.; Ehlman, E.; Evers, B. M.; Rychahou, P.; 
Frieboes, H. B.; Bae, Y.; Halofluorochromic Polymer Nanoassemblies for Early and 
Accurate Detection of Liver Metastatic Colorectal Cancer Tumors, Pharm. Res. 
 
6. Rheiner, S.; Reichel, D.; Rychahou, P.; Izumi, T.; Yang, H.-S.; Bae, Y.; Polymer 
Nanoassemblies with Hydrophobic Pendant Groups in the Core Induce False Positive 
264 
siRNA Transfection in Luciferase Reporter Assays, Int. J. Pharm. 2017, 528, 536-546 
(DOI 10.1016/j.ijpharm.2017.06.056) 
 
5. Park, J. E.; Chun, S.-E.; Reichel, D.; Min, J. S.; Lee, S.-C.; Han, S.; Ryoo, G.; Oh, Y.; 
Park, S.-H.; Ryu, H.-M.; Kim, K. B.; Lee, H.-Y.; Bae, S. K.; Bae, Y.; Lee, W.; 
Polymer Micelle Formulation for the Proteasome Inhibitor Drug Carfilzomib: 
Anticancer Efficacy and Pharmacokinetic Studies in Mice, PLoS ONE. 2017, 12, 1-12 
(DOI 10.1371/journal.pone.0173247) 
 
4. Reichel, D.; Bae, Y.; Comparison of Dialysis- and Solvatofluorochromism-based 
Methods to Determine Drug Release Rates from Polymer Nanoassemblies, Pharm. 
Res. 2017, 34, 394-407. (DOI 10.1007/s11095-016-2070-6) 
 
3. Reichel, D.; Lee, M. J.; Lee, W.; Kim, K. B.; Bae, Y.; Tethered Polymer 
Nanoassemblies for Sustained Carfilzomib Release and Prolonged Suppression of 
Proteasome Activity, Ther. Deliv. 2016, 7, 665-681. (DOI 10.4155/tde-2016-0041) 
 
2. Ao, L.; Reichel, D.; Hu, D.; Jeong, H. Y.; Kim, K. B.; Bae, Y.; Lee, W.; Polymer 
Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic 
Stability and Anti-Cancer Efficacy in Human Multiple Myeloma and Lung Cancer 
Cell Lines, J. Pharmacol. Exp. Ther. 2015, 355, 168-173.  (DOI 
10.1124/jpet.115.226993) 
 
1. Reichel, D.; Rychahou, P.; Bae, Y. Polymer Nanoassemblies with Solvato- and Halo-
fluorochromism for Drug Release Monitoring and Metastasis Imaging, Ther. Deliv. 
2015, 6, 1221-1237. (DOI 10.4155/tde.15.59) 
 
Conference Proceedings 
 
4. Rychahou, P.; Bae, Y.; Reichel, D.; Zaytseva, Y.; Lee, E. Y.; Weiss, H. L.; Evers, B. 
M.; Targeting Colorectal Cancer Lung Metastasis Microenvironment with PI3K 
Inhibitors and Chemotherapy (American Association for Cancer Research, 
Washington, DC), Cancer Res., 2017, 77, 201. (DOI 10.1158/1538-7445.AM2017-
201) 
 
3. Park, J. E.; Chun, S.-E.; Reichel, D.; Park, J.; Min, J. S.; Ryoo, G.; Oh, Y.; Bae, S. K.; 
Yeo, Y.; Bae, Y.; Lee, W.; Novel Polymer Micelle and Nanocrystal Formulations for 
the Proteasome Inhibitor Drug Carfilzomib: Pharmacokinetic and Pharmacodynamic 
Studies in Human Lung and Breast Cancer Models (Experimental Biology, Chicago, 
IL), FASEB J., 2017, 31, 822. 
 
2. Park, J. E.; Ao, L.; Chun, S.-E.; Reichel, D.; Hu, D.; Han, S.; Ryoo, G.; Oh, Y.; Park, 
S.-H.; Min, J. S.; Ryu, H.-M.; Bae, S. K.; Lee, H.-Y.; Kim, K. B.; Jeong, H. Y.; Bae, 
Y.; Lee, W. Polymer Micelle Formulation of Proteasome Inhibitor Carfilzomib as a 
Potential Strategy to Improve Metabolic Stability and Anti-Cancer Efficacy in Human 
265 
Multiple Myeloma and Lung Cancer (Japanese Society for the Study of Xenobiotics, 
Matsumoto, Japan), Drug Metab. Pharmacokinet., 2017, 32, 1, S46. (DOI 
10.1016/j.dmpk.2016.10.195) 
 
1. Ao, L.; Reichel, D.; Hu, D.; Jeong, H.-Y.; Kim, K. B.; Bae, Y.; Lee, W.;  
Nanoformulations of Carfilzomib for Improved Metabolic Stability and Anti-Cancer 
Efficacy (Experimental Biology, Boston, MA), FASEB J., 2015, 29, 620. 
 
PRESENTATIONS 
 
Oral Presentations 
 
7. Early Detection of Liver Metastatic Colorectal Cancer by using Polymer Tethered 
Nanoassemblies, Pharmaceutics Graduate Student Research Meeting, June 2016, 
Kansas City, MO 
 
6. Polymer Tethered Nanoassemblies for Cancer Detection and Therapeutics, University 
of Kentucky, May 2016, Lexington, KY 
 
5. Polymer Tethered Nanoassemblies for Improving Cancer Detection and Treatment, 
National Science Foundation EPSCoR Membrane Pillar and University of Kentucky 
Center for Membrane Sciences, March 2016, Lexington, KY 
 
4. Solvatochromic Polymer Tethered Nanoassemblies for Liver Metastasis Detection, 
University of Kentucky, February 2015, Lexington, KY 
 
3. Environment-Sensitive Tethered Nanoassemblies for Cancer Theranostics, 
Pharmaceutics Graduate Student Research Meeting, June 2014, Chicago, IL 
 
2. Tethered Nanoassemblies for Cancer Theranostics, University of Kentucky, April 
2014, Lexington, KY  
 
1. Crosslinked Nanoassemblies for Cancer Theranostics, University of Kentucky, April 
2013, Lexington, KY  
 
Poster Presentations 
 
20. Rychahou, P.; Bae, Y.; Reichel, D.; Zaytseva, Y.; Lee, E. Y.; Weiss, H. L.; Evers, B. 
M.; Targeting Colorectal Cancer Lung Metastasis Microenvironment with PI3K 
Inhibitors and Chemotherapy, American Association for Cancer Research, April 
2017, Washington, DC 
 
19. Park, J.; Chun, S.; Reichel, D.; Park, J.; Min, J.; Ryoo, G.; Oh, Y.; Bae, S.; Yeo, Y.; 
Bae, Y.; Lee, W.; Novel Polymer Micelle and Nanocrystal Formulations for the 
Proteasome Inhibitor Carfilzomib: Pharmacokinetic and Pharmacodynamic Studies 
266 
in Human Lung and Breast Cancer Models, Experimental Biology, April 2017, 
Chicago, IL 
 
18. Park, J. E.; Ao, L.; Chun, S.-E.; Reichel, D.; Hu, D.; Han, S.; Ryoo, G.; Oh, Y.; Park, 
S.-H.; Min, J. S.; Ryu, H.-M.; Bae, S. K.; Lee, H.-Y.; Kim, K. B.; Jeong, H. Y.; Bae, 
Y.; Lee, W.; Polymer Micelle Formulation of Proteasome Inhibitor Carfilzomib as a 
Potential Strategy to Improve Metabolic Stability and Anti-Cancer Efficacy in Human 
Multiple Myeloma and Lung Cancer, Japanese Society for the Study of Xenobiotics, 
October 2016, Matsumoto, Japan 
 
17. Reichel, D.; Rychahou, P.; Bae, Y.; Early Detection of Liver Metastatic Colorectal 
Cancer by Using Polymer Tethered Nanoassemblies, Markey Cancer Center Research 
Day, May 2016, Lexington, KY 
 
16. Reichel, D.; Bae, Y.; Ionic and Hydrophobic Core Modifications of Polymer Tethered 
Nanoassemblies to Control Entrapment and Release of Carfilzomib, Rho Chi 
Research Day, March 2016, Lexington, KY 
 
15. Reichel, D.; Bae, Y.; Effects of Ionic and Hydrophobic Core Modifications on Drug 
Release from Polymer Tethered Nanoassemblies, Drug Discovery and Development 
Symposium, November 2015, Lexington, KY 
 
14. Reichel, D.; Bae, Y.; Controlling Drug Release Properties and Preventing Burst 
Release from Polymer Tethered Nanoassemblies Using Core Environment 
Modifications, Nanobiotechnology Center Symposium, October 2015, Lexington, KY 
 
13. Reichel, D.; Rychahou, P.; Bae, Y.; Polymer Nanoassemblies for Real-time Drug 
Release Monitoring and Ex Vivo Imaging for Theranostics of Metastatic Tumors, 
Pharmaceutics Graduate Student Research Meeting, June 2015 
 
12. Ao, L.; Reichel, D.; Hu, D.; Jeong, H.-Y.; Kim, K. B.; Bae, Y.; Lee, W.;  Polymer 
Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic 
Stability and Anti-Cancer Efficacy, Markey Cancer Center Research Day, May 2015, 
Lexington, KY 
 
11. Reichel, D.; Rychahou, P.; Bae, Y.; Polymer Nanoassemblies for Real-time Drug 
Release Monitoring and Ex Vivo Imaging for Theranostics of Metastatic Tumors, 
Markey Cancer Center Research Day, May 2015, Lexington, KY  
 
10. Ao, L.; Reichel, D.; Hu, D.; Jeong, H.-Y.; Kim, K. B.; Bae, Y.; Lee, W.;  
Nanoformulations of Carfilzomib for Improved Metabolic Stability and Anti-Cancer 
Efficacy, Experimental Biology, March 2015, Boston, MA 
 
267 
9.   Reichel, D.; Bae, Y.; Polymeric Theranostic Tethered Nanoassemblies for Drug 
Release and Tissue pH Monitoring, 6th Annual Biomaterials Day, September 2014, 
Lexington, KY 
 
8.   Reichel, D.; Bae, Y.; Polymeric Theranostic Tethered Nanoassemblies for Drug 
Release and Tissue pH Monitoring, Symposium on Drug Discovery and 
Development, September 2014, Lexington, KY 
 
7.   Piroli, M.; Reichel, D.; Pack, D.; Bae, Y.; Controlling Drug Release from Theranostic 
Polymer Tethered Nanoassemblies, Research Experience for Undergraduates, August 
2014, Lexington, KY 
 
6.   Reichel, D.; Bae, Y.; Nile Blue Tethered Nanoassemblies for Cancer Theranostics, 
Markey Cancer Center Research Day, May 2014, Lexington, KY 
 
5.   Plasko, G.; Reichel, D.; Geddes, J.; Bae, Y.; Crosslinked Nanoassemblies Entrapping 
Fluorescent Probes for Drug Release Monitoring, Research Experience for 
Undergraduates, July 2013, Lexington, KY 
 
4.   Reichel, D.; Bae, Y.; Crosslinked Nanoassemblies for Cancer Theranostics, 
Pharmaceutics Graduate Student Research Meeting, June 2013, Lexington, KY 
 
3.   Reichel,D.; Bae, Y.; Crosslinked Nanoassemblies for Cancer Theranostics, Markey 
Cancer Center Research Day, April 2013, Lexington, KY 
 
2.   Reichel,D.; Glick, L.; Chen, A.; Baretto, J.; Wood, D.; A Comparison of Estrogenic 
Properties of Small Molecules across Several Species Using Biosensors, AIChE, 
October 2012, Pittsburgh, PA 
 
1.   Reichel, D.; Glick, L.; Chen, A.; Saunders, B.; Miskioglu, E.; Wood, D.; High-
Throughput Screening System for the Determination of Estrogenic Properties of 
ICCVAM-Recommended Compounds, AIChE, October 2012, Pittsburgh, PA 
 
